

Mitigation of NADPH oxidase 2 activity as a strategy to inhibit peroxynitrite formation

Jacek Zielonka¹, Monika Zielonka¹, Lynn VerPlank², Gang Cheng¹, Micael Hardy³, Olivier Ouari³, Mehmet Menaf Ayhan³, Radosław Podsiadły^{1,4}, Adam Sikora⁵, J. David Lambeth⁶, Balaraman Kalyanaraman¹

¹From the Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, WI 53226

²The Broad Institute of MIT and Harvard, Cambridge, MA 02142

³Aix-Marseille Université, CNRS, ICR UMR 7273, 13397 Marseille, France

⁴Institute of Polymer and Dye Technology, Faculty of Chemistry, Lodz University of Technology, Stefanowskiego 12/16, 90-924 Lodz, Poland

⁵Institute of Applied Radiation Chemistry, Faculty of Chemistry, Lodz University of Technology, Źeromskiego 116, 90-924 Lodz, Poland

⁶Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322

*Running title: *Nox2 inhibition as anti-nitration strategy*

To whom correspondence should be addressed: Jacek Zielonka, PhD or Balaraman Kalyanaraman, PhD, Department of Biophysics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, Tel: (414) 955-4000; Fax: (414) 955-6512; Email: jzielonk@mcw.edu or balarama@mcw.edu

Keywords: reactive nitrogen species, reactive oxygen species, fluorescence probes, NADPH oxidase inhibitors, high-throughput screening (HTS), superoxide radical anion, hydrogen peroxide, peroxynitrite

ABSTRACT

Using a high-throughput screening (HTS)-compatible assays for superoxide and hydrogen peroxide, we identified potential inhibitors of NADPH oxidase (Nox2) isoform from a small library of bioactive compounds. By using multiple probes (hydroethidine, hydropropidine, Amplex Red, and coumarin boronate) with well-defined redox chemistry that form highly diagnostic marker products upon reaction with superoxide (O_2^-), hydrogen peroxide (H_2O_2), and peroxynitrite ($ONOO^-$), the number of false positives was greatly decreased. Selected hits for Nox2 were further screened for their ability to inhibit $ONOO^-$ formation in activated macrophages. New diagnostic marker product for $ONOO^-$ is reported. We conclude that the newly developed HTS/ROS assays could also be used to identify potential inhibitors of $ONOO^-$

formed from Nox2-derived O_2^- and nitric oxide synthase (NOS)-derived nitric oxide.

INTRODUCTION

NADPH oxidase (Nox) enzymes (Nox1-5, Duox1/2) have been proposed as potential therapeutic targets in the treatment of a variety of inflammatory and fibrotic diseases including cancer (1-3). Unlike other redox-active enzymes for which generation of reactive oxygen species (ROS) is an “accidental” byproduct of their primary catalytic function, the only known function of Nox enzymes is generation of ROS (e.g., O_2^- and H_2O_2) (Fig. 1) (4;5). Several Nox isoforms including Nox2 form both O_2^- and H_2O_2 (*via* dismutation of O_2^-), with the exception of Nox4 which generates primarily H_2O_2 with little or no detectable O_2^- (4;5). A major impediment to advancing Nox research is the paucity of selective

inhibitors of Nox isoforms, including Nox1 and 2 (6). This is in part due to the lack of reliable and high-throughput-compatible detection probes and assays that are specific for O_2^- and H_2O_2 . With the recent discovery of new probes with well-defined redox chemistry that form highly diagnostic marker products upon reaction with ROS/RNS both under *in vitro* and *in vivo* conditions and high-throughput global profiling assays (Table 1) (7), we can now screen a small library of bioactive compounds. One of the objectives of this study is to identify small molecule inhibitors of Nox2 isoform using the high-throughput screening (HTS)/ROS based assay(s) that largely eliminate false positives. Previously, we reported the power of our newly-developed HTS/ROS assays in identifying true “hits” for Nox2 inhibition and eliminating false positives at the outset (8). Typically, the chemiluminescent probe, L-012, has been used in Nox assay (9). Comparison between L-012 assay and our HTS/ROS assay revealed that L-012 increased false positives by at least a factor of 4, and that this increase is due to inhibition of peroxidase enzyme used in the L-012/Nox assay (10). A related objective of this study is also to identify new small molecule inhibitors of RNS (e.g., peroxy nitrite). Peroxy nitrite ($ONOO^-$) is a potent oxidizing and nitrating species formed from a diffusion-controlled reaction between O_2^- and nitric oxide (NO) (11;12) (Fig. 1), and has been implicated in various neurodegenerative and cardiovascular diseases (13-15). Although ongoing efforts focus on antinitration strategies mostly through direct scavenging of $ONOO^-$ and/or related species (16), a better approach is to suppress the sources of generation of O_2^- (Nox) and/or inhibition of nitric oxide synthase, particularly inducible nitric oxide synthase (iNOS) (Fig. 1) (17;18). In this study, we identified several candidate Nox2 inhibitors through HTS-based ROS assays from testing a library of >2,000 bioactive compounds at the Broad Institute. Selected hits for Nox2 inhibition were further tested for inhibition of $ONOO^-$ formation in activated macrophages. Results suggest that the HTS/ROS strategy developed herein could be used to identify Nox2 inhibitors that inhibit $ONOO^-$ formation. In this study we also discovered a new diagnostic marker product for specific detection and quantitation of peroxy nitrite in biological systems. One of the objectives of this study is to

also use these candidate inhibitors of Nox2 as potential inhibitors of $ONOO^-$ generated via Nox2 intermediacy.

EXPERIMENTAL PROCEDURES

Materials – All compounds in the HTS library were routinely dissolved in DMSO and stored at -20°C. DMSO concentration (<1%) was kept the same in both control and treatment conditions. In confirmatory studies, stock solutions were prepared at higher concentrations (typically 10 mM or higher), such that the final concentration of the solvent vehicle was kept minimal (<0.3% v/v) upon dilution. Hydropropidine (HPr^+), coumarin boronic acid (CBA), and *ortho*-mito-phenylboronic acid (*o*-MitoPhB(OH)₂) were synthesized according to published procedures (19-22). Deuterated (d_{15}) analogs of *o*-MitoPhB(OH)₂ and *o*-MitoPhNO₂ were synthesized in the analogous protocol to *o*-MitoPhB(OH)₂ but using deuterated triphenylphosphine (d_{15} -PPh₃), while d_{15} -*o*-MitoPhOH was synthesized by oxidation of d_{15} -*o*-MitoPhB(OH)₂ by excess H₂O₂. Amplex Red (10-acetyl-3,7-dihydroxyphenoxyazine), resorufin, and 7-hydroxycoumarin were purchased from Cayman and Sigma-Aldrich. Hydroethidium (HE) was from Invitrogen. Authentic standards of 2-hydroxyethidium (2-OH-E⁺) and 2-hydroxypropidium (2-OH-Pr⁺⁺) were synthesized as described previously (19;23;24). Stock solutions of CBA, HE and Amplex Red were prepared at 20-100 mM concentration in DMSO and stored at -80°C. For experiments involving HOCl, DMSO was replaced with ethanol. Horseradish peroxidase (HRP, type VI), superoxide dismutase (SOD), catalase (CAT) and all other reagents were obtained from Sigma-Aldrich.

For organic synthesis, THF was distilled under dry argon atmosphere in the presence of sodium and benzophenone. All reagents were used as received without further purification. The reactions were monitored by TLC on silica gel Merck 60F254. Crude materials were purified by flash chromatography on Merck Silica gel 60 (0.040-0.063 mm). ³¹P NMR, ¹H NMR and ¹³C NMR spectra were recorded with Bruker DPX 300 or 400 spectrometers at 121.49, 300.13 and 75.54 MHz, respectively. ³¹P NMR measurements were carried out in CDCl₃ using 85% H₃PO₄ as an

external standard with broad-band ^1H decoupling. ^1H NMR and ^{13}C NMR measurements were carried out in CDCl_3 using TMS or CDCl_3 as internal reference, respectively. Chemical shifts (δ) are reported in ppm and coupling constant J values in hertz. Mass spectrometry analyses were performed at the University of Aix-Marseille (Spectropole).

HTS Compatible Cellular Models of Nox2–Human promyelocytic leukemia HL60 cells (Sigma) differentiated into neutrophil-like cells by all-trans-retinoic acid (ATRA) were used as the HTS-compatible source of Nox2 model system for screening Nox2 inhibitors (25;26). HL60 cells were incubated with ATRA (1 μM) for 4–5 days for converting nondifferentiated cells into differentiated cells. Nox2 activation was achieved by treating differentiated HL60 (*d*HL60) cells with phorbol myristate acetate (PMA, 1 μM) (8).

High-throughput screening of the small library of bioactive compounds at the Broad Institute. To test the inhibitory effects of the compounds included in the library of the bioactive compounds, we preincubated *d*HL60 cells with the potential inhibitors for 30 min, followed by addition of PMA and appropriate probe, as shown in Table 2. After 90 min incubation at 37 °C in CO_2 -free incubator, the extent of oxidation of the probes was measured with Perkin Elmer Envision plate reader using the excitation/emission filter sets: 485 nm/590 nm, 355 nm/460 nm and 531 nm/595 nm, for hydropropidine + DNA, coumarin boronic acid and Amplex Red + HRP, respectively.

Signal Optimization and Z' Values. HTS Statistics: Z' Parameter – We used the Z' factor method as a measure of the assay quality or performance. As positive control (control+ signal) *d*HL-60 cells were incubated with PMA in the presence of DMSO. The negative control (control–signal) included cells in the presence of phenylarsine oxide (PAO, 1 μM) used as Nox2 inhibitor. The dynamic range was established by the difference between averaged maximal (control+) and minimal (control–) signals. The Z' factor was calculated using the formula (27):

$$Z' = 1 - \frac{3SD_{control+} + 3SD_{control-}}{|mean_{control+} - mean_{control-}|}$$

where $control+$ and $control-$ correspond to PMA-stimulated cells in the presence of DMSO only or 1 μM PAO, respectively, and SD values are the corresponding standard deviations.

The calculated Z' values determined at the Broad Institute in 384-well plates for all three HTS assays (hydropropidine + DNA, coumarin boronic acid and Amplex Red + HRP) were 0.45, 0.64 and 0.79, respectively. Assuming the inhibitor identification threshold of $3 \times$ standard deviation of the neutral (negative) control (DMSO), we can determine positive hits with a 42%, 28% and 15% inhibition for hydropropidine + DNA, coumarin boronic acid and Amplex Red + HRP, respectively.

Oxygen Consumption Experiments– Nox activity was determined by measuring rates of oxygen consumption in PMA-activated differentiated HL60 cells using a Seahorse XF96 extracellular flux analyzer (8;28). Cell suspensions were prepared in phenol red-free RPMI medium (without bicarbonate) and aliquoted (80 μl per well) into 96-well plate to obtain a final cell count of 2×10^4 cells per well. After spinning down the cells, additional RPMI (100 μl per well) was added. Oxygen measurements were initiated, and at the specified time points, inhibitors of Nox were added, followed by injection of PMA. Alternatively cells were pre-incubated with Nox2 inhibitors and transferred into measurement plates, and response to PMA was tested. We used rotenone (1 μM) and antimycin (10 μM) to dissect out the contribution of mitochondrial respiration to the total oxygen consumption rate. This also enables one to monitor the effects of Nox2 inhibitors on mitochondrial respiration (8).

Synthesis of cyclo-*o*-MitoPh – 9,10-Dihydro-9,9-diphenyl-9-phosphoniaphenanthrene bromide (*cyclo-o*-MitoPh) was obtained by adapting the procedures described in the literature (29–31). The scheme for synthesis of *cyclo-o*-MitoPh is shown in Figure 9a. Briefly, after formulation of compound **1** in the presence of n-butyllithium and DMF, compound **2** was reduced by sodium borohydride to obtain compound **3**. Bromination of **3** by PBr_3 afforded compound **4** (29). A solution of 2'-bromo-2-bromomethylbiphenyl **4** (3.3 g, 10 mmol) in methanol (100 ml) was heated under reflux for 24 h. After solvent removal, light yellow liquid

compound was distilled from reaction mixture to obtain 2'-bromo-2-methoxymethylbiphenyl **5** (2.5 g, 90%) with the following parameters:

¹H NMR (400 MHz): δ 7.66-7.64 (1H, d, J = 8.2), 7.55-7.54 (1H, d, J = 7.2), 7.44-7.40 (1H, t), 7.37-7.34 (2H, m), 7.27-7.21 (2H, m), 7.16-7.14 (1H, d, J = 6.5), 4.29-4.26 (1H, d, J = 12.3), 4.17-4.14 (1H, d, J = 12.3), 3.25 (3H, s). ¹³C NMR (300 MHz): δ 141.8-141.4 (d), 140.8-140.2 (d), 136.1 (s), 135.4 (s), 132.5 (s), 131.1 (s), 130.0 (s), 129.6-129.0 (m), 128.1-128.1 (d), 127.9-127.2 (m), 127.1-127.0 (d), 123.6 (s), 72.4-72.0 (d), 58.2-58.1 (d). MS calculated for C₁₄H₁₃BrO: 277.1, found: 277.1.

The Grignard reagent was prepared from 2'-bromo-2-methoxymethylbiphenyl **5** (1.6 g, 5.8 mmol), Mg turnings (0.4 g) and trace amount of iodine in THF (20 mL). Then diphenylphosphinous chloride (1.91 g, 8.6 mmol) in THF (20 mL) was added under argon. The mixture was heated under reflux for 3 h. After addition of diluted HCl, compound was extracted with diethyl ether from aqueous solution. The ether phase was dried with Na₂SO₄ and solvent and some volatile part of residue was distilled. 2'-Diphenylphosphino-2-methoxymethylbiphenyl **6** was recrystallized from ethanol (380 mg, 15%).

The NMR parameters of **6**: ³¹P NMR (121.49 MHz): δ -13.76; ¹H NMR (400 MHz) δ 7.37-7.44 (1H, d, J = 7.70), 7.26-6.92 (16H, m), 6.75-6.72 (1H, d, J = 7.52), 4.02 (2H, s), 3.09 (3H, s).

2'-Diphenylphosphino-2-methoxymethylbiphenyl **6** (380 mg, 0.88 mmol) was dissolved in 10 mL HBr in glacial acetic acid and heated under reflux for 3 h. The solvent was removed and the 9,10-Dihydro-9,9-diphenyl-9-phosphoniaphenanthrene (*cyclo-o-MitoPh*) was recrystallized from ethyl acetate/ethanol (290 mg, 93%). The parameters for *cyclo-o-MitoPh* are as follows:

³¹P NMR (121.49 MHz): δ 12.68; ¹H NMR (300.13 MHz): δ 8.10-8.03 (2H, m), 7.93-7.80 (5H, m), 7.75-7.66 (3H, m), 7.64-7.52 (5H, m), 7.40-7.29 (3H, m); 5.25 (2H, d, J = 14.2). ¹³C NMR (300 MHz): δ 149.9 (s), 141.87 (s), 136.2 (d), 135.2 (d), 134.2 (s), 134.0 (s), 133.0 (s), 132.9 (s), 132.8 (s), 132.5 (s), 132.3 (s), 130.7 (s), 130.4 (s), 130.3 (s), 129.6 (s), 128.9 (s), 128.8 (s), 127.8 (s), 127.7 (s), 126.8-126.7 (d), 125.0 (s), 124.9 (s),

116.5 (s), 115.4 (s), 25.7 (s). MS calculated for C₂₅H₂₀P⁺: 351.1, found: 351.1.

HPLC analyses of the specific products formed from oxidation of probes – HPLC-based analyses of the products of oxidation of HE and CBA probes were carried out using Agilent 1100 system equipped with absorption and fluorescence detectors, as described elsewhere (7;8). Rapid simultaneous monitoring of superoxide and hydrogen peroxide was carried out as reported previously (8), but Supelco Ascentis Express Phenyl-Hexyl column (5 cm × 4.6 mm, 2.7 μm) was used. The compounds were eluted isocratically using mobile phase consisting of water (65%), acetonitrile (35%) and trifluoroacetic acid (0.1%) at the flow rate of 2 mL/min. The column temperature was set at 30 °C. Under these conditions the following probes and products were monitored: HE (0.30 min), 2-OH-E⁺ (0.60 min), E⁺ (0.67 min), E⁺-E⁺ (1.30 min), CBA (0.35 min) and COH (0.42 min). This method was also used in the rapid quantitative analyses of 2-OH-E⁺ or COH formation from HE or CBA in RAW 264.7 cells generating O₂^{·-} or ONOO⁻.

LC-MS/MS analyses of o-MitoPhB(OH)₂-derived products – Analyses of o-MitoPhB(OH)₂ and its oxidation/nitration products were performed as described recently (21;32). The method was modified for newly characterized products including *cyclo-o-MitoPh*, and deuterated analogs used as internal standards for quantitative analyses.

Dose response analyses – For determination of the apparent IC₅₀ values the dose response fitting application was used, as implemented in OriginPro 9.1.0 program (OriginLab Corporation). The equation used for the fitting was as follows:

$$y = A_1 + \frac{A_2 - A_1}{1 + 10^{(\log IC_{50} - \log c)p}}$$

where y is the measured quantity (proportional to Nox2 enzyme activity), A₁ and A₂ correspond to bottom and top asymptotes, p to Hill slope and c is the compound's concentration.

RESULTS

Overview of HTS/ROS Assays Used in the Identification of Nox Inhibitors – In order to reliably identify inhibitors of Nox isoforms, we developed the following primary and secondary assays for HTS/ROS analysis (Fig. 2), as recently

described (8). Hydropropidone (HPr^+) was used as a primary probe for extracellular O_2^- measurement (19). HPr^+ reacts with O_2^- ($k = 1.2 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$) to form a specific and diagnostic marker product, 2-hydroxypropidium (2-OH- Pr^{++}) (19). 2-OH- Pr^{++} fluorescence quantum yield is enhanced >10-fold in the presence of added DNA. Coumarin-7-boronic acid (CBA) was used as another primary assay probe for measuring H_2O_2 . CBA reacts with H_2O_2 (catalase-sensitive) considerably slower ($k = 1.5 \text{ M}^{-1}\text{s}^{-1}$), as compared to its catalase-insensitive reaction with ONOO^- ($k = 1.1 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$), to form a highly fluorescent product, 7-hydroxycoumarin (COH) (33). Over the duration of the reaction between CBA and H_2O_2 , there was significantly less spontaneous decomposition of CBA as compared to other boronate probes (33;34).

The addition of PMA (activator of PKC signaling pathway) to differentiated HL60 cells (overexpressing Nox2) in the presence of HPr^+ and DNA causes a linear increase in 2-OH- Pr^{++} fluorescence (O_2^- reaction) that was inhibited by SOD and not by catalase (Fig. 2). Concomitantly, there is an increase in COH fluorescence (H_2O_2 reaction with CBA) that is inhibited by catalase and not by SOD (Fig. 2).

In the secondary assay, we used the probe hydroethidine (HE) and detected 2-hydroxyethidium (2-OH-E $^+$) (specific product of HE reaction with O_2^-) using UHPLC (Fig. 2). For measuring H_2O_2 , the probe Amplex Red was used in the presence of HRP to monitor resorufin (formed from Amplex Red oxidation with $\text{H}_2\text{O}_2/\text{HRP}$) using a plate reader. The addition of PMA to differentiated HL60 cells in the presence of Amplex Red and HRP causes an increase in the fluorescence intensity of resorufin that is abrogated by catalase but not by SOD (Fig. 2). Under these conditions, O_2^- is detected by measuring 2-OH-E $^+$ (by HPLC) that was inhibited by SOD and not by catalase (Fig. 2). These assays provide the foundation for rigorous measurements of O_2^- and H_2O_2 using three different probes for high-throughput screening studies (8).

Screening the Library of Bioactive Compounds: Identification of Potential Nox2 Inhibitors—We applied the ROS/HTS assays, as discussed above, to screen a subset library of bioactive drugs as Nox2 inhibitors at the Broad Institute Probe Development Center. First, we

fulfilled the HTS assay “readiness” criteria for the primary and secondary assay probes (HPr^+ , CBA, and Amplex Red).

The list of 2,029 compounds, together with the results of screening of their normalized effects on Nox2 activity using HPr^+ , CBA and Amplex Red probes are shown in Supplemental Table 1. The stepwise protocol used in the HTS/ROS studies at Broad Institute is shown in Table 2. The effects of 2,029 compounds on O_2^- formation by monitoring the formation of 2-OH- Pr^{++} in PMA-activated differentiated HL-60 cells are shown in Figure 3. 2-OH- Pr^{++} formation in the presence of DMSO and phenylarsine oxide (1 μM) was normalized to 0% (no effect) and -100% (complete inhibition) (Fig. 3a). We set a 50% inhibition (indicated by a green dashed line) as a threshold criterion for a “hit” (Fig. 3a). Blue dots indicate compounds inhibiting 2-OH- Pr^{++} formation by >50% and red dots indicate compounds exhibiting <50% inhibition (Fig. 3a). Figure 3b shows the plate-to-plate comparison showing the reproducibility of data for each compound and the pie chart (*inset* in Fig. 3b) shows 63 out of 2,029 compounds exhibit >50% inhibition of 2-OH- Pr^{++} formation (blue chart with positive >50% inhibition in both plates). Figure 3, c and d show similar results for COH formation from CBA. One hundred fifty-four compounds from the screened library inhibited COH formation by >50% in both plates (Fig. 3d, *inset*). Corresponding results obtained using the Amplex Red probe measuring H_2O_2 are shown in Figure 3, e and f.

The three-dimensional hit correlation plot for all three assay probes, HPr^+ , CBA and Amplex Red is shown in Figure 4a. Of the 2,029 compounds tested, 49 compounds (2.4%, blue pie chart in Fig. 4b) were identified as “hits” with all three probes (Table 3), using 50% inhibition threshold. The color red corresponds to negative result for all three probes (-/-); magenta, for compounds that scored a positive result for a single probe (+/-); green for compounds that scored positively with two probes (+/+); and blue for positive results for all three probes (+/++). The list of “positive hits” shown in blue, together with the average extent of inhibition at ~30 μM concentration is shown (Table 3). This list contains FDA approved drugs that include dopamine receptor blockers and drugs used in the

treatment of schizophrenia, antimalarial, and antifungal agents. Some of these drugs have been previously used or identified as inhibitors of Nox isoforms (35;36). Interestingly, the compound, mitoxantrone, identified as the most potent inhibitor of Nox2 activity in dHL60 cells (Table 2) strongly inhibited pancreatic ductal adenocarcinoma survival (37). The positive hits were further evaluated in order to filter out *pan assay interference compounds* (38;39). Of the 49 hits, 9 were tested positive when screened against the library of the *pan assay interference compounds*, as defined in ref. (38) and shown in Table 3.

Confirmatory Assays: Dose Response and Oxygen Consumption Measurements— We confirmed the inhibitory effect of compounds selected from positive “hits” (Table 3) on Nox2 activity by determining their dose response. We screened over 20 commercially available compounds selected from Table 3 for the confirmatory assays. The apparent IC₅₀ values for inhibition of Nox2 activity in dHL60 model determined with a fluorescence plate reader using the CBA-based assay are shown in Table 4. Next, the effect of selected compounds on Nox2 activity was tested by HPLC-based simultaneous monitoring of O₂^{·-} and H₂O₂ (Fig. 5, *a* and *b*), by measuring oxygen consumption stimulated by Nox2 activation using the 96-well plate-based extracellular flux analyzer (Seahorse XF96, Fig. 5, *c* and *d*) and by monitoring the inhibitory effect on spin-trapped superoxide adduct using DEPMPO (*not shown*). Figure 5*a* shows the results of the confirmatory assays for selected compounds, sulconazole, mefloquine, cetylpyridinium cation, and DPI on formation of 2-hydroxyethidium, the specific marker product for O₂^{·-}. Similarly, Figure 5*b* shows the effect of these compounds on 7-hydroxycoumarin (COH), the product of the reaction of CBA probe with H₂O₂. The IC₅₀ values for these compounds to inhibit O₂^{·-} and H₂O₂ production also compare favorably with those measured using Nox2-mediated oxygen consumption. We next verified that at these concentrations sulconazole, mefloquine, and cetylpyridinium cation inhibited formation of the DEPMPO-superoxide adduct. All three compounds completely blocked formation of DEPPMPO-·OOH adduct, when used at 100 μM

for sulconazole and mefloquine or 10 μM with cetylpyridinium and DPI cations (data not shown).

Inhibition of Nox2 in Activated RAW264.7 Macrophages

Following the experiments on dHL60 cells, we tested whether the selected hits can also inhibit Nox2 activity in a different cellular model for Nox2 activity, namely PMA-stimulated RAW264.7 cells. Activation of RAW264.7 cells in the presence of hydroethidine probe led to a significant increase in the HPLC peak of 2-hydroxyethidium (monitored with a fluorescence detector) (Fig. 6*a*), as reported earlier (7). We measured the yield of 2-OH-E⁺ upon PMA-induced Nox2 activation in the presence of several compounds identified as apparent Nox2 inhibitors in dHL60 cells, with DPI used as a positive control for Nox2 inhibition. At these concentrations, all of the compounds tested decreased the intensity of the peak of 2-OH-E⁺ (Fig. 6*a*, fluorescence mode), confirming the ability of these compounds to inhibit Nox2 activity in intact cells. Quantitative analysis of the HPLC data (Fig. 6*b*) based on the use of authentic standards for 2-OH-E⁺, E⁺ and E⁺-E⁺ shows that the compounds inhibit the yield of 2-OH-E⁺, while having no effect on ethidium (E⁺), the non-specific oxidation product (with the exception of benzethonium cation), and variable effects on the one-electron oxidation dimeric product (diethidium, E⁺-E⁺). These results confirm that the HTS “hits” for Nox2 identified using the differentiated HL60 cells also inhibit O₂^{·-} formation from Nox2 in RAW 264.7 cells.

Do Nox2 Inhibitors also Inhibit Generation of Peroxynitrite?— Next, we tested whether the compounds listed in Table 4 that inhibit Nox2 activity in PMA-stimulated RAW 264.7 cells could also inhibit generation of peroxynitrite formed from O₂^{·-} and ·NO reaction in the same cellular model. RAW macrophages were stimulated to co-generate both ·NO and O₂^{·-} via activation of inducible nitric oxide synthase (iNOS) and Nox2 (using LPS, interferon-gamma, and phorbol ester), as reported earlier (7). CBA was used to monitor ONOO⁻ in cell-free systems and from activated macrophages by monitoring COH (catalase-insensitive) generation (7;20;33). Results show that several but not all Nox2 inhibitors identified from the screen of the bioactive library using dHL60 model inhibited ONOO⁻-dependent COH formed from CBA. Of

note, the compounds inhibiting ONOO^- formation in RAW 264.7 cells also inhibited Nox2 activity in these cells, as demonstrated in Figure 6. Figure 7b shows the dose-dependent inhibition of ONOO^- formed from activated macrophages in the presence of selected hits for Nox2 inhibition (e.g., DPI, sulconazole, mefloquine and cetylpyridinium). As shown, DPI potently inhibits ONOO^- formation with an IC_{50} of 0.4 μM . However, DPI being a non-selective inhibitor of flavoproteins may also block $^{\bullet}\text{NO}$ production by inhibition of iNOS. The IC_{50} values for sulconazole, mefloquine and cetylpyridinium cation to inhibit ONOO^- formation were determined to be 33, 36, and 4 μM , respectively. These values compare favorably with their IC_{50} values to inhibit O_2^- generation in PMA-stimulated RAW 264.7 cells (Fig. 7a) and dHL60 Nox2 model (Table 4). These results suggest that HTS/ROS assay with CBA can be used to identify novel inhibitors of ONOO^- formation as well.

Specific detection of a cyclized product during peroxynitrite reaction with ortho-substituted mitophenylboronic acid – Recently we developed a new probe, *o*-MitoPhB(OH)₂ that rapidly reacts with ONOO^- forming a minor product, *o*-MitoPhNO₂, that is very specific for ONOO^- (Fig. 8a) and is unaffected by glutathione or other biologically-relevant reductants (21;22). As this product is not fluorescent, we used HPLC with absorption detection for quantitative analyses and confirmed it is formed in RAW 264.7 cells in activated macrophages (22). However, using an LC-MS/MS method we found that this product (i.e., *o*-MitoPhNO₂) was detected in a relatively low yield (21). Quantitative analysis of the LC-MS data revealed an additional minor product ($m/z = 351$) formed during the reaction between *o*-MitoPhB(OH)₂ and ONOO^- . The same product was detected in extracts from RAW 264.7 cells, when activated to produce ONOO^- (see below). The structure of this product was assigned to *cyclo-o*-MitoPh (Fig. 8a, shown in red) formed by radical-induced intramolecular cyclization mechanism (Fig. 8a, minor radical pathway). This was supported by the observation that during the reaction of ONOO^- with *d*₁₅-*o*-MitoPhB(OH)₂ (with all protons on triphenylphosphonium moiety substituted by deuterium) the product with $m/z = 365$ amu is formed, indicating the loss of one deuterium atom. The identity of this product was

further verified by independent synthesis of *cyclo-o*-MitoPh (Fig. 9a), and structure confirmed by mass spectrometry, NMR and X-ray crystallography (Fig. 9b). The LC-MS/MS parameters (retention time, m/z value, ms/ms fragmentation pattern) of the minor product of *o*-MitoPhB(OH)₂ reaction with authentic ONOO^- were identical to those of the authentic *cyclo-o*-MitoPh (Fig. 8, a and c). The specificity of this product was tested using other oxidants (H_2O_2 , HOCl) which are known to oxidize boronic compounds and comparing the product identities and distribution (Fig. 8, b and c). Consistently with our previous research on the chemical reactivity of boronic compounds (20;32;40), the reaction between *o*-MitoPhB(OH)₂ and H_2O_2 yielded a single phenolic product (*o*-MitoPhOH), while additional minor products were detected with HOCl and ONOO^- . In addition to cyclized (*cyclo-o*-MitoPh) and nitrated (*o*-MitoPhNO₂) products, products of nitration of *o*-MitoPhOH were also formed in the presence of excess ONOO^- . These products showed up at the m/z value of 414, and were assigned to isomers of *o*-MitoPh(NO₂)OH (Fig. 8a) (22). In addition, a small amount of the protonated form of triphenylphosphonium oxide (TPP=O, $m/z=279$) was also detected. With HOCl, the minor product observed (using excess of HOCl) is chlorinated phenol *o*-MitoPh(Cl)OH (Fig. 8a), showing up as a double peak attributed to two isomers. Interestingly, other oxidation products, including triphenylphosphine oxide and brominated phenolic product (*o*-MitoPh(Br)OH) were also formed (Fig. 8). While triphenylphosphine oxide formation can be explained by a nucleophilic attack of ClO^- on the phosphorus atom of the triphenylphosphonium moiety, the brominated phenolic product indicates formation of HOBr via oxidation of the bromide anion [present as a counterion of *o*-MitoPhB(OH)₂ probe] by HOCl (41;42). To test if *o*-MitoPhB(OH)₂ can distinguish between peroxynitrite and myeloperoxidase (MPO)-mediated oxidation/nitration, we determined the products formed by MPO in the presence of hydrogen peroxide, with or without nitrite (Fig. 10a). The results indicate that both *cyclo-o*-MitoPh and *o*-MitoPhNO₂ products are specific for ONOO^- , while MPO in the presence of nitrite leads to nitration of the phenolic product, formed from oxidation of *o*-MitoPhB(OH)₂ by H_2O_2 . The

quantitative analysis of the oxidation/nitration of *o*-MitoPhB(OH)₂ by ONOO⁻ indicates that yields of the minor, specific products, *cyclo-o*-MitoPh and *o*-MitoPhNO₂ are 10.5 ± 0.5% and 0.5 ± 0.1%, respectively (Fig. 10b). In the case of MPO-mediated oxidation in the presence of sodium nitrite, the major product seems to be nitrated phenols (*o*-MitoPh(NO₂)OH). The other product detected was triphenylphosphine oxide, formed by MPO/H₂O₂ system both in the absence and presence of nitrite (*not shown*).

Next we investigated the formation of peroxynitrite-specific products in activated macrophages and the effect of selected Nox2 inhibitors on the reaction products of *o*-MitoPhB(OH)₂ and ONOO⁻ (Fig. 11). We have shown previously that stimulation of RAW 264.7 cells leads to formation of *o*-MitoPhOH and small amounts of *o*-MitoPhNO₂ (21;22). As shown in Figure 11, the most exclusive minor product detected in cells was the cyclized product, *cyclo-o*-MitoPh. In fact, the amount of *o*-MitoPhNO₂ formed in cells is less than 5% of the yield of *cyclo-o*-MitoPh (Fig. 11c). The analysis of the effect of inhibitors on the yield of the major, phenolic oxidation product of *o*-MitoPhB(OH)₂ give mixed results, with mefloquine actually increasing the yield of this product. This suggests the possibility of multiple pathways of the formation and/or metabolism of the phenolic product inside the cells. On the other hand, results show that selected candidate Nox2 inhibitors, including cetylpyridinium, sulconazole, mefloquine and DPI inhibit formation of *cyclo-o*-MitoPh and *o*-MitoPhNO₂, the diagnostic products for ONOO⁻ (Fig. 11c). This is consistent with the results of measurements of extracellular ONOO⁻ (Fig. 7b) and further demonstrates the added value of determining the specific minor product(s) for ONOO⁻ reaction with *o*-MitoPhB(OH)₂.

DISCUSSION

Significance of Nox Inhibition— Nox enzyme-derived ROS/RNS are now recognized to play a central role in both inflammatory and fibrotic diseases (1;2). The former includes both classical inflammatory conditions (e.g., arthritis, inflammatory bowel disease) and nonclassical conditions in which inflammation plays a central pathogenic role. For example, inflammatory lung

diseases include ARDS (acute respiratory distress syndrome), asthma, and COPD (chronic obstructive pulmonary disease), while other inflammatory conditions include Alzheimer's and Parkinson's diseases, ischemic stroke, and organ reperfusion injury during transplantation (43). Fibrotic diseases include liver fibrosis (e.g., following viral infection), idiopathic pulmonary fibrosis, and diabetic kidney disease. Nox2 has been implicated in inflammatory diseases, and Nox4 in fibrotic diseases (1;2). Existing therapies for both classes of diseases include steroids and other anti-inflammatory approaches, but have proven to be ineffective. Therefore, there is a need for developing novel anti-inflammatory and antifibrotic agents based on other molecular targets. Nox enzymes are especially promising in this regard due to mounting evidence in humans and in other experimental models (44). Peroxynitrite, the product of diffusion-controlled reaction of nitric oxide and superoxide, has been implicated in several inflammatory diseases (15), including neurodegenerative diseases and chemotherapy-induced nephrotoxicity (45). Recent data also suggest the involvement of ONOO⁻ in traumatic brain injury-induced neurodegeneration via activation of calpain in neurons (46;47).

It has been proposed that Nox2-derived ROS/RNS from myeloid-derived suppressor cells in the tumor microenvironment are potentially responsible for decreased T cell reactivity and immunosuppressive effects (48). In this regard, small molecular weight compounds that inhibit Nox2 activity could play a vital role in providing additional mechanistic insight on immune system in tumor microenvironment. The role of Nox/ROS in biology is paradoxical (49). High levels of O₂⁻ generated from Nox2 are essential for cell killing and host defense, whereas in other cells, low levels of ROS (O₂⁻ and H₂O₂ or both) generated from Nox are important for cell signaling (e.g., NF-κB activation). Nox inhibitors effectively abrogated proliferation of various cancer cell models (50). Preliminary results show that several compounds identified as potential Nox2 inhibitors (Table 4) significantly inhibit proliferation of human pancreatic cancer cells (*not shown*). It is likely that follow-up studies will greatly improve the potency and selectivity of hit compounds using medicinal chemistry. Although the present study is restricted to the Nox2 isoform, future investigations will

broaden the scope of work to include other Nox isoforms using the appropriate HTS-compatible cell lines.

HTS/ROS/RNS Assay – ROS/RNS do not represent a single entity, but encompass a wide range of reactive species that exhibit oxidizing, nitrating, nitrosating, and halogenating properties (51;52). To better understand the pathophysiological consequences of ROS/RNS, it is crucial to identify and characterize the species that are specifically responsible for a given “biologic and toxicologic” effect, and to inhibit the specific sources of ROS/RNS generation (53). Doxorubicin, one of the most widely used chemotherapeutics, causes myocardial inflammation that is attributed to Nox-induced ROS/RNS formation in inflammatory cells (54–56). Genetic disruption of Nox2 mitigated doxorubicin-mediated contractile dysfunction, oxidative/nitrative stress, and inflammation (56). Thus, selective targeting of Nox2 may provide a novel therapeutic strategy for mitigation of ROS/RNS and cardiotoxic side effects, while maximizing its antitumor efficacy (56). To date, only a limited number of Nox isoform selective inhibitors are available (57;58). This is in part due to serious limitations of the existing ROS/RNS assays as described below.

Previous approaches have used sensitive but nonselective and artifact-prone ROS/RNS probes (59) for detecting Nox-derived oxidants, resulting in a high rate of false positives, and potentially missing weaker but selective hits lost in the “noise”. Many HTS-based H₂O₂ assays to detect Nox inhibitors included the enzyme, HRP. The lack of probes’ selectivity for specific oxidant and susceptibility of the HTS assays to peroxidase substrates and inhibitors led to the controversy over the Nox-inhibitory potency of the positive hits selected, including apocynin, VAS2870 and 2-acetylphenothiazine (36;60;61). In fact, one of the authors recently reported new myeloperoxidase inhibitor, identified during the HTS campaign for Nox2 inhibitors, using L-012 probe as Nox2 activity reporter (62). Using the present HTS/ROS approach, it is conceivable that false positives will be decreased by >75%, with the assay specificity allowing identification of weaker inhibitors which can later be improved through medicinal chemistry. In this work, we describe the use of ROS/RNS-specific probes whose redox chemistry

is better understood with respect to reaction kinetics, stoichiometry and reaction products (63). Selective monitoring of specific ROS in HTS assay is important. For example, these HTS assays can be extended to other cell types to gain new insight regarding enzymatic sources of ROS generation and subsequently unravel the role of ROS in disease-related biological processes. It is conceivable that a similar HTS/ROS assay may be used to identify inhibitors of other oxidants (e.g., hypochlorous acid) and their sources of generation using other fluorescent probes (Table 1).

In this study we identified new, oxidant-specific, products of the reaction of *o*-MitoPhB(OH)₂ with ONOO[−] and HOCl (Fig. 8). In the presence of the excess oxidant, the major, phenolic product undergoes nitration or chlorination reaction, respectively, leading to isomeric nitro- or chloro- derivatives of MitoPhOH. Also, in the presence of HOBr, analogous products [i.e., MitoPh(Br)OH] are formed. With excess ONOO[−] or HOCl, the triphenylphosphine oxide was also formed (Fig. 8). Interestingly, with peroxynitrite, the most exclusive minor product, *cyclo-o*-MitoPh, was formed even when the probe was present in excess of the oxidant. The lack of effect of biologically relevant reductants (GSH, NADH) and low efficiency of trapping of the phenyl radical (22) may be explained by rapid intramolecular cyclization due to addition of the phenyl radical to the benzene ring of the triphenylphosphonium moiety (Fig. 8a). As this product is not formed with any other oxidant or nitrating agent tested, it can serve as a specific diagnostic product of ONOO[−], and should be used as the ultimate proof of peroxynitrite intermediacy.

Inhibitory Mechanism of Nox2 Positive Hits on ROS Formation – Screening of the library of over 2000 bioactive compounds generated relatively high amount positive hits, with the lowest yield (3.1%) using the hydropropidine-based assay. This was expected, as the compounds tested show a variety of biological activities and do not predominantly target NADPH oxidase. However, screening of a large, chemically-diverse library of compounds will produce significantly lower yield of active compounds. The HTS-compatibility of the three assays (HPr⁺, CBA and Amplex Red-based) and the use of rapid HPLC analyses in the 384-well plate format will enable

rapid, orthogonal screenings to filter out false-positives. Additionally, the use of chemical structure-based filters to remove *pan assay interference compounds* should further decrease the amount of compounds selected for post-screening studies/hit optimization process.

HL60 cells differentiated into a neutrophil-like phenotype by DMSO or ATRA exhibited high expression of Nox2 as confirmed by Western blotting of both membrane-bound gp91^{phox} and cytosolic p47^{phox} subunits (8). The differentiated cells were compared with nondifferentiated cells in their response to PMA, an activator of protein kinase C, leading to the phosphorylation of the p47^{phox} cytosolic subunit, which, in turn, binds to p22^{phox} membrane protein. After the assembly of all cytosolic and membrane components, NADPH is oxidized, and its electrons are transferred to oxygen, generating O₂[•]. Small molecules can inhibit O₂[•] and H₂O₂ by targeting specific steps of Nox activation; Nox expression, ligand receptor binding, trafficking of Nox components to cell membrane, activation and assembly of Nox complex, NADPH binding and electron transfer from the active site of the enzyme (64). In order to identify target of inhibition of Nox2, it is essential to perform a comprehensive analysis of phosphorylation of proteins of the regulatory subunits and the effect of inhibitors on phosphorylation and translocation of the cytosolic subunits to the membrane. These aspects will be a part of our future research. Some of the Nox2 inhibitors (e.g., promazines) identified in this work have previously been shown to block Nox2

activity in cell-free assays (36). Of added significance is the fact that selected hits also affect basal mitochondrial respiration in dHL60 cells (Fig. 5, *c* and *d*). Whereas sulconazole inhibits PMA response (Nox2 activation) and basal respiration similarly, other compounds are more selective in their inhibition of Nox2 activity, with little or less pronounced inhibition of mitochondrial function at selected concentrations. While the inhibition of basal mitochondrial respiration and Nox2 activity may be linked, the inhibition of mitochondrial respiration *per se* is unlikely to block Nox2 activity. In fact, we have previously shown that rotenone, an inhibitor of mitochondrial complex I, inhibits basal mitochondrial respiration in dHL60 cells, without affecting the Nox2 activity, as measured by PMA-stimulated increase in the rate of oxygen consumption (8). It is also worth noting that DPI, a non-selective inhibitor of flavoenzymes, inhibits Nox2 activity at significantly lower concentration (0.1 μM) than required for inhibiting the basal mitochondrial respiration (\approx 1 μM) (Fig. 5*d*).

The proposed method of high-throughput screening of Nox inhibitors in intact cells will likely yield many positive hits that affect the Nox enzyme indirectly, as discussed above. The detailed mechanistic studies may provide new information on the pathways/factors controlling Nox enzyme activity and yield potentially new inhibitors for clinical trials, based on drug repurposing strategy.

Acknowledgments: This work was supported by National Institutes of Health grant R01 HL073056 (to B.K.). LC-MS/MS analyses were performed at the Cancer Center Bioenergetics Shared Resource at the Medical College of Wisconsin. The work at the Broad Institute was supported in part by Molecular Libraries Probe Development Network grant U54 HG005032.

Conflict of interest: The authors declare that they have no conflicts of interest with the contents of this article.

Author contributions: BK conceived and coordinated the study and wrote the paper. JZ designed, performed, analyzed and interpreted the data, prepared the figures, and revised the paper critically. MZ performed the experiments and provided the technical assistance. GC designed and performed the Seahorse experiments and obtained cell proliferation data. MH and MMA synthesized hydropropidine and *cyclo-o*-MitoPh product, respectively. OO provided assistance in these syntheses and structure analyses. RP synthesized *o*-MitoPhB(OH)₂, its oxidation/nitration products and corresponding deuterated analogs. AS helped in characterization of minor products of *o*-MitoPhB(OH)₂ oxidation. JDL revised the manuscript for intellectual content. LV provided training, assisted in screening of the bioactive libraries at

Broad Institute and performed first pass analysis of the screening results. All authors reviewed the results and approved the final version of the manuscript.

REFERENCES

1. Bulua, A. C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K. Y., Sack, M. N., Kastner, D. L., and Siegel, R. M. (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). *J. Exp. Med.* **208**, 519-533
2. Hecker, L., Cheng, J., and Thannickal, V. J. (2012) Targeting NOX enzymes in pulmonary fibrosis. *Cell Mol. Life Sci.* **69**, 2365-2371
3. Leto, T. L., Morand, S., Hurt, D., and Ueyama, T. (2009) Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. *Antioxid. Redox. Signal.* **11**, 2607-2619
4. Lambeth, J. D. (2004) NOX enzymes and the biology of reactive oxygen. *Nat. Rev. Immunol.* **4**, 181-189
5. Nisimoto, Y., Diebold, B. A., Cosentino-Gomes, D., and Lambeth, J. D. (2014) Nox4: a hydrogen peroxide-generating oxygen sensor. *Biochemistry* **53**, 5111-5120
6. Altenhofer, S., Radermacher, K. A., Kleikers, P. W., Wingler, K., and Schmidt, H. H. (2015) Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. *Antioxid. Redox. Signal.* **23**, 406-427
7. Zielonka, J., Zielonka, M., Sikora, A., Adamus, J., Joseph, J., Hardy, M., Ouari, O., Dranka, B. P., and Kalyanaraman, B. (2012) Global profiling of reactive oxygen and nitrogen species in biological systems: high-throughput real-time analyses. *J. Biol. Chem.* **287**, 2984-2995
8. Zielonka, J., Cheng, G., Zielonka, M., Ganesh, T., Sun, A., Joseph, J., Michalski, R., O'Brien, W. J., Lambeth, J. D., and Kalyanaraman, B. (2014) High-throughput assays for superoxide and hydrogen peroxide: design of a screening workflow to identify inhibitors of NADPH oxidases. *J. Biol. Chem.* **289**, 16176-16189
9. Daiber, A., August, M., Baldus, S., Wendt, M., Oelze, M., Sydow, K., Kleschyov, A. L., and Munzel, T. (2004) Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012. *Free Radic. Biol. Med.* **36**, 101-111
10. Zielonka, J., Lambeth, J. D., and Kalyanaraman, B. (2013) On the use of L-012, a luminol-based chemiluminescent probe, for detecting superoxide and identifying inhibitors of NADPH oxidase: a reevaluation. *Free Radic. Biol. Med.* **65**, 1310-1314
11. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc. Natl. Acad. Sci. U. S. A.* **87**, 1620-1624
12. Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. *J. Biol. Chem.* **266**, 4244-4250

13. Beckman, J. S. (2009) Understanding peroxynitrite biochemistry and its potential for treating human diseases. *Arch. Biochem. Biophys.* **484**, 114-116
14. Al, G., I, Khoo, N. K., Knaus, U. G., Griendlung, K. K., Touyz, R. M., Thannickal, V. J., Barchowsky, A., Nauseef, W. M., Kelley, E. E., Bauer, P. M., Darley-Usmar, V., Shiva, S., Cifuentes-Pagano, E., Freeman, B. A., Gladwin, M. T., and Pagano, P. J. (2011) Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. *Free Radic. Biol. Med.* **51**, 1271-1288
15. Pacher, P., Beckman, J. S., and Liaudet, L. (2007) Nitric oxide and peroxynitrite in health and disease. *Physiol. Rev.* **87**, 315-424
16. Ye, Y., Quijano, C., Robinson, K. M., Ricart, K. C., Strayer, A. L., Sahawneh, M. A., Shacka, J. J., Kirk, M., Barnes, S., Accavitti-Loper, M. A., Radi, R., Beckman, J. S., and Estevez, A. G. (2007) Prevention of peroxynitrite-induced apoptosis of motor neurons and PC12 cells by tyrosine-containing peptides. *J. Biol. Chem.* **282**, 6324-6337
17. Guzik, T. J. and Harrison, D. G. (2006) Vascular NADPH oxidases as drug targets for novel antioxidant strategies. *Drug Discov. Today* **11**, 524-533
18. Cifuentes-Pagano, E., Meijles, D. N., and Pagano, P. J. (2014) The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls. *Antioxid. Redox. Signal.* **20**, 2741-2754
19. Michalski, R., Zielonka, J., Hardy, M., Joseph, J., and Kalyanaraman, B. (2013) Hydropropidone: a novel, cell-impermeant fluorogenic probe for detecting extracellular superoxide. *Free Radic. Biol. Med.* **54**, 135-147
20. Zielonka, J., Sikora, A., Hardy, M., Joseph, J., Dranka, B. P., and Kalyanaraman, B. (2012) Boronate probes as diagnostic tools for real time monitoring of peroxynitrite and hydroperoxides. *Chem. Res. Toxicol.* **25**, 1793-1799
21. Zielonka, J., Sikora, A., Adamus, J., and Kalyanaraman, B. (2015) Detection and differentiation between peroxynitrite and hydroperoxides using mitochondria-targeted arylboronic acid. *Methods Mol. Biol.* **1264**, 171-181
22. Sikora, A., Zielonka, J., Adamus, J., Debski, D., Dybala-Defratyka, A., Michalowski, B., Joseph, J., Hartley, R. C., Murphy, M. P., and Kalyanaraman, B. (2013) Reaction between peroxynitrite and triphenylphosphonium-substituted arylboronic acid isomers: identification of diagnostic marker products and biological implications. *Chem. Res. Toxicol.* **26**, 856-867
23. Zhao, H., Joseph, J., Fales, H. M., Sokoloski, E. A., Levine, R. L., Vasquez-Vivar, J., and Kalyanaraman, B. (2005) Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 5727-5732
24. Zielonka, J., Vasquez-Vivar, J., and Kalyanaraman, B. (2008) Detection of 2-hydroxyethidium in cellular systems: a unique marker product of superoxide and hydroethidine. *Nat. Protoc.* **3**, 8-21
25. Teufelhofer, O., Weiss, R. M., Parzefall, W., Schulte-Hermann, R., Micksche, M., Berger, W., and Elbling, L. (2003) Promyelocytic HL60 cells express NADPH oxidase and are excellent

- targets in a rapid spectrophotometric microplate assay for extracellular superoxide. *Toxicol. Sci.* **76**, 376-383
26. Seitz, P. M., Cooper, R., Gatto, G. J., Jr., Ramon, F., Sweitzer, T. D., Johns, D. G., Davenport, E. A., Ames, R. S., and Kallal, L. A. (2010) Development of a high-throughput cell-based assay for superoxide production in HL-60 cells. *J. Biomol. Screen.* **15**, 388-397
 27. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J. Biomol. Screen.* **4**, 67-73
 28. Nicholls, D. G., rley-Usmar, V. M., Wu, M., Jensen, P. B., Rogers, G. W., and Ferrick, D. A. (2010) Bioenergetic profile experiment using C2C12 myoblast cells. *J. Vis. Exp.* **46**, pii:2511
 29. Oba, M., Iida, M., and Nishiyama, K. (2001) Generation and Reactions of Transient 9-Silaphenanthrene Derivative. *Organometallics* **20**, 4287-4290
 30. Cookson, E. A. and Crofts, P. C. (1966) Phosphorus heterocycles. Part I. A conjugated cyclic methylenephosphorane. *J. Chem. Soc. C*, 2003-2005
 31. Goy, R., Apfel, U. P., Elleouet, C., Escudero, D., Elstner, M., Görls, H., Talarmin, J., Schollhammer, P., González, L., and Weigand, W. (2013) A Silicon-Heteroaromatic System as Photosensitizer for Light-Driven Hydrogen Production by Hydrogenase Mimics. *Eur. J. Inorg. Chem.* **2013**, 4466-4472
 32. Sikora, A., Zielonka, J., Lopez, M., Dybala-Defratyka, A., Joseph, J., Marcinek, A., and Kalyanaraman, B. (2011) Reaction between peroxy nitrite and boronates: EPR spin-trapping, HPLC Analyses, and quantum mechanical study of the free radical pathway. *Chem. Res. Toxicol.* **24**, 687-697
 33. Zielonka, J., Sikora, A., Joseph, J., and Kalyanaraman, B. (2010) Peroxynitrite is the major species formed from different flux ratios of co-generated nitric oxide and superoxide: direct reaction with boronate-based fluorescent probe. *J. Biol. Chem.* **285**, 14210-14216
 34. Van de Bittner, G. C., Dubikovskaya, E. A., Bertozzi, C. R., and Chang, C. J. (2010) In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 21316-21321
 35. Cohen, H. J., Chovaniec, M. E., and Ellis, S. E. (1980) Chlorpromazine inhibition of granulocyte superoxide production. *Blood* **56**, 23-29
 36. Seredenina, T., Chiriano, G., Filippova, A., Nayernia, Z., Mahiout, Z., Fioraso-Cartier, L., Plastre, O., Scapozza, L., Krause, K. H., and Jaquet, V. (2015) A subset of N-substituted phenothiazines inhibits NADPH oxidases. *Free Radic. Biol. Med.* **86**, 239-249
 37. Burkhardt, R. A., Peng, Y., Norris, Z. A., Tholey, R. M., Talbott, V. A., Liang, Q., Ai, Y., Miller, K., Lal, S., Cozzitorto, J. A., Witkiewicz, A. K., Yeo, C. J., Gehrmann, M., Napper, A., Winter, J. M., Sawicki, J. A., Zhuang, Z., and Brody, J. R. (2013) Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. *Mol. Cancer Res.* **11**, 901-911

38. Baell, J. B. and Holloway, G. A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *J. Med. Chem.* **53**, 2719-2740
39. Baell, J. and Walters, M. A. (2014) Chemistry: Chemical con artists foil drug discovery. *Nature* **513**, 481-483
40. Sikora, A., Zielonka, J., Lopez, M., Joseph, J., and Kalyanaraman, B. (2009) Direct oxidation of boronates by peroxynitrite: mechanism and implications in fluorescence imaging of peroxynitrite. *Free Radic. Biol. Med.* **47**, 1401-1407
41. Ximenes, V. F., Morgan, N. H., and de Souza, A. R. (2015) Hypobromous acid, a powerful endogenous electrophile: Experimental and theoretical studies. *J. Inorg. Biochem.* **146**, 61-68
42. Kumar, K. and Margerum, D. W. (1987) Kinetics and mechanism of general-acid-assisted oxidation of bromide by hypochlorite and hypochlorous acid. *Inorg. Chem.* **26**, 2706-2711
43. Drummond, G. R., Selemidis, S., Griendling, K. K., and Sobey, C. G. (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. *Nat. Rev. Drug Discov.* **10**, 453-471
44. Jaquet, V., Scapozza, L., Clark, R. A., Krause, K. H., and Lambeth, J. D. (2009) Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. *Antioxid. Redox Signal.* **11**, 2535-2552
45. Mukhopadhyay, P., Horvath, B., Zsengeller, Z., Zielonka, J., Tanchian, G., Holovac, E., Kechrid, M., Patel, V., Stillman, I. E., Parikh, S. M., Joseph, J., Kalyanaraman, B., and Pacher, P. (2012) Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. *Free Radic. Biol. Med.* **52**, 497-506
46. Deng, Y., Thompson, B. M., Gao, X., and Hall, E. D. (2007) Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury. *Experimental Neurology* **205**, 154-165
47. Khan, M., Dhammu, T. S., Matsuda, F., Annamalai, B., Dhindsa, T. S., Singh, I., and Singh, A. K. (2016) Targeting the nNOS/peroxynitrite/calpain system to confer neuroprotection and aid functional recovery in a mouse model of TBI. *Brain Res.* **1630**, 159-170
48. Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., and Gabrilovich, D. I. (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. *J. Immunol.* **182**, 5693-5701
49. Holmstrom, K. M. and Finkel, T. (2014) Cellular mechanisms and physiological consequences of redox-dependent signalling. *Nat. Rev. Mol. Cell Biol.* **15**, 411-421
50. Bonner, M. Y. and Arbiser, J. L. (2012) Targeting NADPH oxidases for the treatment of cancer and inflammation. *Cell Mol. Life Sci.* **69**, 2435-2442
51. Winterbourn, C. C. (2008) Reconciling the chemistry and biology of reactive oxygen species. *Nat. Chem. Biol.* **4**, 278-286

52. Kalyanaraman, B. (2013) Teaching the basics of redox biology to medical and graduate students: Oxidants, antioxidants and disease mechanisms. *Redox Biol.* **1**, 244-257
53. Murphy, M. P., Holmgren, A., Larsson, N. G., Halliwell, B., Chang, C. J., Kalyanaraman, B., Rhee, S. G., Thornalley, P. J., Partridge, L., Gems, D., Nystrom, T., Belousov, V., Schumacker, P. T., and Winterbourn, C. C. (2011) Unraveling the biological roles of reactive oxygen species. *Cell Metab.* **13**, 361-366
54. Bendall, J. K., Cave, A. C., Heymes, C., Gall, N., and Shah, A. M. (2002) Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. *Circulation* **105**, 293-296
55. Mukhopadhyay, P., Rajesh, M., Batkai, S., Kashiwaya, Y., Hasko, G., Liaudet, L., Szabo, C., and Pacher, P. (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. *Am. J. Physiol Heart Circ. Physiol* **296**, H1466-H1483
56. Zhao, Y., McLaughlin, D., Robinson, E., Harvey, A. P., Hookham, M. B., Shah, A. M., McDermott, B. J., and Grieve, D. J. (2010) Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy. *Cancer Res.* **70**, 9287-9297
57. Borbely, G., Szabadkai, I., Horvath, Z., Marko, P., Varga, Z., Breza, N., Baska, F., Vantus, T., Huszar, M., Geiszt, M., Hunyady, L., Buday, L., Orfi, L., and Keri, G. (2010) Small-molecule inhibitors of NADPH oxidase 4. *J. Med. Chem.* **53**, 6758-6762
58. Wind, S., Beuerlein, K., Eucker, T., Muller, H., Scheurer, P., Armitage, M. E., Ho, H., Schmidt, H. H., and Wingler, K. (2010) Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. *Br. J. Pharmacol.* **161**, 885-898
59. Gianni, D., Taulet, N., Zhang, H., DerMardirossian, C., Kister, J., Martinez, L., Roush, W. R., Brown, S. J., Bokoch, G. M., and Rosen, H. (2010) A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. *ACS Chem. Biol.* **5**, 981-993
60. Heumuller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H., Busse, R., Schroder, K., and Brandes, R. P. (2008) Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. *Hypertension* **51**, 211-217
61. Hirano, K., Chen, W. S., Chueng, A. L., Dunne, A. A., Seredenina, T., Filippova, A., Ramachandran, S., Bridges, A., Chaudry, L., Pettman, G., Allan, C., Duncan, S., Lee, K. C., Lim, J., Ma, M. T., Ong, A. B., Ye, N. Y., Nasir, S., Mulyanidewi, S., Aw, C. C., Oon, P. P., Liao, S., Li, D., Johns, D. G., Miller, N. D., Davies, C. H., Browne, E. R., Matsuoka, Y., Chen, D. W., Jaquet, V., and Rutter, A. R. (2015) Discovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor. *Antioxid. Redox. Signal.* **23**, 358-374
62. Li, Y., Ganesh, T., Diebold, B. A., Zhu, Y., McCoy, J. W., Smith, S. M., Sun, A., and Lambeth, J. D. (2015) Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase. *ACS Med. Chem. Lett.* **6**, 1047-1052
63. Kalyanaraman, B., Darley-Usmar, V., Davies, K. J., Dennery, P. A., Forman, H. J., Grisham, M. B., Mann, G. E., Moore, K., Roberts, L. J., and Ischiropoulos, H. (2012) Measuring reactive

- oxygen and nitrogen species with fluorescent probes: challenges and limitations. *Free Radic. Biol. Med.* **52**, 1-6
64. Streeter, J., Thiel, W., Brieger, K., and Miller, F. J., Jr. (2013) Opportunity Nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. *Cardiovasc. Ther.* **31**, 125-137

FIGURE LEGENDS

FIGURE 1. Generation of reactive oxygen and reactive nitrogen species from NADPH oxidase and nitric oxide synthase, and their abrogation by Nox inhibitors and ROS/RNS scavengers.

FIGURE 2. Detection of superoxide and hydrogen peroxide generated from Nox2. Primary and secondary assays. (a) Increase in fluorescence intensity due to formation of superoxide-specific product, 2-OH-Pr⁺⁺, in dHL60 cells activated by PMA. (b) Increase in fluorescence intensity due to catalase-sensitive H₂O₂ oxidation product, COH, in dHL60 cells and PMA. (c) Increase in fluorescence intensity due to formation of resorufin. (d) HPLC chromatogram of 2-OH-E⁺, the specific product of HE and O₂^{•-}, in control and PMA-activated dHL60 cells in the presence of SOD and CAT [adapted from ref. (8)].

FIGURE 3. Results of screening of a library of bioactive compounds (\approx 2,000) using three probes: hydropropidine (50 μ M) in the presence of DNA (0.1 mg/ml) as a probe for O₂^{•-} (a and b); and coumarin boronic acid (100 μ M, c and d) or Amplex Red (50 μ M) in the presence of HRP (0.1 U/ml, e and f) as probes for H₂O₂. dHL60 cells were stimulated with PMA (1 μ M) to induce Nox2 activity in HBSS medium supplemented with HEPES buffer (25 mM) and dtpa (0.1 mM). (a, c, and e) Schemes of oxidation of the probes and the results of screening after normalization. (b, d, and f) Plate-to-plate reproducibility data and number of negative/inconclusive/positive hits for each assay. Score “0” (red color) corresponds to *negative*, “1” (green color) to *inconclusive* and “2” (blue color) to *positive* hits.

FIGURE 4. Results of screening of a library of bioactive compounds (\approx 2,000) using three probes: hydropropidine (50 μ M) in the presence of DNA (0.1 mg/ml) as a probe for O₂^{•-}; and coumarin boronic acid (100 μ M) or Amplex Red (50 μ M) in the presence of HRP (0.1 U/ml) as probes for H₂O₂. (a) Correlation of the results of the three assays for Nox2 activity. (b) Results of screening as a percentage of positive hits in one, two or all three assays. All experimental conditions are as described in Figure 3.

FIGURE 5. Results of confirmatory assays for selected positive hits from Nox2 inhibitor screening. Dose response results of four selected inhibitors of Nox2 on 2-OH-E⁺ (a) and COH (b) formation in PMA-activated dHL60 cells, using the HPLC-based assay for simultaneous monitoring of O₂^{•-} and H₂O₂. (c) The effect of the same four inhibitors on oxygen consumption (mitochondrial respiration and NADPH oxidase activation) measured using the Seahorse extracellular flux analyzer. Concentrations of inhibitors: DPI, 0.1 μ M; sulconazole, 30 μ M; mefloquine, 30 μ M; cetylpyridinium chloride, 10 μ M. (d) Dose-dependent response to the same four inhibitors on basal mitochondrial respiration (Δ OCR_{Basal}, shown in blue) and the NADPH activation by PMA injection (Δ OCR_{PMA}, shown in red).

FIGURE 6. Effect of selected hits on HE oxidation profiles in PMA-stimulated RAW 264.7 macrophages. (a) HPLC chromatograms at 290 nm (absorption detector) and the HPLC fluorescence traces (excitation/emission wavelengths, as shown). (b) Quantitative analyses of intracellular levels of HE and its oxidation products, after normalization to protein level. Concentrations of agents: PMA, 1 μ M; DPI, 1 μ M; sulconazole, 100 μ M; mefloquine, 100 μ M; cetylpyridinium chloride, 10 μ M; benzethonium chloride, 100 μ M; hexachlorophene, 100 μ M.

FIGURE 7. Inhibition of O₂^{•-} and ONOO⁻ formation from activated RAW 264.7 cells by selected positive hits: sulconazole, mefloquine, cetylpyridinium chloride and DPI. Cells were treated with inhibitors for 30 min in DPBS containing glucose and pyruvate followed by addition of PMA (1 μ M) and the probe and incubated for 1 h at 37 °C. After incubation, the extracellular media were analyzed for 2-OH-E⁺ or COH levels using a rapid HPLC method. (a) RAW 264.7 cells were stimulated with PMA (1 μ M) in the presence of HE (10 μ M). (b) RAW 264.7 cells were pretreated overnight with LPS (0.5 μ g/ml) and IFN γ (50 units/ml) and stimulated with PMA (1 μ M) in the presence of CBA (100 μ M).

FIGURE 8. Detection and characterization of specific products from the probe, *o*-MitoPhB(OH)₂. (a) Proposed mechanism of oxidation of *o*-MitoPhB(OH)₂ by ONOO⁻, H₂O₂ and HOCl. The major oxidation product, common for all oxidants, is shown in *blue*, and peroxy nitrite-specific cyclization product is shown in *red*. Dashed arrows indicate the possible subsequent oxidation/nitration/halogenation reactions of the major product, *o*-MitoPhOH. (b) Mass spectra of the products determined from the online spectra of the corresponding LC-MS peaks. (c) LC-MS/MS traces (multiple reaction monitoring, indicated by parent ion > fragment ion pair) or LC-MS traces (single ion monitoring, indicated by the m/z value monitored) of the products detected during the reaction between *o*-MitoPhB(OH)₂ probe and the authentic ONOO⁻, H₂O₂ and HOCl.

FIGURE 9. Independent synthetic scheme for *cyclo-o*-MitoPh and structure determination by x-ray diffraction. (a) Synthesis, and (b) the crystal structure of *cyclo-o*-MitoPh.

FIGURE 10. Comparison of the products formed from oxidation of *o*-MitoPhB(OH)₂ by peroxy nitrite and myeloperoxidase. (a) LC-MS/MS traces (multiple reaction monitoring, indicated by parent ion > fragment ion pair) of the products detected during the reaction between *o*-MitoPhB(OH)₂ probe (280 μM) and ONOO⁻ (100 μM), H₂O₂ (1 mM), H₂O₂ (1 mM) + MPO (10 nM), H₂O₂ (1 mM) + NaNO₂ (10 mM) and H₂O₂ (1 mM) + NaNO₂ (10 mM) + MPO (10 nM). (b) Results of titration of *o*-MitoPhB(OH)₂ (280 μM) with ONOO⁻ and MPO. *o*-MitoPhB(OH)₂ was incubated with MPO in the presence of H₂O₂ (1 mM) and NaNO₂ (10 mM) in 0.1 M phosphate buffer (pH 7.4) for 1 h at 25 °C.

FIGURE 11. Effect of selected positive hits for Nox2 inhibition on formation of *o*-MitoPhB(OH)₂ oxidation/nitration products, *o*-MitoPhOH, *cyclo-o*-MitoPh and *o*-MitoPhNO₂. (a) Scheme showing the major and minor products of the reaction of *o*-MitoPhB(OH)₂ and ONOO⁻. (b) LC-MS/MS traces corresponding to *o*-MitoPhOH, *cyclo-o*-MitoPh and *o*-MitoPhNO₂, recorded during analysis of extracts of RAW 264.7 cells incubated with *o*-MitoPhB(OH)₂. Concentration of standards were: 100 nM (*o*-MitoPhOH), 30 nM (*cyclo-o*-MitoPh) and 1 nM (*o*-MitoPhNO₂). (c) Quantitative analysis of the intracellular levels *o*-MitoPhOH, *cyclo-o*-MitoPh and *o*-MitoPhNO₂, detected in cells stimulated to produce ONOO⁻ in the absence or presence of Nox2 inhibitors, as indicated. RAW 264.7 cells were stimulated with IFNγ, LPS and PMA (shown as I/L + P) and incubated for 1 h in the presence of *o*-MitoPhB(OH)₂ (50 μM). Inhibitors were added immediately before addition of PMA and the probe. Concentrations of agents: LPS, 0.5 μg/ml; IFNγ, 50 units/ml; PMA, 1 μM; DPI, 1 μM; sulconazole, 100 μM; mefloquine, 100 μM; cetylpyridinium chloride, 10 μM.

TABLE 1. Structures of ROS/RNS-specific probes, their reaction products and detection methods.

TABLE 2. Step-by-step protocol applied to screen the library of bioactive compounds at the Broad Institute.

TABLE 3. Positive hits obtained during screening of the library of bioactive compounds using three probes: hydropropidine (50 μM) in the presence of DNA (0.1 mg/ml) as a probe for O₂^{•-}; and coumarin boronic acid (100 μM) or Amplex Red (50 μM) in the presence of HRP (0.1 U/ml) as probes for H₂O₂. Differentiated HL60 cells were stimulated with PMA (1 μM) to induce Nox2 activity in HBSS medium supplemented with HEPES buffer (25 mM) and dtpa (0.1 mM).

TABLE 4: IC₅₀ values for selected positive hits, determined by monitoring the effect of the compounds on the rate of oxidation of coumarin boronic acid (100 μM) as a probe for H₂O₂. Differentiated HL60 cells were stimulated with PMA (1 μM) to induce Nox2 activity in HBSS medium supplemented with

HEPES buffer (25 mM) and dtpa (0.1 mM) and the extent of probe oxidation was monitored in 384-well plates using fluorescence plate reader.

TABLE 1








Probe	Diagnostic product(s)	ROS/RNS species	Detection technique(s)
Hydropropidine (HPr^+)	2-Hydroxypropidium (2-OH- Pr^{++}) 	O_2^- -specific product	<ul style="list-style-type: none"> • HPLC with fluorescence detection • LC-MS • Fluorimetry of the complex of 2-OH-Pr^{++} with DNA
Coumarin boronic acid (CBA) 	7-Hydroxycoumarin (COH) 	H_2O_2 (catalase-sensitive) ONOO^- (catalase-insensitive) HOCl (catalase-sensitive, MPO inhibitor-sensitive)	<ul style="list-style-type: none"> • HPLC with fluorescence detection • LC-MS • Fluorimetry
	cyclo- <i>o</i> -MitoPh	ONOO ⁻ -specific product	<ul style="list-style-type: none"> • LC-MS
	2-Hydroxyethidium (2-OH-E ⁺) 	O_2^- -specific product	<ul style="list-style-type: none"> • HPLC with fluorescence detection • LC-MS • Fluorimetry of the complex of 2-OH-E⁺ with DNA
Hydroethidine (HE) 	2-Chloroethidium (2-Cl-E ⁺) 	HOCl-specific product	<ul style="list-style-type: none"> • LC-MS
	Resorufin 	H_2O_2 (HRP-dependent, catalase-sensitive)	<ul style="list-style-type: none"> • HPLC with fluorescence detection • Fluorimetry

TABLE 2

(i) Cell culture and differentiation of HL-60 cells
1. Grow HL60 cells in RMPI medium containing 10% FBS and antibiotics.
2. To a new flask add HL60 cells (10^5 cells/mL) and add all <i>trans</i> retinoic acid (ATRA, final concentration: 1 μ M).
3. Incubate the cells for 4 days.
(ii) Preparation of cell suspension
1. Transfer cell suspension into centrifuge tubes and spin down the cells.
2. Remove the medium (supernatant) and resuspend the cells in HBSS containing 25 mM HEPES buffer (pH 7.4) and 0.1 mM dtpa.
3. Count the cells and prepare the cell suspension in HBSS containing 25 mM HEPES buffer (pH 7.4) and 0.1 mM dtpa at the density of 10^5 cells/mL.
(iii) Cell inhibition
1. Aliquot the cell suspension into black 384-well plates using Thermo Multidrop Combi instrument under sterile conditions.
2. Add 100 nL of compound solutions (5-10 mM in DMSO) using a CyBi® -Well (CyBio) equipped with a 100 nL pintoool.
3. Incubate the cells with inhibitors for 30 min at 37°C in a CO ₂ -free incubator.
(iv) Plate reader-based 384-well-plate-based assays
1. Add 10 μ L/well of probes (5× solutions in HBSS containing 25 mM HEPES buffer (pH 7.4), 0.1 mM dtpa and 0.1 mg/ml BSA) to the 384-well plates containing cells with inhibitors using a Thermo Multidrop Combi instrument. From this point minimize the exposure of plates to light.
2. Add 10 μ L/well of PMA (5× solutions in HBSS containing 25 mM HEPES buffer (pH 7.4), 0.1 mM dtpa and 0.1 mg/ml BSA) to the 384-well plates containing cells with compounds and probes using another Thermo Multidrop Combi instrument.
3. Incubate the activated cells with probes for 90 min at 37°C in a CO ₂ -free incubator.
4. Read the fluorescence intensity in the 384-well plates using an Envision (Perkin Elmer) plate reader.

TABLE 3

no.	Compound name	HPr ⁺ + DNA	CBA	Amplex Red + HRP	
		Normalized score			
1	Miconazole nitrate	-125.8	-128.7	-97.9	
2	Methiothepin maleate ^a	-109.5	-101.8	-84.8	
3	Mitoxantrone•HCl ^a	-108.1	-104.0	-83.1	
4	NNC 55-0396•2HCl	-105.2	-93.9	-80.2	
5	Nonoxynol-9	-101.7	-112.9	-77.2	
6	5-Nonyloxytryptamine oxalate	-97.0	-111.0	-82.9	
7	10-DEBC•HCl ^a	-96.8	-100.4	-82.6	
8	Thioridazine•HCl	-96.4	-94.9	-74.2	
9	GW 7647	-96.2	-132.0	-80.6	
10	Diphenyleneiodonium chloride	-95.6	-73.6	-58.4	
11	nTZDpa	-94.7	-96.3	-72.1	
12	Cetylpyridinium chloride	-93.9	-82.9	-78.3	
13	Suloctidil	-91.2	-94.5	-100.3	
14	Lylamine•HCl	-90.5	-107.4	-82.8	
15	Perphenazine	-88.8	-102.8	-74.1	
16	RS 39604•HCl	-88.1	-123.7	-74.1	
17	Trifluoperazine•HCl	-86.4	-94.4	-88.6	
18	NNC 26-9100	-86.1	-111.4	-88.3	
19	Gambogic acid	-84.7	-98.8	-87.8	
20	Ginkgolic acid	-84.0	-77.8	-63.4	
21	Fluphenazine•HCl	-80.4	-104.1	-88.6	
22	Chlorpromazine	-79.7	-95.8	-86.9	
23	Amsacrine	-78.8	-99.1	-83.8	
24	Amiodarone•HCl	-77.5	-94.3	-67.7	
25	SNAP 5089	-76.9	-102.4	-88.8	
26	Benzethonium chloride	-76.9	-97.7	-87.3	
27	Thimerosal	-76.1	-91.3	-71.2	
28	GR 127935•HCl	-73.3	-77.5	-90.6	
29	Hexachlorophene	-68.3	-83.6	-64.5	
30	Benzbromarone	-67.3	-92.1	-76.4	
31	Embelin ^a	-65.0	-87.3	-69.4	
32	CGP 71683•HCl	-64.7	-79.8	-71.9	
33	Tamoxifen citrate	-63.9	-73.6	-66.6	
34	Demethylasterriquinone B1 ^a	-63.7	-104.4	-86.9	
35	RS 17053•HCl	-63.4	-75.6	-69.1	
36	IKK 16	-63.2	-77.9	-59.7	
37	Mefloquine	-62.7	-98.5	-90.8	
38	GW 3965•HCl	-62.4	-91.7	-87.4	
39	Dyclonine•HCl	-62.4	-92.9	-85.7	
40	Thiothixene ^a	-61.9	-73.0	-52.6	
41	Chlorprothixene•HCl ^a	-58.4	-94.3	-80.2	
42	Sulconazole nitrate	-58.2	-71.3	-60.0	
43	Trimipramine maleate	-57.9	-101.5	-82.4	
44	Tioconazole	-57.9	-91.6	-83.8	
45	Trimeprazine tartrate ^a	-56.2	-67.2	-84.8	
46	A-7•HCl	-56.1	-95.9	-76.8	
47	Mibepradil•2HCl	-51.0	-89.3	-70.5	
48	Triflupromazine•HCl	-50.9	-79.0	-60.1	
49	L 655240 ^a	-50.2	-93.3	-72.1	

^a Identified as *pan assay interference compound* (38)

TABLE 4

no.	Compound	IC ₅₀ (μM)	
		mean	SD
1	Amiodarone•HCl	11	2
2	Amoxapine	16	4
3	Benzbromarone	13	1.5
4	Benzethonium chloride	23	0.7
5	Cetylpyridinium chloride	2.3	0.3
6	Chlorpromazine•HCl	13	0.6
7	Clotrimazole	59	25
8	Diphenyleneiodonium	0.08	0.07
9	Dyclonine	39	16
10	Econazole nitrate	22	1.1
11	Hexachlorophene	2.2	0.4
12	Mefloquine•HCl	16	0.4
13	Miconazole	15	6.5
14	Mitoxantrone	18	12
15	Phenylarsine oxide	0.2	0.04
16	Promazine•HCl	31	1.6
17	Sulconazole nitrate	19	2.6
18	Suloctidil	7.7	3.5
19	Tamoxifen citrate	18	0.5
20	Thimerosal	2.2	0.6
21	Thioridazine	9.3	2.1
22	Tioconazole	9.2	0
23	Trifluoperazine	9	2.2
24	Triflupromazine•HCl	12	2.6


FIGURE 1


FIGURE 2


FIGURE 3


FIGURE 4


FIGURE 5


FIGURE 6


FIGURE 7




FIGURE 8**a****b****c**



FIGURE 9



FIGURE 10

FIGURE 11

Mitigation of NADPH oxidase 2 activity as a strategy to inhibit peroxynitrite formation

Jacek Zielonka, Monika Zielonka, Lynn VerPlank, Gang Cheng, Micael Hardy, Olivier Ouari,
Mehmet Menaf Ayhan, Radoslaw Podsiadly, Adam Sikora, J. David Lambeth,
Balaraman Kalyanaraman

SUPPLEMENTAL DATA

SUPPLEMENTAL TABLE S-1: List of all the compounds tested for Nox2 activity (using three different probes) at Broad Institute Screening Facility, and the normalized scores.

Supplemental Table S-1

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+_DNA		CBA		Amplex Red_HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1	HEMADO		BRD-A00267231-001-01-1	-16.0	-18.0	29.5	39.9	37.5	18.5
2	(+)-UH 232 maleate		BRD-A00327403-103-01-9	9.2	20.3	23.6	-4.7	12.3	24.4
3	AF-DX 116		BRD-A00520476-001-03-3	-17.6	0.7	-3.4	7.5	3.1	6.2
4	BIPERIDEN		BRD-A00546892-001-01-8	-6.4	3.5	-0.5	-9.5	1.2	7.6
5	DYPHYLLINE		BRD-A00827783-001-15-4	-14.7	3.0	-5.4	-11.1	3.1	18.6
6	ALPRENOLOL		BRD-A00993607-003-15-4	-16.4	-40.9	-21.4	-20.7	-9.4	-6.3
7	HEXESTROL		BRD-A01078468-001-08-0	-12.0	38.2	-30.9	-22.3	-7.4	-10.0
8	Salmeterol		BRD-A01320529-001-05-9	-8.7	-10.1	-18.0	-18.8	-22.3	-17.2
9	FLUMETHASONE		BRD-A01346607-001-03-4	6.7	4.3	4.6	0.8	9.8	11.5
10	WB 4101 hydrochloride		BRD-A01493904-003-05-5	2.1	-16.5	-13.6	-16.4	-0.9	-2.6
11	CHLORMADINONE ACETATE		BRD-A01593789-001-02-3	-40.9	-17.7	-34.9	-25.4	-12.4	-11.0
12	BUPIVACAINE HYDROCHLORIDE		BRD-A01636364-003-08-6	4.6	10.3	0.8	-12.8	4.4	9.6
13	NAFTOPIDIL DIHYDROCHLORIDE		BRD-A01787639-300-04-5	-10.1	-4.4	-6.2	-0.9	-11.7	-16.9
14	NITRENDIPINE		BRD-A02006392-001-09-9	-53.2	-4.3	-33.7	-27.4	-16.2	-19.2
15	BETAMETHASONE		BRD-A02180903-001-03-7	-16.4	-8.1	11.2	19.7	18.2	18.7
16	DIHYDROCELASTRYL DIACETATE		BRD-A02267565-001-02-3	20.1	-7.1	-43.6	-31.0	-33.0	-42.4
17	ETHINYLMESTRADIOL		BRD-A02367930-001-03-7	11.6	6.9	-30.6	-12.8	-4.6	0.0
18	NMDA		BRD-A02508087-001-01-1	6.5	-14.2	5.3	17.7	6.9	19.8
19	Betaxolol hydrochloride		BRD-A02759312-003-11-2	-5.8	15.2	-7.1	-3.8	12.2	7.8
20	DEOXYANDIROBIN		BRD-A02799884-001-03-7	-7.7	-3.1	-11.4	-6.1	-10.0	-7.6
21	MEPIVACAINE HYDROCHLORIDE		BRD-A03216249-003-12-8	-28.6	-1.6	-2.1	6.4	5.4	-6.8
22	ICI-89406		BRD-A03359064-001-01-5	2.4	8.4	21.4	18.1	19.5	26.1
23	ROSMARINIC ACID		BRD-A03397678-001-06-2	37.8	30.7	-8.9	3.4	-57.1	-52.8
24	METOPROLOL TARTRATE		BRD-A03623303-045-05-3	-3.3	-13.0	-9.5	-9.7	8.2	-1.3
25	CP 55,940		BRD-A03816571-001-01-0	-11.6	-15.7	-64.2	-82.3	-40.4	-45.0
26	METHSCOPOLAMINE BROMIDE		BRD-A03932035-004-03-5	-21.8	21.8	18.3	26.2	22.1	21.0
27	YO-2		BRD-A04026261-001-01-0	1.5	0.4	18.5	20.6	22.5	12.4
28	?-Funaltrexamine hydrochloride		BRD-A04231641-003-01-3	2.4	-7.9	-9.9	3.5	-4.8	-5.0
29	U-54494A hydrochloride		BRD-A04258855-003-01-7	-11.6	3.7	1.7	-3.3	0.2	2.6
30	SKF 83959 hydrobromide		BRD-A04260165-004-02-4	-32.6	-34.7	-25.6	-30.7	-54.3	-55.7
31	DEXCHLORPHENIRAMINE MALEATE		BRD-A04553218-050-08-9	-9.8	-11.8	-33.9	-41.3	-17.8	-10.9
32	2-[(4-Phenylpiperazin-1-yl)methyl]-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one		BRD-A04661934-001-01-1	0.5	-2.0	-25.5	-32.7	-13.3	-10.4
33	Didibutyryl-cAMP, sodium salt		BRD-A04706586-236-01-7	-7.4	-3.4	6.2	4.0	0.0	3.2
34	NORGESTIMATE		BRD-A04756508-001-01-5	-22.2	-17.5	-30.7	-9.3	-8.1	0.2
35	1,2alpha-EPOXYDEACETOXYDIHYDROGEDUNIN		BRD-A04975445-001-03-3	9.9	-5.9	-4.2	10.8	6.7	-2.7
36	BUPROPION		BRD-A05186015-003-09-9	0.4	-4.3	-0.3	-5.7	10.3	3.1
37	Ipratropium bromide		BRD-A05352148-004-02-0	12.4	-4.9	10.8	2.0	-2.9	0.7
38	TRIDESACETOXYKHIVORIN		BRD-A05422420-001-03-4	-26.0	17.0	-16.4	-11.1	-8.3	2.5
39	(?)-Bay K 8644		BRD-A05457250-001-04-3	-6.7	-5.8	-11.8	-11.4	-14.8	-9.1
40	SOLIDAGENONE		BRD-A05666893-001-03-4	-14.5	-13.0	-48.3	-40.6	-32.0	-34.3
41	HEDERAGENIN		BRD-A05987535-001-03-8	-9.6	-4.9	22.4	33.9	23.8	28.3
42	ETICLOPRIDE HYDROCHLORIDE		BRD-A05994177-003-02-5	3.3	5.1	-24.7	-8.9	-17.9	-18.9
43	EPOXYGEDUNIN		BRD-A06232236-001-03-0	-13.4	-15.3	-5.1	6.0	-5.1	-8.5

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
44	N-Benzylnaltrindole hydrochloride		BRD-A06276885-003-01-1	-34.6	-50.6	15.6	9.3	-85.3	-83.6
45	TERFENADINE		BRD-A06352418-001-15-0	-12.0	-18.8	-85.5	-84.0	-41.5	-52.5
46	HYDROQUINIDINE		BRD-A06390036-001-03-8	-7.5	-13.3	-8.0	4.8	0.6	4.1
47	DEACETYLGEDUNIN		BRD-A06561405-001-03-7	-15.5	-15.3	-29.6	-19.3	-32.7	-14.9
48	FUSIDIC ACID		BRD-A06935312-001-03-5	7.8	8.0	3.2	22.8	13.2	8.7
49	HYDROCORTISONE HEMISUCCINATE		BRD-A07000685-001-03-6	4.4	-11.2	0.4	21.4	1.8	7.9
50	ONDANSETRON		BRD-A07195938-001-01-3	6.9	-13.7	0.6	3.2	7.4	5.1
51	4-(3-BUTOXY-4-METHOXYBENZYL)IMIDAZOLIDIN-2-ONE		BRD-A07207424-001-09-0	7.4	15.4	8.7	28.6	17.6	30.3
52	8-M-PDOT		BRD-A07232941-001-01-9	-7.1	-2.8	8.3	28.6	19.2	11.9
53	LABETALOL HYDROCHLORIDE		BRD-A07440155-003-16-3	-9.9	-8.3	9.7	15.5	3.9	9.2
54	MECLOCYCLINE SULFOSALICYLATE		BRD-A07600638-060-03-7	35.9	28.7	-24.4	-13.7	-30.7	-57.0
55	Cilnidipine		BRD-A07875874-001-01-6	-8.7	-15.8	-37.0	-44.3	-20.4	-25.8
56	Methiothepin maleate		BRD-A07932845-103-01-5	-111.0	-108.1	-101.2	-102.4	-83.8	-85.8
57	FAMPROFAZONE		BRD-A08255417-001-06-3	-24.6	1.9	-54.5	-23.9	-15.3	-10.0
58	DOXYCYCLINE HYDROCHLORIDE		BRD-A08545410-003-03-7	5.3	5.1	-86.9	-93.1	-90.1	-89.7
59	ALFLUZOSIN		BRD-A09056319-001-05-5	-24.6	-2.4	19.3	24.4	10.7	16.6
60	STRYCHNINE		BRD-A09094913-001-03-1	-9.3	-1.6	-5.6	8.5	11.4	15.3
61	NORETHINDRONE ACETATE		BRD-A09349126-001-06-5	-9.4	-12.6	-14.6	-6.3	-7.4	-14.3
62	MEBEVERINE HYDROCHLORIDE		BRD-A09467419-003-14-1	-3.9	3.8	0.8	17.2	-8.3	-0.4
63	Flecainide acetate		BRD-A09472452-015-11-9	16.3	-3.4	3.9	17.2	15.0	12.3
64	BICUCULLINE (+)		BRD-A09495397-001-03-5	-14.7	-1.7	-3.4	0.8	-2.5	12.0
65	HOMATROPINE BROMIDE		BRD-A09539288-004-03-6	0.4	-4.8	-4.0	-0.5	4.9	6.6
66	SKF 81297 hydrobromide		BRD-A09828896-004-04-5	2.9	4.4	-0.3	-14.5	-41.7	-39.8
67	ALGESTERONE ACETOPHENIDE		BRD-A09977907-001-01-9	-7.4	-5.2	-8.2	20.1	-1.7	8.9
68	PROPRANOLOL HYDROCHLORIDE (+/-)		BRD-A10070317-003-17-6	-14.0	-14.5	-74.9	-48.8	-44.1	-37.9
69	DEXAMETHASONE		BRD-A10188456-001-03-1	0.5	-2.1	21.9	22.2	-1.7	11.5
70	Norketamine hydrochloride		BRD-A10355991-003-01-8	-3.5	-16.4	-14.1	-17.0	-0.5	2.8
71	Cyclopiazonic Acid		BRD-A10420615-001-03-6	-1.3	12.4	0.0	-8.7	-4.8	3.5
72	SULPIRIDE		BRD-A10715913-001-03-8	-12.9	9.2	16.4	7.0	-7.1	5.9
73	EFAROXAN HYDROCHLORIDE		BRD-A10739734-003-05-6	-2.8	-4.6	5.9	26.4	1.6	2.0
74	Imiloxan hydrochloride		BRD-A10903566-003-02-8	-10.1	-9.6	-5.7	-12.3	6.5	5.1
75	CARVEDILOL		BRD-A10977446-001-05-5	-6.0	-15.7	-24.0	-31.8	-12.9	-17.7
76	BECLOMETHASONE DIPROPIONATE		BRD-A11319535-001-02-8	-12.1	-8.2	5.1	13.5	0.0	7.0
77	DEHYDROCHOLIC ACID		BRD-A11551002-001-03-8	5.1	11.2	-3.6	-5.6	-0.9	-3.1
78	SB 205607 dihydrobromide		BRD-A11609859-303-01-2	-3.2	-5.4	-0.7	-3.5	-4.3	-3.3
79	Wortmannin		BRD-A11678676-001-03-4	48.9	43.2	21.5	21.4	-4.7	-8.5
80	ENILCONAZOLE		BRD-A11776908-001-06-9	-7.7	-3.6	-20.5	-13.1	-4.5	1.5
81	AM 92016 hydrochloride		BRD-A11813248-003-01-6	-24.5	-17.3	-45.0	-38.1	-38.5	-39.4
82	PROTOVERATRINE A		BRD-A12055418-001-03-7	-23.7	21.6	-10.9	17.6	0.3	16.5
83	1,7-DIDEACETOXY-1,7-DIOXO-3-DEACETYLKHIVORIN		BRD-A12372458-001-03-7	-4.8	-3.4	-16.3	15.8	-9.6	-1.1
84	p-FLUOROPHENYLALANINE		BRD-A12490356-001-03-0	-13.8	-1.1	-2.6	0.9	5.1	5.4
85	(-)U-50488 hydrochloride		BRD-A12822115-003-01-6	-0.8	3.5	5.8	13.1	-22.0	-12.0
86	FLUOROMETHOLONE		BRD-A13133631-001-03-2	8.4	-11.0	-7.0	-11.7	5.2	8.5
87	DOXAZOSIN MESYLATE		BRD-A13188892-066-13-2	-6.4	2.6	14.0	10.8	1.9	7.2
88	PERILLYL ALCOHOL		BRD-A13323580-001-03-0	-22.6	7.3	-7.8	10.0	-3.6	-7.0
89	KHIVORIN		BRD-A13569698-001-03-7	-10.8	1.7	-5.3	-19.5	-10.8	-8.3

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
90	DOBUTAMINE HYDROCHLORIDE		BRD-A13912374-003-03-6	45.3	23.9	54.3	58.2	-12.9	-12.3
91	SULINDAC		BRD-A13946108-001-08-0	1.1	16.9	-10.6	1.2	-20.7	-19.4
92	TC 1		BRD-A13964793-001-01-8	12.1	14.0	39.5	36.8	12.8	23.1
93	3alpha-ACETOXYDIHYDRODEOXYGEDUNIN		BRD-A14098586-001-03-1	-23.6	-14.7	-22.4	-29.2	1.7	4.8
94	OXPHENONIUM BROMIDE		BRD-A14208071-004-10-7	11.3	1.9	6.5	17.5	16.9	21.4
95	SN-6		BRD-A14316475-001-01-5	-15.3	-23.0	-52.6	-45.6	-47.6	-56.6
96	IDRA 21		BRD-A14344385-001-02-4	-5.5	-35.7	-5.3	17.2	5.0	8.9
97	Scopolamine hydrobromide		BRD-A14566392-004-03-5	-6.8	14.0	5.2	17.8	10.0	7.5
98	UB 165 fumarate		BRD-A14574269-051-01-4	-8.1	-7.9	6.3	-4.9	-5.6	14.2
99	MESTRANOL		BRD-A14798026-001-01-8	8.9	5.8	30.6	44.2	9.1	-2.9
100	ALAPROCLATE		BRD-A14966924-001-03-0	-29.1	-27.3	-25.1	-22.2	-13.5	-17.9
101	Benazepril hydrochloride		BRD-A15131297-003-01-9	-16.0	57.2	12.3	25.5	6.5	7.3
102	FLUOCINONIDE		BRD-A15297126-001-03-5	-21.4	3.5	-27.5	-15.8	-3.2	-0.8
103	BMY 14802 hydrochloride		BRD-A15435692-003-01-5	3.3	-3.9	60.3	-8.2	15.9	11.5
104	6-HYDROXYANGOLENSIC ACID METHYL ESTER		BRD-A15454510-001-03-6	1.4	-1.1	0.1	1.6	-9.0	-11.2
105	SDZ 21009		BRD-A15530910-001-01-3	-4.1	-0.9	-26.6	-31.4	3.9	1.5
106	ISOFLUPREDNONE ACETATE		BRD-A15670677-001-01-0	15.1	-17.7	-6.2	-15.8	-2.8	7.9
107	TELITHROMYCIN		BRD-A15798299-001-02-5	-4.6	-3.4	23.9	25.4	1.3	3.8
108	REBAMIPIDE		BRD-A15909516-001-03-3	0.6	-11.6	20.5	18.0	3.5	7.4
109	MODAFINIL		BRD-A16332958-001-04-0	-1.2	-5.8	6.0	4.7	0.5	9.7
110	BUTOCONAZOLE		BRD-A16665823-001-01-2	-50.8	-32.1	-85.7	-82.4	-61.3	-69.1
111	BADGE		BRD-A16694057-001-03-5	2.8	-13.9	20.4	27.9	1.2	0.9
112	ISOXSUPRINE HYDROCHLORIDE		BRD-A16700644-003-03-6	16.7	16.0	-7.1	-4.9	-18.0	-16.1
113	2-Chloro-N6-cyclopentyladenosine		BRD-A16827030-001-01-7	0.2	-10.3	6.1	7.8	24.6	13.5
114	8beta-HYDROXYCARAPIN, 3,8-HEMIACETAL		BRD-A17120244-001-03-4	-6.2	15.3	-1.5	0.9	-1.8	21.0
115	CARPROFEN		BRD-A17411484-001-05-1	2.3	1.3	-13.9	-8.0	-1.9	-1.2
116	BW 723C86 hydrochloride		BRD-A17428743-003-03-3	-19.3	-23.9	-39.5	-47.7	-51.0	-39.0
117	MDL 72832 hydrochloride		BRD-A17453586-003-01-5	7.2	-8.7	-32.3	-18.8	13.5	16.3
118	BAMBUTEROL HYDROCHLORIDE		BRD-A17462676-003-06-6	-20.4	0.3	-5.4	-3.9	5.4	8.5
119	IBUPROFEN		BRD-A17655518-001-12-9	16.0	-6.5	-1.8	-10.2	6.1	10.4
120	a-Methyl-5-hydroxytryptamine maleate		BRD-A17745711-103-01-0	-25.8	-19.9	5.6	6.5	-37.3	-39.7
121	DIHYDROMUNDULETONE		BRD-A17831693-001-03-2	16.9	8.6	-11.5	6.9	-3.3	-17.5
122	TROLOX		BRD-A17846016-001-07-1	-41.4	-10.6	32.9	17.6	-30.1	-30.6
123	CPCCOEt		BRD-A1802423-001-01-6	-2.6	11.1	23.3	12.9	13.9	8.8
124	Etoposide		BRD-A18419789-001-01-4	9.9	0.6	-4.0	11.5	-12.4	-12.9
125	ESTRIOL		BRD-A18620900-001-04-5	-16.4	5.1	-22.5	-24.9	-1.1	-9.1
126	IDAZOXAN HYDROCHLORIDE		BRD-A18696154-003-14-3	-12.9	-29.3	-38.3	-45.6	-38.8	-41.6
127	DIHYDROROTENONE		BRD-A18788061-001-03-7	24.2	16.7	-8.2	3.9	-13.2	-10.9
128	7-Hydroxy-DPAT hydrobromide		BRD-A18795974-004-02-4	-0.2	22.3	20.7	30.8	12.4	3.2
129	ESTRADIOL		BRD-A18917088-001-03-1	17.4	-17.6	-16.6	-25.9	-20.1	-24.4
130	TRIMIPRAMINE MALEATE		BRD-A19195498-050-09-1	-58.3	-57.6	-103.7	-99.4	-82.3	-82.5
131	Vimpocetine		BRD-A19374631-001-01-0	-14.8	-9.4	-31.3	-27.9	-28.0	-21.0
132	METHYLPHENIDATE HYDROCHLORIDE		BRD-A19585813-003-01-7	11.1	-12.2	-9.3	6.1	4.9	13.6
133	MIANSERIN HYDROCHLORIDE		BRD-A19661776-003-16-9	-12.3	-9.6	-22.7	-11.5	-33.9	-26.7
134	Atovaquone		BRD-A19795905-001-05-6	-19.9	5.3	1.4	26.3	9.1	22.4
135	MEDRYSONE		BRD-A20126139-001-03-4	-1.0	-18.6	-33.0	-20.2	-12.2	-8.7

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
136	3-DEOXO-3beta-ACETOXYDEOXYDIHYDROGEDUNIN		BRD-A20182314-001-03-4	30.5	10.2	20.0	18.0	-1.8	0.2
137	ATENOLOL		BRD-A20239487-001-15-7	7.9	23.4	11.3	13.1	12.5	0.4
138	Danazol		BRD-A20243730-001-01-4	-63.6	-53.3	-84.3	-86.0	-37.8	-34.9
139	18alpha-GLYCYRRHETINIC ACID		BRD-A20256229-001-04-8	-21.5	-18.0	-73.8	-66.0	-29.2	-11.6
140	CHLORMEZANONE		BRD-A20348246-001-08-3	21.4	-0.1	-10.2	-22.3	-8.0	-4.6
141	DEOXYSSAPPANONE B 7,3'-DIMETHYL ETHER ACETATE		BRD-A20368188-001-03-2	1.8	-4.2	12.1	43.8	-21.5	-19.0
142	IB-MECA		BRD-A20527803-001-01-2	-12.8	4.0	24.1	38.9	24.5	14.1
143	CANRENONE		BRD-A20644369-001-04-5	-12.7	-11.3	-25.0	-14.2	-21.0	-16.8
144	WAY 213613		BRD-A20968261-001-01-3	6.6	1.2	-27.7	-18.0	5.6	12.2
145	EPI(13)TORULOSOL		BRD-A21113731-001-03-3	-16.8	-0.1	-15.9	-8.4	-12.0	-23.0
146	MEROGEDUNIN		BRD-A21423998-001-03-4	3.5	-10.9	-4.7	-3.1	-6.9	-10.6
147	SNAP 5089		BRD-A21428877-003-01-9	-68.0	-85.9	-98.2	-106.5	-87.4	-90.2
148	Naltriben mesylate		BRD-A21723284-066-01-7	-7.5	-3.3	-20.4	0.0	-48.2	-52.3
149	AMLODIPINE BESYLATE		BRD-A22032524-074-04-0	-26.6	-27.2	-61.5	-67.3	-54.7	-57.5
150	SULMAZOLE		BRD-A22081593-001-06-1	-3.4	-10.2	5.2	12.0	14.1	19.1
151	PHENOTHIRIN		BRD-A22106989-001-02-7	-18.5	-4.5	-7.7	25.1	25.8	36.8
152	PARAMETHADIONE		BRD-A22128695-001-01-8	-10.8	5.5	-3.9	-2.0	-5.3	7.2
153	ESTROPIPATE		BRD-A22143024-231-02-0	-5.2	-15.9	5.8	6.4	3.9	15.6
154	TERAZOSIN HYDROCHLORIDE		BRD-A22256192-003-14-4	-7.9	-8.4	103.5	129.1	0.9	2.1
155	DROFENINE HYDROCHLORIDE		BRD-A22267103-003-08-1	-9.8	-10.3	-41.0	-26.1	-37.5	-30.0
156	BENFLUOREX HYDROCHLORIDE		BRD-A22305049-003-08-6	-38.7	-33.0	-71.9	-61.0	-47.7	-52.3
157	PANTOPRAZOLE		BRD-A22380646-001-02-3	-3.1	-13.2	-0.4	15.5	3.3	-12.0
158	Procaterol hydrochloride		BRD-A22684332-003-03-1	7.1	3.4	20.6	18.2	16.3	12.4
159	SB 205384		BRD-A22707317-001-02-5	0.1	-5.2	-4.8	-3.2	2.5	6.6
160	BVT 948		BRD-A22713669-001-01-9	6.9	-6.6	19.0	25.1	-18.3	-26.8
161	Vinblastine sulfate		BRD-A22783572-065-01-3	4.6	7.4	20.2	24.1	11.8	9.0
162	TENOXICAM		BRD-A22844106-001-16-1	71.6	37.9	63.4	64.3	11.0	11.3
163	DIHYDROGEDUNIN		BRD-A22963354-001-03-6	-20.7	2.6	0.3	2.4	-27.4	-35.7
164	CLINDAMYCIN HYDROCHLORIDE		BRD-A23034328-003-06-7	-20.0	-23.1	-1.4	1.2	2.8	2.6
165	ITRACONAZOLE		BRD-A23067620-001-01-7	1.4	21.9	-11.8	2.9	-25.6	-25.3
166	PHENIRAMINE MALEATE		BRD-A23072235-050-09-4	-15.9	5.5	1.4	31.2	7.2	4.8
167	ESTRADIOL ACETATE		BRD-A23226398-001-04-3	-2.8	4.8	-13.1	-23.6	3.5	8.5
168	RIFAMPIN		BRD-A23603052-001-02-4	79.1	82.7	5.0	12.0	-51.2	-47.8
169	NAS-181		BRD-A23683907-334-01-0	32.8	23.7	34.7	18.5	11.6	17.2
170	Taxol		BRD-A23723433-001-01-2	4.5	-0.3	13.4	30.0	9.1	-0.5
171	THIAMYLAL SODIUM		BRD-A23970436-236-03-4	-20.4	-32.2	-10.9	-5.9	-8.8	-10.3
172	Saclofen		BRD-A24122750-001-02-9	-4.4	13.4	3.5	-2.7	6.8	5.3
173	OFLOXACIN		BRD-A24228527-001-19-0	3.5	-12.8	31.1	50.7	5.9	19.3
174	ANABASINE HYDROCHLORIDE		BRD-A24284985-003-03-8	27.0	16.5	8.9	32.6	3.4	10.9
175	HEAT hydrochloride		BRD-A24429032-003-01-6	-39.4	-40.4	-75.1	-79.4	-51.0	-52.9
176	PUERARIN		BRD-A24433358-001-04-2	-16.6	-6.7	-2.3	24.4	5.5	11.4
177			BRD-A24514565-236-01-6	7.7	7.8	27.8	31.3	4.6	18.4
178	ISOETHARINE MESYLATE		BRD-A24587114-066-14-2	7.0	12.7	43.6	58.2	12.8	21.8
179	HYDROCORTISONE VALERATE		BRD-A25143711-001-01-4	-15.9	-41.7	-60.1	-44.7	-40.7	-49.1
180	AMINOGLUTETHIMIDE		BRD-A25234499-001-09-2	-1.9	0.1	15.0	25.0	14.5	5.8
181	DEOXYGEDUNIN		BRD-A25243629-001-03-9	-5.9	-8.6	-27.6	-16.3	-30.9	-34.7

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
182	DEACETOXY-7-OXOGEDUNIN		BRD-A25408073-001-03-9	-0.9	15.4	-17.6	-7.9	0.8	-10.8
183	FENBUTYRAMIDE		BRD-A25537246-001-03-7	-8.7	-9.6	-0.9	0.1	1.4	4.9
184	EMETINE		BRD-A25687296-300-03-5	2.2	-23.0	-19.1	-7.8	-16.6	-12.1
185	ANISODAMINE HYDROBROMIDE		BRD-A25706161-001-03-9	-10.7	-11.4	-0.3	8.5	11.6	16.7
186	CGS 9343B		BRD-A26032986-050-01-3	11.9	-8.5	-2.5	-5.5	-6.9	-6.2
187	CLOBETASOL PROPIONATE		BRD-A26095496-001-03-2	29.1	1.8	3.2	-0.4	5.0	13.3
188	bulleyaconitine A		BRD-A26097136-001-01-8	-23.8	-0.8	5.5	27.2	14.7	20.9
189	PROPAFENONE HYDROCHLORIDE		BRD-A26334849-003-16-7	-21.1	-13.2	-48.5	-46.8	-15.4	-24.7
190	CHLORTHALIDONE		BRD-A26384407-001-15-2	14.4	-3.3	1.3	2.9	-2.8	14.8
191	ERGONOVINE MALEATE		BRD-A26387268-050-03-6	4.5	14.2	85.6	53.7	-15.4	-2.3
192	NICARDIPINE HYDROCHLORIDE		BRD-A26711594-003-06-4	20.4	14.2	11.5	-2.6	-10.6	-6.7
193	DESONIDE		BRD-A26858303-001-01-0	2.3	-22.8	-17.9	-0.8	-7.6	0.7
194	18-AMINOABIETA-8,11,13-TRIENE SULFATE		BRD-A27080191-065-03-6	2.9	-36.9	-96.4	-80.6	-47.6	-68.2
195	DPN		BRD-A27143604-001-01-2	7.3	0.6	-7.1	-5.7	7.0	8.4
196	ALTRENOGEST		BRD-A27554692-001-01-3	9.3	-3.9	-28.2	-25.4	-20.9	-23.2
197	PREDNISOLONE		BRD-A27887842-001-03-2	-11.8	-9.1	21.7	32.1	16.2	18.8
198	GRISEOFULVIC ACID		BRD-A27914728-001-03-3	6.5	-25.3	-36.2	6.2	13.6	8.3
199	2-Hydroxysaclofen		BRD-A27924917-001-01-7	-1.4	-3.6	1.6	19.5	6.4	-7.2
200	AMINOBENZTROPINE		BRD-A28095882-001-05-7	2.7	0.5	-1.0	0.7	-3.5	-1.0
201	AMT hydrochloride		BRD-A28318179-003-03-6	-10.6	0.5	13.1	11.5	14.7	21.8
202	L-689,560		BRD-A28422058-001-01-0	-1.5	-0.8	18.9	-9.5	23.7	21.5
203	SELEGILINE HYDROCHLORIDE		BRD-A28545468-003-10-9	4.3	6.5	9.6	-0.9	5.1	3.7
204	STRYCHNINE METHIODIDE		BRD-A28702443-005-01-0	3.9	42.7	-39.0	-0.1	4.3	6.7
205	PACLITAXEL		BRD-A28746609-001-05-7	7.9	-8.0	-13.3	-10.3	4.8	7.0
206	TETRAHYDROZOLINE HYDROCHLORIDE		BRD-A28856712-003-15-3	-10.0	8.4	1.9	12.1	13.5	15.5
207	PROXYPHYLLINE		BRD-A28887267-001-13-6	-18.2	-23.6	22.2	3.0	16.9	12.0
208	TRICHLORMETHIAZIDE		BRD-A28940325-001-15-8	-8.3	-9.2	-42.4	-6.6	3.0	-7.1
209	PUROMYCIN HYDROCHLORIDE		BRD-A28970875-300-03-1	25.5	16.4	27.5	24.6	3.8	9.1
210	ETHISTERONE		BRD-A29111201-001-03-0	6.6	-8.6	-36.4	-19.6	4.1	0.4
211	ACEBUTOLOL HYDROCHLORIDE		BRD-A29260609-003-15-3	22.4	45.9	-7.7	29.5	20.1	18.7
212	PCA 4248		BRD-A29289453-001-03-9	0.8	2.7	18.0	21.3	4.9	8.4
213	CANRENOIC ACID, POTASSIUM SALT		BRD-A29322418-237-03-2	0.3	-12.2	2.9	-0.6	14.3	19.3
214	DROPROPIZINE		BRD-A29349577-001-15-6	13.5	4.5	5.8	28.7	10.5	13.9
215	FISSINOLIDE		BRD-A29371732-001-03-8	-2.1	0.6	-10.6	-14.5	-0.5	-5.2
216	CARBINOXAMINE MALEATE		BRD-A29426959-050-07-4	-2.8	-0.4	-23.8	-27.7	-4.2	-2.1
217	RWJ 21757		BRD-A29437505-001-01-6	1.9	4.8	22.4	24.9	24.3	15.6
218	BICALUTAMIDE		BRD-A29485665-001-03-7	-27.1	8.9	-82.7	-76.2	-24.7	-33.1
219	STICTIC ACID		BRD-A29578214-001-08-4	68.1	59.9	-21.9	16.0	3.1	11.7
220	NOMIFENSINE MALEATE		BRD-A29644307-050-10-5	0.0	24.7	8.5	4.2	3.0	-0.5
221	DISOPYRAMIDE PHOSPHATE		BRD-A29734509-011-06-0	-17.9	19.6	11.9	25.4	11.3	12.9
222	LORGUIMIDE SODIUM		BRD-A29854054-236-07-6	2.9	23.2	2.4	12.6	-0.4	0.9
223	VANCOMYCIN HYDROCHLORIDE		BRD-A30133509-003-03-6	12.9	3.4	-9.1	30.0	34.7	23.8
224	MR 16728 hydrochloride		BRD-A30590053-003-01-1	3.2	9.4	-29.1	-42.3	-5.3	-8.8
225	LFM-A13		BRD-A30655177-001-06-6	-11.8	6.8	15.2	25.8	13.0	17.3
226	DIPERODON HYDROCHLORIDE		BRD-A30693873-003-06-0	-27.3	-26.9	-39.4	-37.8	-22.2	-19.1
227	TRIAMCINOLONE DIACETATE		BRD-A30717181-001-03-5	8.3	17.1	3.9	13.0	4.3	3.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
228	FLORFENICOL		BRD-A30886737-001-01-1	14.4	10.5	-16.7	-1.3	22.5	25.9
229	SDZ WAG 994		BRD-A31007383-001-01-0	-7.7	-2.3	3.3	0.9	-6.7	-6.7
230	DESACETYLCOLFOR SIN		BRD-A31087826-001-01-7	14.0	30.8	7.7	8.4	6.0	6.5
231	FLUOXETINE		BRD-A31159102-003-16-3	-39.0	-19.3	-80.0	-88.4	-57.1	-58.0
232	TCB2		BRD-A31195449-004-01-9	-11.8	-5.6	-13.2	-21.4	5.4	-3.6
233	CGP 20712 dihydrochloride		BRD-A31575449-300-01-4	-14.2	-3.6	-5.1	1.4	-5.8	-1.9
234	3-AMINO-beta-PINENE		BRD-A31576716-003-03-4	-6.9	6.6	-3.1	6.3	23.5	9.7
235	PROCYCLIDINE HYDROCHLORIDE		BRD-A31800922-003-15-2	-17.7	-31.0	-24.4	9.2	7.5	-4.1
236	formestane		BRD-A31801025-001-01-0	8.9	-7.1	41.8	36.4	-8.3	-8.8
237	3-DEACETYLKHIVORIN		BRD-A31863775-001-03-8	11.6	-19.5	-0.2	1.0	2.1	-7.0
238	(S)-Timolol maleate		BRD-A31916785-103-01-0	-6.1	1.1	-9.5	-2.3	3.6	8.9
239	OLEANOIC ACID		BRD-A31962514-001-03-4	6.4	10.4	-9.3	-16.9	-17.5	-17.8
240	Methyllycaconitine citrate		BRD-A32164164-048-01-4	-0.3	10.0	7.8	-3.8	17.5	19.9
241	11alpha-HYDROXYPROGESTERONE HEMISUCCINATE		BRD-A32440707-001-01-1	-27.1	-11.6	10.3	26.7	3.3	8.5
242	TRANDOLAPRIL		BRD-A32505112-001-03-6	12.7	8.6	6.3	0.6	2.0	1.1
243	ACECLIDINE		BRD-A32673558-001-01-7	-13.8	-10.0	9.5	5.0	-9.6	3.0
244	SALINOMYCIN, SODIUM		BRD-A32757659-236-03-4	2.9	-7.1	-40.8	-20.6	-25.9	-20.3
245	MRS 1845		BRD-A32949107-001-01-7	18.9	3.0	11.0	18.6	-15.0	-19.6
246	TI CONAZOLE		BRD-A33084557-001-01-7	-58.3	-57.5	-94.3	-88.9	-83.4	-84.1
247	DEHYDRODIHYDROROTENONE		BRD-A33119430-001-03-0	8.5	32.9	-18.2	8.8	9.1	8.4
248	Sotalol hydrochloride		BRD-A33168282-003-06-5	-7.6	-4.1	6.4	20.2	9.1	6.9
249	OXFENDAZOLE		BRD-A33447119-001-03-3	-20.4	6.0	24.2	41.1	8.3	11.5
250	LOE 908 hydrochloride		BRD-A33676200-003-01-7	23.2	34.5	23.2	40.4	7.9	1.2
251	GITOXIN		BRD-A33810106-001-03-7	23.1	17.9	13.9	26.8	35.5	32.5
252	SUPROFEN		BRD-A34006693-001-07-1	-26.4	25.6	-52.8	10.2	29.2	24.0
253	SUL OCTIDIL		BRD-A34205397-001-03-7	-91.6	-90.7	-94.9	-94.1	-98.9	-101.8
254	ZOPICLONE		BRD-A34309505-001-10-1	6.2	35.7	24.9	15.5	11.7	12.8
255	4'-DEMETHYLEPIPODOPHYLLOTOXIN		BRD-A34380114-001-03-0	24.5	21.8	8.2	9.3	-17.6	-1.8
256	URSOLIC ACID		BRD-A34492468-001-04-3	2.7	-7.5	0.4	22.5	7.4	20.7
257	CGP 12177 hydrochloride		BRD-A34706053-003-01-9	-9.1	-11.1	4.6	-5.1	9.9	9.7
258	HOMOSALATE		BRD-A34751532-001-04-4	-26.1	-25.0	32.5	30.2	42.1	32.3
259	ANABASAMINE HYDROCHLORIDE		BRD-A34774643-003-06-3	-10.8	17.0	29.6	8.5	-4.1	18.1
260	DEACETOXY(7)-OXOKHIVORINIC ACID		BRD-A34842997-001-03-1	-14.1	-3.7	-44.6	4.7	1.9	4.4
261	1,3-DIDEACETYL-7-DEACETOXY-7-OXOKHIVORIN		BRD-A34891365-001-03-2	-25.2	-18.1	2.8	-25.1	-15.2	-15.5
262	rutin		BRD-A34907681-001-01-7	0.2	-15.6	15.5	4.8	-15.5	-17.8
263	PREGNENOLONE		BRD-A35054627-001-05-5	-9.8	-9.7	-0.9	-5.0	-4.6	0.2
264	NECA		BRD-A35338386-001-04-6	6.9	-1.1	5.3	-2.0	19.9	18.0
265	L-803,087 trifluoroacetate		BRD-A35511923-019-01-6	-25.4	-27.7	11.2	18.2	-36.3	-56.8
266	CGP 37157		BRD-A35623999-001-04-0	-16.2	-14.7	-38.3	-45.1	-22.8	-18.6
267	2-[(4-(2-Methoxyphenyl)piperazin-1-yl)methyl]-6-methyl-2,3 dihydroimidazo[1,2c]quinazolin-5(6H)-one		BRD-A35871558-001-01-4	-4.4	1.6	-12.6	15.0	3.0	-3.0
268	PREGNENOLONE SUCCINATE		BRD-A35912562-001-01-0	-0.9	-2.9	-35.7	-52.3	-27.4	-32.1
269	APOMORPHINE HYDROCHLORIDE		BRD-A35931254-003-03-5	31.5	33.3	-60.9	-25.3	-51.4	-55.3
270	MEGESTROL ACETATE		BRD-A35989968-001-03-4	-10.2	18.0	-21.2	-16.9	-12.3	-8.0
271	AMCINONIDE		BRD-A36010170-001-03-2	7.6	2.9	-2.1	-4.2	11.9	1.0
272	ESTRADIOL BENZOATE		BRD-A36066264-001-03-1	-41.6	-8.0	-68.1	-65.5	-41.0	-42.6
273	Remacemide hydrochloride		BRD-A36074203-003-03-5	-14.3	-9.0	-42.2	-54.1	-19.3	-4.5

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
274	SULFINPYRAZONE		BRD-A36217750-001-09-8	-34.3	-12.6	-12.2	0.0	4.9	3.1
275	NYLIDRIN HYDROCHLORIDE		BRD-A36267905-003-12-7	17.8	6.9	5.6	8.2	-10.2	-14.1
276	CEFUROXIME AXETIL		BRD-A36322567-001-01-6	8.6	4.0	-14.1	20.9	9.4	24.8
277	BIOTIN		BRD-A36603537-001-07-3	-10.2	5.0	13.8	-6.0	3.6	2.5
278	GLYCOCHOLIC ACID		BRD-A36636859-001-01-6	14.2	-14.5	-27.2	-24.9	15.1	13.0
279	GAMBOGIC ACID		BRD-A37011749-001-03-1	-85.4	-84.1	-101.2	-96.4	-87.2	-88.4
280	BRL 52537 hydrochloride		BRD-A37347161-003-01-8	21.0	22.8	18.1	27.0	-21.3	-17.0
281	TULOBUTEROL		BRD-A37441042-003-03-0	13.1	-9.2	24.4	22.7	17.8	13.2
282	Naloxone hydrochloride		BRD-A37541666-003-01-6	3.9	-4.0	2.2	1.4	-8.1	-2.7
283	SB 203580 hydrochloride		BRD-A37704979-003-01-2	-9.9	-20.4	-6.8	-8.7	5.7	-3.1
284	ICI 204,448 hydrochloride		BRD-A37776212-003-02-5	25.4	4.1	28.6	39.9	14.5	18.2
285	TRIAMCINOLONE		BRD-A37780065-001-03-7	12.9	-2.6	28.8	38.0	15.5	16.3
286	ANTHOTHECOL		BRD-A37828317-001-03-0	-23.7	6.4	46.3	-62.1	-33.3	-31.1
287	ESTRONE		BRD-A37959677-001-03-7	24.6	10.5	-8.3	-3.7	-12.4	1.0
288	KETOCONAZOLE		BRD-A38350138-001-03-1	-48.8	-24.2	-80.4	-81.2	-63.6	-70.2
289	CYCLOTHIAZIDE		BRD-A38675539-001-05-1	-7.0	2.4	-23.7	11.2	23.2	19.9
290	KU14R		BRD-A38747044-001-01-5	13.9	-5.8	5.9	19.3	30.8	24.2
291	FLUDROCORTISONE ACETATE		BRD-A38749782-001-03-3	0.1	-15.1	-1.8	-9.8	4.2	1.0
292	GW 311616 hydrochloride		BRD-A38898897-003-01-0	-2.2	-4.2	2.6	-1.3	8.6	22.7
293	METHOXAMINE HYDROCHLORIDE		BRD-A39189014-003-14-4	2.0	-9.8	10.3	-7.7	9.1	5.4
294	RABEPRAZOLE SODIUM		BRD-A39390670-236-04-0	295.6	314.3	76.7	89.4	32.0	30.0
295	NORETHINDRONE		BRD-A39415247-001-06-2	24.7	11.3	-1.7	15.9	2.1	-10.2
296	OMDM-2		BRD-A39522003-001-01-0	20.0	2.0	7.8	11.5	36.2	20.9
297	DEOXYKHIVORIN		BRD-A39660642-001-03-1	5.2	-3.3	-15.2	-13.8	-6.4	-8.9
298	ESTRADIOL VALERATE		BRD-A39747742-001-03-5	-47.6	0.1	-39.3	-51.7	0.2	10.7
299	HYDROXYPROGESTERONE		BRD-A39791822-001-04-4	4.2	3.9	-22.3	-13.4	-6.9	-12.2
300	Eplerenone		BRD-A39969961-001-01-3	-2.1	-5.5	-4.3	-10.2	2.3	6.4
301	GITOXIGENIN DIACETATE		BRD-A40022950-001-03-7	-14.2	-24.9	-41.0	-13.2	9.9	6.3
302	DICHLORISONE ACETATE		BRD-A40195998-001-01-9	-11.5	-16.9	-35.0	19.3	15.4	17.0
303	CARAPIN		BRD-A40253167-001-03-7	14.4	-0.7	-36.7	-18.0	4.2	-10.8
304	7-DESACETOXY-6,7-DEHYDROGEDUNIN		BRD-A40431293-001-01-0	-19.7	-22.4	-32.7	-20.4	-23.9	-20.8
305	KETOROLAC TROMETHAMINE		BRD-A40639672-234-09-9	13.9	11.0	24.0	17.5	18.5	16.4
306	GEMIFLOXACIN MESYLATE		BRD-A40787240-066-03-8	22.6	4.1	22.9	11.4	26.2	23.8
307	PK 11195		BRD-A41451487-001-04-7	-23.0	4.8	-63.1	-52.4	-33.1	-26.6
308	Naloxone benzoylhydrazone		BRD-A41833852-001-01-9	12.6	-13.6	9.7	11.4	8.9	0.8
309	ENTANDROPHRAGMIN		BRD-A41916216-001-03-9	17.5	28.8	-3.3	9.2	12.6	-0.2
310	BRUCINE		BRD-A41995253-001-03-7	5.3	-3.2	-2.5	-9.2	2.3	-0.5
311	L-152,804		BRD-A42553870-001-05-1	38.5	42.9	26.0	18.3	4.4	4.4
312	CETIRIZINE HYDROCHLORIDE		BRD-A42571354-300-07-0	20.7	17.1	21.8	13.8	2.3	4.5
313	IOPANIC ACID		BRD-A42628519-001-07-4	-11.2	2.5	-43.6	-49.9	-15.8	-18.3
314	API-2		BRD-A42649439-001-02-8	-11.6	-7.4	11.9	7.4	-8.9	-5.1
315	MELENGESTROL ACETATE		BRD-A42746051-001-01-1	-21.1	-9.4	-26.9	-38.5	-36.3	-31.9
316	ORNIDAZOLE		BRD-A42759514-001-09-8	13.1	6.9	12.7	3.8	9.9	2.2
317	DEHYDROABIETAMIDE		BRD-A42929532-001-03-8	21.8	-10.1	-65.5	-57.9	-12.2	-33.9
318	Cantharidin		BRD-A43076080-001-03-3	-6.2	-6.1	29.7	23.6	2.7	-3.4
319	PINACIDIL		BRD-A43882281-001-11-4	10.3	3.9	-2.6	-0.2	-0.2	9.7

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
320	L 368899 hydrochloride		BRD-A43930669-003-01-0	9.1	2.4	3.4	-9.0	8.4	12.7
321	TETRAHYDROPALMATINE		BRD-A43940795-001-03-6	-5.8	-2.3	11.9	5.7	-1.4	-2.1
322	Reboxetine mesylate		BRD-A43974499-066-01-1	-2.0	-8.6	-32.8	-45.1	-27.3	-20.3
323	TRANLYLCYPROMINE SULFATE		BRD-A43974575-065-04-4	-4.1	-2.5	23.1	34.1	4.9	14.9
324	HOMATROPINE METHYLBROMIDE		BRD-A4399749-004-03-3	-19.4	-6.1	12.5	1.7	10.7	6.8
325	DOXYLAMINE SUCCINATE		BRD-A44008656-036-15-9	-16.5	-14.1	15.4	11.0	-0.7	5.6
326	INDOPROFEN		BRD-A44090213-001-15-7	-4.5	-16.4	-1.4	6.0	10.8	3.6
327	Dihydroergocristine mesylate		BRD-A44701612-066-01-9	9.6	13.4	-3.1	-30.9	-16.8	-23.8
328	Mifepristone		BRD-A44780397-001-01-1	-25.6	-32.3	-5.9	-4.3	-26.6	-17.7
329	PROGLUMIDE		BRD-A44863528-001-08-2	23.1	4.9	4.1	18.2	28.4	11.3
330	BOLDINE		BRD-A44966919-001-09-8	9.3	20.7	-15.1	42.9	-13.8	-15.4
331	METHYL PREDNISOLONE SODIUM SUCCINATE		BRD-A45044890-236-01-5	9.6	-3.1	18.5	-6.2	6.2	9.8
332	UBP 302		BRD-A4549626-001-02-8	-7.7	5.0	0.7	0.7	4.3	9.2
333	QUINACRINE HYDROCHLORIDE		BRD-A45889380-300-04-8	10.4	4.2	-43.0	-39.7	-27.6	-13.5
334	CLIDINIUM BROMIDE		BRD-A46066006-004-15-0	11.3	20.8	8.8	21.6	31.9	25.2
335	HYDROCORTISONE PHOSPHATE TRIETHYLAMINE		BRD-A46186775-369-01-2	-14.9	-21.1	1.3	14.6	-0.2	6.7
336	TETRAMIZOLE HYDROCHLORIDE		BRD-A46393198-003-10-9	9.5	10.1	13.7	9.8	5.1	5.8
337	DEOXYSSAPPANONE B 7,4'-DIMETHYL ETHER		BRD-A46460777-001-03-4	29.3	8.6	10.1	-7.6	-68.3	-67.7
338	PROSCILLARIDIN		BRD-A46600320-001-01-1	-0.8	9.6	14.9	11.7	-0.8	7.3
339	Colchicine		BRD-A46684810-001-04-6	2.5	10.9	10.6	9.3	0.8	5.9
340	Ouabain		BRD-A46747628-001-01-9	-14.5	-6.2	8.9	31.1	21.1	13.6
341	CRUSTECDYSONE		BRD-A46778020-001-03-4	15.4	9.6	-50.0	21.1	12.4	13.4
342	LEVOBUNOLOL HYDROCHLORIDE		BRD-A46876182-003-01-0	12.0	21.4	-9.2	5.1	4.1	13.9
343	Citalopram hydrobromide		BRD-A47598013-004-06-1	-4.0	4.6	-16.5	-23.9	-14.4	-22.3
344	NPC 15199		BRD-A47633927-001-01-8	-17.1	-11.7	12.2	4.1	11.4	14.3
345	8-Hydroxy-DPAT hydrobromide		BRD-A48015106-004-03-0	4.4	26.6	24.8	46.8	4.7	14.1
346	TRIHEXYPHENIDYL HYDROCHLORIDE		BRD-A48180038-003-15-1	-1.3	1.5	-17.8	29.8	16.1	-2.3
347	MITOMYCIN C		BRD-A48237631-001-03-0	26.3	16.1	-1.7	4.5	10.9	19.8
348	PHCCC		BRD-A48257147-001-01-9	-17.6	15.8	-43.0	-49.3	-4.9	-2.8
349	AJMALINE		BRD-A48300215-001-03-0	3.6	7.5	30.5	34.5	7.0	2.2
350	SALSOLINE		BRD-A48323445-001-03-4	14.3	8.1	20.8	-4.5	-29.8	-31.9
351	GEDUNIN		BRD-A48397526-001-03-0	-11.5	-11.8	-62.2	-15.2	-17.7	-23.7
352	PIOGLITAZONE HYDROCHLORIDE		BRD-A48430263-003-06-5	-5.3	-7.0	-22.3	-14.4	7.8	8.0
353	IVERMECTIN		BRD-A48570745-001-01-1	-2.0	6.3	-25.7	-29.1	-29.1	-27.7
354	TESTOSTERONE PROPIONATE		BRD-A48720949-001-03-2	-9.6	6.1	5.1	16.2	-15.4	-8.8
355	METHACYCLINE HYDROCHLORIDE		BRD-A49035384-003-12-3	82.4	67.9	32.2	12.4	-12.2	-4.0
356	SKF 89976A hydrochloride		BRD-A49046702-003-03-4	-9.4	-3.2	-7.3	2.2	-8.0	0.4
357	Galanthamine hydrobromide		BRD-A49148672-004-01-6	-11.5	-3.1	21.0	4.8	2.3	3.2
358	DONEPEZIL HYDROCHLORIDE		BRD-A49160188-003-04-4	2.6	-6.5	19.7	-5.0	17.1	20.7
359	Lansoprazole		BRD-A49172652-001-13-1	-7.2	-1.5	-12.1	-3.9	6.2	11.2
360	TRIMEPRAZINE TARTRATE		BRD-A49225603-045-05-0	-64.4	-48.1	-67.0	-67.4	-82.4	-87.3
361	KHAYANTHONE		BRD-A49243397-001-03-1	13.2	7.6	-39.9	-14.0	-12.1	-15.6
362	Ro 60-0175		BRD-A49370193-051-01-7	-43.3	-39.5	-62.3	-70.3	-51.3	-47.8
363	DESOXYMETASONE		BRD-A49447682-001-01-6	-10.8	-13.0	-13.8	-15.7	4.5	9.4
364	(?)-AC 7954 hydrochloride		BRD-A49544621-003-01-0	-7.7	6.0	-25.7	-52.5	-22.0	-22.7
365	FLURANDRENOLIDE		BRD-A49765801-001-03-3	-11.2	-14.8	2.5	0.4	2.6	8.0

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
366	clindamycin		BRD-A49912425-001-01-1	42.1	-2.9	5.3	24.1	13.1	15.1
367	FLUMETHAZONE PIVALATE		BRD-A50064262-001-03-9	0.6	0.3	23.8	19.5	-2.1	5.8
368	TERBUTALINE HEMISULFATE		BRD-A50157456-065-12-3	0.4	4.0	-45.5	9.4	-9.3	-8.9
369	MECLIZINE HYDROCHLORIDE		BRD-A50311610-300-06-2	17.7	8.8	4.1	67.9	8.0	63.1
370	PIPRONIL		BRD-A50675702-001-04-8	-11.2	-24.9	-29.0	-24.9	-32.8	-23.8
371	Fenoldopam hydrochloride		BRD-A50684349-003-01-1	2.9	3.6	4.9	5.8	-14.0	-16.9
372	MDL 73005EF hydrochloride		BRD-A50764878-003-01-0	13.0	-17.2	5.6	0.8	-3.6	3.2
373	NORGESTREL		BRD-A50928468-001-03-7	-15.6	-6.5	-34.2	-28.3	-22.0	-16.6
374	8-Hydroxy-PIPAT oxalate		BRD-A51381734-034-01-1	-5.4	4.7	-19.4	0.2	-23.1	-19.2
375	Noscapine hydrochloride		BRD-A51393488-003-01-9	-14.2	-12.5	-3.4	-21.0	6.3	14.0
376	Yohimbine hydrochloride		BRD-A51410489-003-02-8	0.7	0.6	-23.1	-3.8	-7.4	-7.2
377	3 a-[4-Chlorophenyl]phenylmethoxy]tropane hydrochloride		BRD-A51713165-003-01-8	-15.9	-20.7	-87.0	-92.8	-39.1	-48.1
378	Venlafaxine HCl		BRD-A51714012-003-01-1	11.3	16.9	13.3	30.0	6.0	0.4
379	ECONAZOLE NITRATE		BRD-A51820102-008-16-4	-41.5	-53.8	-58.6	-68.7	-62.1	-63.1
380	BRL 15572 hydrochloride		BRD-A51829654-003-02-8	-6.2	-4.4	4.2	16.6	28.7	30.4
381	ICI-185,282		BRD-A51929314-001-01-4	14.1	9.0	-26.0	-23.3	-8.6	-9.1
382			BRD-A52530684-003-01-7	-3.5	1.9	27.3	25.5	-5.4	-3.9
383	SKF 83566 hydrobromide		BRD-A52588987-004-04-1	-5.8	11.0	-16.4	-9.4	-12.3	-16.9
384	Tetrandole mesylate		BRD-A52660433-066-01-3	-90.3	-92.9	25.8	40.1	-64.2	-68.3
385	CHRYSANTHEMIC ACID		BRD-A52893269-001-03-2	1.8	-17.1	6.3	-16.9	8.5	14.9
386	Tianeptine		BRD-A53077924-236-01-4	20.3	-16.1	34.9	40.3	22.1	3.4
387	EPITESTOSTERONE		BRD-A53131506-001-01-3	-0.6	3.3	-3.8	-20.6	0.4	5.7
388	METHYLPREDNISOLONE		BRD-A53176877-001-03-5	10.2	45.7	17.3	14.8	-10.9	-11.6
389	AMIPRIOLOSE		BRD-A53484347-003-03-1	4.9	-6.7	6.4	5.1	2.1	12.3
390	PIPENZOLATE BROMIDE		BRD-A53561827-004-15-7	12.7	14.3	-7.1	28.1	-1.2	3.6
391	ORPHENADRINE CITRATE		BRD-A53576514-048-06-9	5.0	-16.7	-25.1	-5.3	-4.9	3.7
392	PRILOCAINE HYDROCHLORIDE		BRD-A53952395-003-15-2	-9.0	-8.4	-20.1	1.4	3.1	20.6
393	RACEPHEDRINE HYDROCHLORIDE		BRD-A54236247-003-03-5	-5.2	-6.7	10.6	22.3	10.8	5.7
394	CORTISONE ACETATE		BRD-A54487287-001-03-9	-14.1	-2.0	26.8	30.4	24.1	15.1
395	Prilindole mesylate		BRD-A54490543-066-04-4	-53.9	-44.2	-48.8	-62.2	-50.2	-51.8
396	SOLIFENACIN SUCCINATE		BRD-A54596827-036-01-4	-37.8	4.2	-18.5	-23.2	-17.6	-21.3
397	Dihydroergotamine mesylate		BRD-A54845972-066-01-5	-1.9	-8.3	-11.3	-7.1	-8.6	-13.1
398	ETOMIDATE		BRD-A54880345-001-11-8	-11.3	-6.9	-11.1	2.9	-2.4	4.6
399	(RS)-(-)-Sulpiride		BRD-A55272860-001-08-8	-6.5	12.6	5.5	8.0	20.0	7.0
400	STROPHANTHIDIN		BRD-A55312468-001-03-9	-21.2	-3.5	-32.1	19.6	29.1	5.6
401	CGP 54626 hydrochloride		BRD-A55369275-003-01-2	-8.1	-7.6	7.8	0.1	22.2	19.4
402	TESTOSTERONE		BRD-A55393291-001-05-7	-18.3	0.8	-18.5	11.0	0.3	11.5
403	COLFOR SIN		BRD-A55416093-001-03-1	3.8	4.4	4.6	-13.1	9.2	9.0
404	Methotrexate		BRD-A55424491-001-08-2	-22.3	4.5	23.6	25.0	13.2	10.8
405	BNTX maleate		BRD-A55484088-050-01-7	-23.6	-27.8	28.6	33.9	-35.6	-42.2
406	CYTISINE		BRD-A55579717-001-03-2	11.1	-1.5	-27.2	-11.5	3.8	2.1
407	H-7 dihydrochloride		BRD-A55756846-300-01-0	-22.3	-10.8	20.6	-27.2	7.6	-1.8
408	PRIMAQUINE DIPHOSPHATE		BRD-A55913614-316-06-2	-12.6	7.6	-36.9	-48.9	-29.5	-24.1
409	OMEPRAZOLE		BRD-A55962179-001-08-0	-20.7	35.2	-0.4	2.6	-12.2	-1.6
410	ZILEUTON		BRD-A56359832-001-04-6	-2.0	5.6	14.8	9.3	-12.4	-13.3
411	ALTHIAZIDE		BRD-A56675431-001-07-3	5.8	18.0	20.4	26.3	9.3	21.6

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
412	11a-ACETOXYPROGESTERONE		BRD-A56884981-001-02-6	4.6	11.8	-5.6	-2.2	13.7	26.7
413	SQ 22536		BRD-A56987319-001-05-3	0.4	-9.5	-2.0	-3.7	10.9	23.5
414	PERUVOSIDE		BRD-A57089740-001-03-1	1.9	12.9	1.2	-10.6	12.9	5.7
415	CHLORCYCLIZINE HYDROCHLORIDE		BRD-A57133233-003-06-0	10.9	2.5	-66.7	-49.1	-20.1	-19.9
416	PIROXICAM		BRD-A57382968-001-18-3	41.2	64.2	27.6	25.2	-7.1	4.7
417	(-)Bicuculline methiodide		BRD-A57798559-005-01-2	-17.9	-3.3	-15.8	-3.5	15.2	10.2
418	NIMODIPINE		BRD-A58048407-001-09-7	-12.5	-8.1	-10.1	-20.2	-8.9	-4.5
419	OXYPHENCYCLIMINE HYDROCHLORIDE		BRD-A58193911-003-12-0	-9.6	-23.6	-28.5	16.2	1.2	0.1
420	SELAMECTIN		BRD-A58564983-001-03-8	-5.0	4.4	13.6	19.6	22.5	22.3
421	N-ACETYLPROLINE		BRD-A58587171-001-04-9	-19.4	-5.7	2.0	17.5	-0.4	1.1
422	RITODRINE HYDROCHLORIDE		BRD-A59174698-003-12-8	1.9	10.2	16.4	6.2	4.0	-6.4
423	7-Hydroxy-PIPAT maleate		BRD-A59391763-103-01-9	-10.7	-11.3	5.5	21.8	4.1	8.9
424	DEXPANTHENOL		BRD-A59413292-001-04-1	-10.7	-1.3	2.8	10.0	12.7	12.5
425	12a-HYDROXY-5-DEOXYDEHYDROMUNDUSERONE		BRD-A59471422-001-02-6	-8.0	-4.4	-13.1	-16.7	6.7	-11.5
426	7-DEACETYLKHIVORIN		BRD-A59539786-001-03-8	10.5	16.3	16.8	4.1	0.5	-6.8
427	AMYGDALIN		BRD-A59552297-001-03-3	-0.8	1.2	34.9	18.8	9.8	11.8
428	3-NOR-3-OXOPANASINSAN-6-OL		BRD-A59682351-001-03-1	23.4	-1.1	-22.6	8.3	5.6	7.9
429	Fluticasone propionate		BRD-A59943784-001-01-8	-23.8	-13.3	-9.5	-1.6	12.5	-2.1
430	Amisulpride		BRD-A60197193-001-05-4	8.3	-14.3	15.0	4.0	8.6	7.3
431	BUDESONIDE		BRD-A60571864-001-03-3	-1.7	2.4	-11.1	-19.2	-8.3	-10.7
432	CAFESTOL		BRD-A60717068-001-01-0	-22.2	-21.1	-42.0	-30.7	-24.8	-25.0
433	2'-MeCCPA		BRD-A60877539-001-01-3	-2.5	8.2	30.7	15.0	36.1	30.2
434	GLICLAZIDE		BRD-A61154809-001-08-4	-14.8	-48.2	18.6	-5.2	7.0	14.3
435	Eliprodil		BRD-A61392169-001-01-9	25.1	13.1	-18.3	-11.8	-6.5	-14.1
436	METOLAZONE		BRD-A61793559-001-08-1	-3.3	2.3	-4.5	7.3	6.0	11.4
437	WAY 161503 hydrochloride		BRD-A62021152-003-01-8	-3.9	-3.9	-6.6	11.1	1.4	-8.8
438	MDL 11,939		BRD-A62057054-001-01-5	-16.6	-8.9	6.3	-12.6	20.1	17.2
439	TOTAROL		BRD-A62129005-001-03-8	17.3	4.4	85.4	-14.0	-25.3	-20.6
440	Cycloheximide		BRD-A62184259-001-02-8	-0.1	4.5	-2.1	-17.0	11.7	13.3
441	ZM 226600		BRD-A62209527-001-03-7	-33.2	-21.6	-8.5	0.8	-9.7	-8.5
442	EDOXUDINE		BRD-A62505706-001-03-1	-1.5	17.3	6.9	-4.9	-0.5	-2.5
443	PREDNISONE		BRD-A62525898-001-04-5	8.0	3.6	18.3	-2.9	10.7	12.7
444	CORTISONE		BRD-A62731508-001-04-1	16.0	-1.3	3.6	25.7	23.6	18.0
445	RIFAXIMIN		BRD-A62879835-001-03-4	37.0	39.6	-26.4	8.2	-46.8	-47.2
446	Cabergoline		BRD-A63043573-001-01-6	-10.4	-12.0	11.5	7.7	18.7	22.9
447	Rimcazole dihydrochloride		BRD-A63346720-300-01-1	-36.3	-35.9	-91.9	-95.0	-81.1	-84.4
448	EPIESTRIOL		BRD-A63433173-001-01-3	-4.5	13.6	-42.4	1.0	9.9	15.2
449	Ro 04-5595		BRD-A63546914-003-01-2	-17.9	-18.8	-54.4	-63.4	-43.8	-48.4
450	Methylergometrine maleate		BRD-A63667919-103-01-9	34.3	33.9	68.2	82.3	4.5	3.9
451	PD 123319 difluoroacetate		BRD-A63836183-362-01-1	-25.3	-18.8	11.0	-1.0	21.0	21.7
452	N-BENZYL TROPAN-4-OL		BRD-A64068566-001-01-1	-2.7	33.4	-12.7	6.7	16.7	3.7
453	MEXILETINE HYDROCHLORIDE		BRD-A64092382-003-09-2	-33.9	-1.7	0.5	15.3	16.4	7.2
454	SODIUM DEHYDROCHOLATE		BRD-A64125466-236-03-8	-12.0	-4.6	10.1	-9.2	8.5	21.3
455	SKF 77434 hydrobromide		BRD-A64227845-004-02-8	9.5	11.2	-19.7	-25.7	-25.1	-29.7
456	(-)Terreic acid		BRD-A64228451-001-04-3	95.0	79.6	10.6	18.5	-5.3	-3.1
457	LANATOSIDE C		BRD-A64242993-001-03-1	29.5	30.8	21.8	11.1	33.6	30.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
458	JOSAMYCIN		BRD-A64243931-001-01-8	-2.4	9.4	18.1	-4.4	3.6	21.9
459	Cyclosporin A		BRD-A64290322-001-01-6	-18.6	-10.0	-27.3	-15.4	-16.1	-22.5
460	MEXICANOLIDE		BRD-A64523751-001-03-6	3.6	2.6	20.7	-1.9	2.5	3.5
461	CV 1808		BRD-A64933752-001-01-0	-8.9	-5.9	25.9	38.9	18.7	26.5
462	Mirtazepine		BRD-A64977602-001-04-3	0.2	-4.1	10.6	4.2	16.7	8.0
463	OXYBUTYNIN CHLORIDE		BRD-A65013509-003-13-7	-15.0	-8.3	0.0	-27.6	-17.7	-5.3
464	DIHYDROERGOCRISTINE		BRD-A65076780-001-02-1	13.2	-10.6	32.8	13.9	-31.9	-28.2
465	ATPA		BRD-A65145453-001-02-0	-14.1	-10.8	11.3	18.4	17.5	27.1
466	LOBELINE HYDROCHLORIDE		BRD-A65243462-003-03-6	-11.0	-4.3	-8.4	9.1	10.1	4.2
467	Cimaterol		BRD-A65440446-001-03-3	-15.0	-10.8	0.8	15.9	5.3	22.4
468	FLUNISOLIDE		BRD-A65449987-001-06-2	-18.3	-13.9	-3.4	9.8	1.0	1.2
469	ginsenoside-Rc		BRD-A65550283-001-01-9	3.8	-2.3	12.0	4.8	7.5	9.5
470	RX 821002 hydrochloride		BRD-A65597028-003-02-4	-6.3	-7.5	-5.3	-5.9	-5.6	2.5
471	Zacopride hydrochloride		BRD-A65615053-003-01-4	-10.2	-1.3	10.9	22.7	13.7	16.3
472	CANDESARTAN CILEXTIL		BRD-A65671304-001-03-4	-63.7	-70.0	16.3	2.1	-78.1	-78.8
473	HYDROCORTISONE ACETATE		BRD-A65767837-001-03-6	-5.6	-0.5	-11.7	-2.2	5.1	-3.8
474	(S)-WAY 100135 dihydrochloride		BRD-A66369147-300-01-5	11.1	-20.0	12.1	13.7	11.8	15.1
475	HTMT dimaleate		BRD-A66435872-313-01-8	-15.4	-20.6	-19.6	5.0	-5.8	2.4
476	ACETYLPHENYLALANINE		BRD-A66443329-001-05-3	9.3	45.5	-6.2	5.9	-1.8	-8.5
477	OXACILLIN SODIUM		BRD-A66481418-236-03-2	15.7	0.6	13.1	22.0	12.1	23.6
478	DIGOXIGENIN		BRD-A66491790-001-01-1	12.3	14.1	11.7	-12.3	20.6	12.6
479	NALTREXONE HYDROCHLORIDE		BRD-A66559694-001-03-8	17.5	10.3	-15.2	-2.6	-14.0	-13.1
480	Medetomidine hydrochloride		BRD-A66563878-003-01-8	-8.0	-7.4	-9.6	-7.9	-1.7	-6.6
481	BETAMETHASONE 17,21-DIPROPIONATE		BRD-A66861218-001-03-5	-38.9	-12.9	4.3	13.6	-9.0	6.5
482	DIFLORASONE DIACETATE		BRD-A66869276-001-01-1	-23.3	-28.5	15.0	-14.9	-3.4	-7.8
483	NORCANTHARIDIN		BRD-A66914119-001-04-0	11.6	-0.4	-2.8	-13.5	12.1	13.7
484	Nemonapride		BRD-A66927094-001-01-7	-14.0	-5.1	-19.2	-25.2	-8.3	6.3
485	7-OXOCHOLESTEROL		BRD-A67138712-001-03-8	-24.2	-14.7	0.8	21.3	0.3	9.7
486	O-BENZYL-L-SERINE		BRD-A67259561-001-02-6	-8.6	20.7	-11.1	18.7	11.7	-3.8
487	NCS-382		BRD-A67433117-001-01-8	-10.5	-4.2	-2.8	2.6	4.2	7.6
488	4-P-PDOT		BRD-A67482312-001-01-8	-11.2	1.3	-24.9	-23.4	1.4	7.1
489	3beta-HYDROXYDEOXODIHYDRODEOXYGEDUNIN		BRD-A67508925-001-03-5	5.5	-12.4	-52.8	-39.5	-18.2	-22.2
490	NAFRONYL OXALATE		BRD-A67862938-034-09-9	-4.9	3.0	-9.8	-22.4	15.7	16.1
491	BRL 44408 maleate		BRD-A67949680-103-01-4	-8.5	26.7	32.6	19.7	12.9	19.3
492	Daunorubicin hydrochloride		BRD-A68009927-003-02-9	-20.2	-1.9	-22.4	-29.0	-7.2	-6.3
493	BROMPHENIRAMINE MALEATE		BRD-A68723818-050-18-4	1.8	-33.9	-35.1	-27.8	-9.7	-10.2
494	AZELASTINE HYDROCHLORIDE		BRD-A68888262-003-07-8	-14.4	-26.3	-58.9	-50.7	-64.3	-66.6
495	DAPT		BRD-A68929948-001-01-9	-3.3	-4.1	-8.8	-20.7	1.8	8.8
496	CEDRENONE		BRD-A69143712-001-03-6	-19.0	-19.5	-44.0	-53.5	-43.5	-43.6
497	CARBIDOPA		BRD-A69512159-001-03-2	32.2	41.7	56.2	33.8	-37.4	-33.7
498	DILTIAZEM HYDROCHLORIDE		BRD-A69636825-003-03-9	25.0	15.4	-44.2	-55.4	-11.8	-6.8
499	MINOCYCLINE HYDROCHLORIDE		BRD-A69651145-003-04-9	28.3	26.4	-5.2	-8.6	-51.1	-50.0
500	FLUMEQUINE		BRD-A69777949-001-15-0	11.0	17.9	-25.7	-7.7	8.8	-6.7
501	EUCATROPINE HYDROCHLORIDE		BRD-A69786436-003-03-3	17.9	9.3	35.1	26.7	7.5	16.1
502	CYCLOSPORINE		BRD-A69815203-001-05-0	-2.1	-41.1	-20.9	-20.2	-6.8	-2.9
503	AMINOPENTAMIDE		BRD-A69917777-065-01-4	-10.6	-5.6	-17.5	16.8	5.8	10.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
504	Bromocriptine mesylate		BRD-A69960130-066-01-4	15.3	19.8	35.1	16.7	24.8	26.2
505	SECNIDAZOLE		BRD-A70083328-001-12-8	14.0	9.4	21.4	9.7	22.6	26.9
506	PG-9 maleate		BRD-A70268693-103-01-9	-7.6	-1.6	-41.3	-58.5	-8.2	-4.7
507	PSB 36		BRD-A70407468-001-01-2	22.8	16.1	27.1	25.4	20.9	21.4
508	SULCONAZOLE NITRATE		BRD-A70649075-008-17-5	-54.8	-61.6	-66.6	-76.1	-57.5	-62.6
509	3beta-ACETOXYDEOXODIHYDROGEDUNIN		BRD-A71001587-001-03-4	-27.5	-34.3	15.1	5.2	-20.0	-3.4
510	FENDILINE HYDROCHLORIDE		BRD-A71033472-003-15-5	9.0	9.9	-58.4	-50.6	-33.2	-35.8
511	LUFENURON		BRD-A71774530-001-02-6	15.3	9.0	-15.7	0.1	10.7	2.2
512	PRAVASTATIN SODIUM		BRD-A71816415-236-03-5	20.5	15.9	0.1	10.6	3.9	4.3
513	MUNDULONE ACETATE		BRD-A71960694-001-01-5	-3.8	0.2	28.4	35.1	5.3	8.6
514	SR 202		BRD-A72066420-001-01-1	20.3	-13.1	6.8	1.3	7.8	11.3
515	METERGOLINE		BRD-A72309220-001-03-3	-20.9	-43.0	-86.3	-84.0	-69.1	-79.5
516	Spiroxatrine		BRD-A72483914-001-02-9	-6.8	-26.6	-20.4	-24.4	-10.6	-11.0
517	GW 6471		BRD-A72596465-001-01-3	11.8	-5.5	9.7	7.7	-9.8	-5.8
518	SKF 96365		BRD-A72703248-003-03-1	0.2	-14.6	0.8	23.7	-10.7	-10.6
519	ASIATIC ACID		BRD-A72758037-001-01-8	-4.5	3.7	-29.2	-37.1	-12.6	-16.6
520	FEXOFENADINE HYDROCHLORIDE		BRD-A73368467-003-07-7	-35.8	-13.6	13.1	1.2	10.3	11.9
521	8-HYDROXYCARAPINIC ACID		BRD-A73559168-001-03-6	8.8	-5.4	-11.8	-7.0	-7.3	4.8
522	EXEMESTANE		BRD-A73741725-001-01-0	12.6	-0.9	10.8	5.0	5.3	9.2
523	Glycodeoxycholic Acid		BRD-A73859745-236-01-8	-0.9	6.5	-9.4	1.2	7.4	13.9
524	DACTINOMYCIN		BRD-A73909368-001-01-5	-1.8	6.8	5.2	7.3	-12.8	-25.7
525	TROXERUTIN		BRD-A74160776-001-03-6	0.9	3.6	-28.6	-10.4	-11.2	2.9
526	ETODOLAC		BRD-A74667430-001-15-2	-26.9	-51.7	0.3	-10.7	-4.1	1.0
527	GATIFLOXACIN		BRD-A74980173-001-06-9	5.4	-9.5	3.9	32.9	12.2	21.5
528	HYDROCORTISONE		BRD-A75172220-001-03-2	22.0	48.2	5.5	-8.7	5.9	12.7
529	DESOXYCORTICOSTERONE ACETATE		BRD-A75402480-001-03-8	-23.2	6.6	-41.8	-51.3	-17.9	-19.0
530	KAWAIN		BRD-A75455249-001-12-9	-28.2	-17.4	-9.0	-18.9	6.0	2.8
531	PD 166793		BRD-A75478957-001-01-6	-9.8	-2.7	5.6	2.6	31.8	27.4
532	ISOXICAM		BRD-A75552914-001-09-3	-9.8	-5.8	7.2	-3.8	6.5	6.7
533	CLEBUTEROL HYDROCHLORIDE		BRD-A75726477-003-14-8	9.6	6.3	25.7	33.9	38.8	31.1
534	SDM25N hydrochloride		BRD-A75769826-003-01-3	-7.3	-21.0	23.2	25.5	-37.7	-40.2
535	LOMEFLOXACIN HYDROCHLORIDE		BRD-A75850590-003-06-4	9.5	48.7	4.8	26.7	14.7	13.0
536	MUROLLADIE-3-ONE		BRD-A75954196-001-03-3	14.0	5.8	6.6	26.8	26.0	8.9
537	Cromakalim		BRD-A76093993-001-01-8	-3.3	-1.7	3.7	-2.5	-13.0	-3.4
538	PANTETHINE		BRD-A76244192-001-01-6	17.3	4.4	-3.4	-2.8	9.1	6.6
539	alpha-DIHYDROGEDUNOL		BRD-A76417540-001-03-3	3.2	4.5	-53.0	-17.3	11.2	0.2
540	RUTOSIDE (rutin)		BRD-A76747559-001-02-3	-13.2	-22.1	-40.9	2.0	-34.1	-35.0
541	QUERCITRIN		BRD-A76899420-001-03-7	34.6	18.6	-27.3	2.9	-37.0	-40.4
542	VESAMICOL HYDROCHLORIDE		BRD-A76904477-003-05-8	14.5	9.4	0.0	37.7	14.5	12.3
543			BRD-A76941896-001-01-6	102.6	108.7	25.0	30.6	-1.6	4.3
544	D609		BRD-A77118605-237-01-2	11.6	22.2	6.5	-10.3	10.6	12.7
545	DEOXYSAPPANONE B TRIMETHYL ETHER		BRD-A77164655-001-03-1	2.3	-15.2	-44.5	-27.6	-24.0	-21.8
546	SYM 2206		BRD-A77218119-001-02-7	-7.2	-2.3	-57.3	-61.0	8.2	-0.8
547	CYCLOPENTOLATE HYDROCHLORIDE		BRD-A77291778-003-15-4	5.8	-16.5	2.4	-9.8	6.5	2.4
548	Salubrinal		BRD-A77299732-001-01-6	19.9	15.0	-9.9	-16.6	-10.6	-11.2
549	RK-682		BRD-A77349281-001-02-2	-66.5	-62.9	36.1	55.0	-60.8	-64.1

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
550	TOTAROL-19-CARBOXYLIC ACID, METHYL ESTER		BRD-A77488069-001-03-4	-11.6	-11.5	-9.1	42.1	23.5	7.6
551	FLUOCINOLONE ACETONIDE		BRD-A77824596-001-03-2	-18.9	-12.9	-3.7	-5.1	-8.6	2.9
552	HYOSCYAMINE		BRD-A78303415-001-03-5	13.3	18.2	23.8	15.0	19.4	11.1
553	Monastrol		BRD-A78377521-001-03-0	-18.9	-5.3	16.6	20.3	11.4	20.2
554	PREDNISOLONE HEMISUCCINATE		BRD-A78391468-001-01-0	-20.6	-5.9	-2.7	6.8	8.6	4.4
555	ICI-118,551 hydrochloride		BRD-A78942461-003-01-3	-13.6	-16.1	-38.9	-26.4	-20.1	-24.0
556	AGN 192403 hydrochloride		BRD-A79038507-003-01-5	-5.1	17.0	18.8	11.5	27.4	31.4
557	BETAMETHAZONE SODIUM PHOSPHATE		BRD-A79380603-304-01-6	-9.7	11.1	20.2	12.6	0.5	7.7
558	TROPICAMIDE		BRD-A79672927-001-10-8	-18.8	-9.5	4.1	21.0	13.8	2.2
559	SIROLIMUS		BRD-A79768653-001-02-1	33.1	13.8	-19.0	-33.2	-18.8	-26.6
560	Memantine hydrochloride		BRD-A79803969-003-06-2	-3.7	-1.2	13.9	6.4	30.5	31.3
561	MIDODRINE HYDROCHLORIDE		BRD-A79981887-003-09-9	8.5	-7.5	-1.2	-2.0	10.6	1.7
562	BENDROFLUMETHIAZIDE		BRD-A80017228-001-15-8	-13.3	2.4	24.2	10.9	4.4	13.2
563	NORSTICTIC ACID		BRD-A80079592-001-03-2	58.6	62.5	-67.2	-57.9	-42.3	-61.8
564	BETAMETHASONE VALERATE		BRD-A80594172-001-03-8	5.9	2.5	-49.2	-20.5	-3.0	-16.0
565	FR 139317		BRD-A80641450-001-01-4	0.8	-11.1	1.5	-3.0	19.7	26.0
566	CLOPERASTINE HYDROCHLORIDE		BRD-A80908310-003-08-8	-1.7	-12.4	-61.5	-43.4	-20.6	-32.2
567	CONVALLATOXIN		BRD-A80968824-001-03-6	-13.0	0.9	33.2	5.5	3.0	22.3
568	GLYCOPYRRROLATE		BRD-A81233518-004-07-0	4.4	3.5	9.6	2.6	14.6	9.5
569	Simvastatin		BRD-A81772229-001-03-2	2.1	-1.6	-3.8	-6.6	3.1	17.0
570	U 18666A		BRD-A81795050-003-01-7	3.3	-10.0	-15.7	-32.3	-17.0	-11.0
571	CGS 21680 hydrochloride		BRD-A81866333-003-01-5	12.6	-1.6	-21.4	-26.8	-14.0	-14.7
572	6alpha-METHYL PREDNISOLONE ACETATE		BRD-A82086877-001-03-1	-3.3	-16.1	0.2	-15.3	-3.0	-1.0
573	Clofarabine		BRD-A82371568-001-01-5	8.6	-2.3	0.7	-7.4	19.0	25.0
574	MICONAZOLE NITRATE		BRD-A82396632-008-14-2	-128.3	-123.4	-126.2	-131.1	-97.9	-97.9
575	MANGIFERIN		BRD-A82440780-001-01-0	107.7	98.2	-36.1	-19.7	-26.2	-39.2
576	ARTENIMOL		BRD-A82452087-001-01-5	-4.3	-17.9	-47.0	-4.3	-1.4	4.7
577	SDZ NKT 343		BRD-A82590476-001-01-1	-8.8	-15.4	-31.2	-33.9	-9.4	-6.3
578	Naltrindole hydrochloride		BRD-A82656074-003-01-2	17.5	9.8	-25.6	-8.5	-48.4	-32.0
579	FINASTERIDE		BRD-A83081521-001-01-5	-26.5	3.8	-15.8	3.1	-3.4	2.9
580	BRAZILIN		BRD-A83326220-001-04-2	305.6	279.8	25.5	30.3	-0.3	5.4
581	2-Cl-IB-MECA		BRD-A83387524-001-01-3	-41.3	-34.6	-59.1	-86.9	-42.8	-37.2
582	ESTRADIOL METHYL ETHER		BRD-A83613346-001-03-4	-9.3	-18.8	-32.1	-50.6	-31.2	-29.6
583	A 61603 hydrobromide		BRD-A83650191-004-01-0	-6.7	7.8	11.8	4.8	-30.5	-27.6
584	Chromanol 293B		BRD-A83695761-001-01-1	1.0	-0.3	12.3	-1.0	21.9	24.2
585	DEXAMETHASONE SODIUM PHOSPHATE		BRD-A83802939-304-03-4	5.5	-3.8	5.0	20.0	10.7	-20.9
586	Tropisetron hydrochloride		BRD-A83859836-003-02-8	-8.7	-6.5	-4.0	0.5	3.9	2.6
587	Calpeptin		BRD-A84045418-001-01-5	16.2	21.1	-21.0	-13.7	2.5	-3.6
588	MELOXICAM SODIUM		BRD-A84174393-236-03-0	13.8	1.0	13.8	-2.8	15.2	8.5
589	Baclofen (R,S)		BRD-A84174873-001-06-0	-37.7	-12.3	32.4	33.3	10.6	5.9
590	MADECASSIC ACID		BRD-A84189249-001-03-2	30.9	60.8	-44.1	-30.9	28.0	16.7
591	BACCATIN III		BRD-A84189516-001-01-2	10.0	-3.5	-10.3	1.9	11.8	11.7
592	L-655,708		BRD-A84389091-001-01-1	7.6	0.8	-6.2	0.5	16.5	8.0
593	Tropanyl-3,5-dimethylbenzoate		BRD-A84389633-001-02-4	5.2	-12.1	-13.0	-20.0	-0.7	-2.4
594	NISOLDIPINE		BRD-A84465106-001-01-2	264.7	329.5	-46.6	-72.4	-16.9	-35.4
595	THIORIDAZINE HYDROCHLORIDE		BRD-A84481105-003-17-2	-96.8	-96.1	-94.0	-95.8	-71.6	-76.8

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
596	3,16-DIDEOXYMEXICANOLIDE-3beta-DIOL		BRD-A84663931-001-03-9	-10.6	-21.8	-47.9	-51.7	-29.1	-30.2
597	DEHYDROROTENONE		BRD-A84913188-001-03-8	8.7	8.4	-41.3	-5.6	2.0	0.0
598	3 a-Bis-(4-fluorophenyl) methoxytropone hydrochloride		BRD-A85216385-003-01-6	-28.4	-45.7	-83.1	-83.6	-58.9	-54.9
599	N6 -Cyclopentyladenosine		BRD-A85234536-001-04-5	8.6	-0.3	6.3	26.7	18.3	21.2
600	(-)Quinpirole hydrochloride		BRD-A85280935-003-01-7	7.5	3.4	12.0	-18.5	10.8	12.4
601	L 670596		BRD-A85472596-001-01-4	-20.7	-22.3	-42.0	-69.6	-28.3	-31.1
602	MDL 72222		BRD-A85587465-001-02-5	-23.2	-11.7	-22.7	-15.4	-10.0	-1.6
603	USNIC ACID		BRD-A85739295-001-03-6	15.3	49.9	21.7	23.4	7.1	11.8
604	(?)1-(1,2-Diphenylethyl)piperidine maleate		BRD-A86415025-103-01-7	-22.1	-29.6	12.2	6.6	13.0	18.4
605	Ganaxolone		BRD-A87005460-001-01-3	-9.3	4.8	-20.0	10.0	-21.2	-12.1
606	CEFPODOXIME PROXETIL		BRD-A87387433-001-01-9	19.5	16.3	12.8	37.5	9.3	5.9
607	Tenidap		BRD-A87479750-001-01-9	-18.0	-19.9	-29.3	-32.9	7.6	0.1
608	NADOLOL		BRD-A87606379-001-13-3	-0.9	0.9	-4.1	-17.6	10.2	10.5
609	PRONETALOL HYDROCHLORIDE		BRD-A87715314-003-09-4	-0.1	-31.5	-37.0	2.0	14.7	6.2
610	EQUILIN		BRD-A88080608-001-03-4	48.1	11.5	-2.9	-25.1	-24.2	-32.6
611	HALCINONIDE		BRD-A88138582-001-03-0	36.0	20.0	-3.0	4.8	4.7	-0.4
612	ALBUTEROL (+/-)		BRD-A88254928-001-05-3	16.4	10.9	2.2	-10.0	4.7	9.2
613	DIHYDROXY (3alpha,12alpha)PREGNAN-20-ONE		BRD-A88284590-001-03-2	10.1	-7.7	-37.5	-20.5	-16.1	-13.5
614	SKF 38393 hydrobromide		BRD-A88548664-004-01-9	6.3	17.7	-12.4	-12.3	-30.1	-37.4
615	BUCKETIN		BRD-A88684804-001-01-9	-1.3	11.3	-2.4	0.2	23.6	19.6
616			BRD-A88691025-001-07-4	-5.7	2.4	-3.3	-0.9	5.5	10.6
617	BISOPROLOL FUMARATE		BRD-A89175223-051-05-6	7.9	-0.3	11.6	20.7	25.4	28.9
618	ICI 192,605		BRD-A89208012-001-01-4	-7.2	-8.3	-66.1	-55.0	-31.6	-16.4
619	jmw-topo1-04		BRD-A89471977-001-05-2	6.9	-2.7	22.5	26.2	6.9	16.2
620	Mefloquine		BRD-A89585551-003-08-3	-52.4	-72.9	-91.6	-105.5	-82.2	-99.4
621	CGP 55845		BRD-A89672324-001-02-2	15.6	-5.3	-4.0	-10.0	1.6	-0.4
622	ALCLOMETAZONE DIPROPIONATE		BRD-A90131694-001-02-8	-11.7	-7.1	-2.2	-4.6	-1.7	9.8
623	ALPINETIN METHYL ETHER		BRD-A90249268-001-04-0	-2.6	-2.8	-42.9	-43.7	-20.1	-19.1
624	Cilastatin sodium		BRD-A90311807-236-01-4	-3.7	-11.0	-9.6	-4.5	9.9	13.5
625	GUAIIFENESIN		BRD-A90515964-001-09-0	15.5	-7.0	-11.0	4.8	3.2	-2.5
626	ESTRONE BENZOATE		BRD-A90969585-001-03-1	5.3	1.5	-11.0	-17.0	11.2	6.9
627	BEPRIDIL HYDROCHLORIDE		BRD-A91008255-003-16-4	-13.9	-33.9	-25.3	-6.1	-36.5	-7.2
628	LAPPACONITINE		BRD-A91353509-001-01-4	1.9	-3.7	-9.7	0.2	-4.0	4.6
629	ESTRADIOL CYPIONATE		BRD-A91452556-001-03-2	-33.3	-1.0	10.5	27.5	47.8	49.7
630	CHLOROQUINE DIPHOSPHATE		BRD-A91699651-316-06-7	-21.5	10.8	-3.5	-3.9	6.3	2.0
631	ESTRADIOL-3-SULFATE, SODIUM SALT		BRD-A91702150-236-03-2	-6.5	-20.3	15.9	8.2	1.1	6.8
632	CAMYLOFINE DIHYDROCHLORIDE		BRD-A91733352-300-01-1	-9.1	-11.0	8.8	-7.2	-1.0	-0.6
633	Siguazodan		BRD-A91992993-001-01-2	5.1	-5.2	-3.4	-10.4	7.2	16.6
634	BETAMETHASONE ACETATE		BRD-A92177080-001-01-3	-6.0	-1.0	-4.1	20.0	5.2	7.6
635	TRIAMCINOLONE ACETONIDE		BRD-A92439610-001-03-2	-21.8	4.0	5.8	23.9	1.1	4.0
636	DEOXYSAPPANONE B 7,3'-DIMETHYL ETHER		BRD-A92542880-001-01-0	12.5	6.1	-24.3	-2.6	-40.9	-38.5
637	RU 28318, potassium salt		BRD-A92585442-237-01-0	-18.8	-14.4	7.7	-13.9	-0.4	15.0
638	TRIMEBUTINE MALEATE		BRD-A92630576-050-14-2	6.8	-16.6	16.6	-6.3	23.1	23.9
639	NALBUPHINE HYDROCHLORIDE		BRD-A92651262-003-03-9	22.6	6.4	17.9	15.3	-18.8	-24.9
640	BICUCULLINE(-) METHIODIDE		BRD-A92652541-005-01-9	-4.2	-7.7	-23.4	-21.0	-13.2	-12.3
641	LUPANINE PERCHLORATE		BRD-A92826379-009-03-4	1.8	5.1	9.5	25.8	7.7	11.6

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
642	SM-21 maleate		BRD-A92933783-103-01-3	-8.8	-11.5	-31.3	-35.6	-23.2	-24.2
643	Ciglitazone		BRD-A93000692-001-03-2	-8.6	-20.8	22.5	5.2	-9.6	-20.8
644	DIGITOXIN		BRD-A93236127-001-03-7	-3.7	11.1	12.6	11.6	-0.2	6.4
645	(+/-)-Clopidogrel hydrochloride		BRD-A93269281-003-01-0	15.4	0.8	2.6	4.5	28.0	22.1
646	DEXAMETHASONE ACETATE		BRD-A93424738-001-03-0	-13.8	-15.9	3.6	2.6	1.1	1.9
647	AF-DX 384		BRD-A93436351-001-01-4	-4.9	-2.4	7.0	-0.4	10.4	6.8
648	PETCM		BRD-A93477898-001-03-4	6.0	33.6	8.5	7.1	7.9	7.5
649	MUNDULONE		BRD-A93572202-001-03-3	-35.2	-38.0	-58.8	-20.4	-22.6	-25.7
650	GR 89696 fumarate		BRD-A93659613-051-03-6	-14.6	-28.0	-38.5	-58.6	-19.0	-12.6
651	ATROPINE SULFATE		BRD-A93739713-065-03-5	-1.3	21.1	-33.9	0.5	-5.0	-0.3
652	17-PA		BRD-A94046266-001-01-4	-17.7	-5.5	2.3	49.8	8.2	19.2
653	TOTAROL ACETATE		BRD-A94366206-001-03-5	7.5	9.4	49.6	12.5	17.7	35.8
654	NTNCB hydrochloride		BRD-A94413429-003-01-6	6.7	-8.0	-3.6	10.3	-25.7	-26.7
655	PREDNISOLONE SODIUM PHOSPHATE		BRD-A94523291-304-01-9	10.9	18.7	9.5	38.8	7.9	11.1
656	BIFONAZOLE		BRD-A94543220-001-12-2	1.0	-14.2	-61.0	-53.3	-13.5	-18.0
657	21-ACETOXPREGNENOLONE		BRD-A94561690-001-02-6	22.1	58.9	-14.6	19.9	43.6	36.6
658	N-Methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl) ethyl]phenylacetamide hydrochloride		BRD-A94675310-003-01-2	-3.0	-8.7	23.7	47.7	7.7	5.8
659	METAXALONE		BRD-A94709349-001-03-4	-12.5	-16.2	-13.9	-13.3	0.8	4.4
660	DIGOXIN		BRD-A94756469-001-03-9	-21.9	10.3	24.2	15.1	15.2	22.2
661	CYPROTERONE ACETATE		BRD-A95207036-001-03-6	-0.2	-3.9	-26.8	-43.2	-21.4	-30.6
662	ANDROSTA-1,4-DIEN-3,17-DIONE		BRD-A95513702-001-03-0	-20.3	-19.7	-9.2	-14.1	1.3	13.0
663	Nisoxetine hydrochloride		BRD-A95696066-003-06-2	-7.6	-8.1	-8.3	-0.6	3.9	12.0
664	INDAPAMIDE		BRD-A95869247-001-14-5	13.3	3.9	6.3	8.2	-8.8	-9.0
665	FPL 55712		BRD-A96456596-001-01-4	-45.0	-43.9	-83.3	-93.3	-45.4	-49.9
666	EBPC		BRD-A96485169-001-05-1	-9.9	-10.3	7.3	9.1	12.8	19.6
667	5alpha-ANDROSTAN-3,17-DIONE		BRD-A96828973-001-05-8	-3.5	-8.5	-23.0	5.9	2.6	-5.9
668	L-732,138		BRD-A96882008-001-01-3	-11.9	-9.8	-14.7	-15.6	-25.0	-27.9
669	HYDROQUININE HYDROBROMIDE HYDRATE		BRD-A96933311-337-01-4	4.0	1.2	7.4	-6.4	0.1	2.5
670	DECAHYDROGAMBOGIC ACID		BRD-A97026779-001-01-3	6.8	-0.5	-5.6	78.5	16.2	29.2
671	FENOTEROL HYDROBROMIDE		BRD-A97104540-004-08-5	1.0	-4.0	16.0	16.2	11.4	12.9
672	ISOKOBUSONE		BRD-A97152619-001-03-7	29.7	26.7	-3.5	13.6	26.0	20.3
673	ROSIGLITAZONE		BRD-A97437073-001-04-9	3.8	-8.5	-0.1	0.2	2.3	8.0
674	PIPERIDOLATE HYDROCHLORIDE		BRD-A97479839-003-08-3	-22.4	18.5	-21.1	-22.0	-16.7	-4.9
675	RANOLAZINE		BRD-A97674275-001-04-3	-2.9	14.4	16.6	-6.5	15.4	25.7
676	PINDOLOL		BRD-A97701745-001-09-5	-4.3	-10.4	20.6	7.7	18.3	22.6
677	KETOPROFEN		BRD-A97739905-001-15-8	-31.6	-32.3	2.3	-12.0	15.8	10.8
678	Talniflumate		BRD-A98378129-001-01-4	-26.0	-17.1	-13.9	-26.3	-26.2	-21.9
679	CARBENOXOLONE SODIUM		BRD-A98702003-304-03-0	1.0	-24.9	-25.2	-16.9	-10.6	5.1
680	Methysergide maleate		BRD-A98725278-103-01-9	33.9	35.3	101.9	113.9	19.1	20.3
681	HYDROXYCHLOROQUINE SULFATE		BRD-A99117172-065-02-4	12.0	3.0	-10.3	22.4	2.2	15.0
682	EVOXINE		BRD-A99268498-001-06-8	8.5	-4.8	110.4	76.1	4.1	-0.1
683	NAFCILLIN SODIUM		BRD-A99402294-236-03-8	-22.2	-30.2	13.8	7.8	-5.3	12.5
684	MT-21		BRD-A99449986-001-01-4	-12.1	5.8	21.6	24.3	-10.8	-13.5
685	ETHOSUXIMIDE		BRD-A99633051-001-05-4	9.1	6.1	13.4	-9.6	-2.7	3.2
686	TRILOSTANE		BRD-A99644790-001-01-6	-6.7	-10.7	-46.8	-29.7	-1.8	1.5
687	Nicergoline		BRD-A99721021-001-01-3	-2.1	-8.6	-23.8	-25.7	-4.4	-13.0

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+_DNA		CBA		Amplex Red_HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
688	P1075		BRD-K00206590-001-01-2	6.7	17.7	21.1	0.9	15.4	14.8
689	PPT		BRD-K00312224-001-03-8	-38.3	-35.8	-75.2	-79.1	8.2	7.1
690	RITA		BRD-K00317371-001-01-2	-29.4	-24.3	25.4	44.3	-31.1	-37.7
691	Ro 08-2750		BRD-K00486786-001-01-4	316.8	315.9	12.8	9.3	-18.9	-3.7
692			BRD-K00535541-311-04-1	-5.6	-1.1	9.5	14.9	2.8	19.1
693	TICLOPIDINE HYDROCHLORIDE		BRD-K00603606-003-13-3	-9.3	-15.9	32.4	11.3	9.0	14.9
694	Altanserin hydrochloride		BRD-K00610438-003-01-7	4.3	2.9	-23.1	-20.9	1.1	-3.8
695	CL 218872		BRD-K00662280-001-04-5	-2.5	-4.0	3.4	7.6	5.6	5.0
696	FAMOTIDINE		BRD-K00673382-001-07-2	1.1	9.6	17.8	12.4	12.3	5.9
697	CL 82198 hydrochloride		BRD-K00675675-003-01-2	-16.4	-8.7	-4.6	12.7	21.4	24.4
698	2',4'-DIHYDROXYCHALCONE		BRD-K00721105-001-01-8	8.0	6.5	-9.3	-30.7	-19.9	-27.4
699	SULFAMETHOXYPYRIDAZINE		BRD-K00938507-001-13-7	-8.6	29.6	0.6	53.1	31.4	22.8
700	CLOXACILLIN SODIUM		BRD-K01244426-236-08-9	-7.4	-24.0	1.0	7.4	16.8	12.4
701	PIMOZIDE		BRD-K01292756-001-13-6	-20.0	-19.7	-60.0	-50.0	-43.2	-30.0
702	2,4-Dichlorophenoxyacetic acid		BRD-K01473791-001-06-3	7.7	16.3	-17.5	-5.6	-16.7	-2.7
703	APIGENIN		BRD-K01493881-001-17-9	11.1	21.3	-39.0	-35.7	-8.5	-15.0
704			BRD-K01567962-001-08-1	1.1	-1.8	25.5	21.2	13.8	20.1
705	LE 300		BRD-K01648091-001-04-2	-17.2	-22.4	19.6	13.4	-16.7	4.7
706	INDOLE-3-CARBINOL		BRD-K01815685-001-07-2	-5.2	-16.1	45.8	38.4	-0.9	2.3
707	CARAPIN-8(9)-ENE		BRD-K01818918-001-03-4	-1.1	20.0	-77.1	-37.0	27.2	-2.4
708	DPCPX		BRD-K01824921-001-10-2	-14.2	-17.2	11.8	31.1	13.1	22.7
709	RS 23597-190 hydrochloride		BRD-K01868942-003-01-9	-35.7	-3.8	20.7	24.2	0.7	6.8
710	WY 14643		BRD-K01902415-001-03-4	-5.0	-3.9	6.0	-5.5	17.8	21.8
711	SUCCINYL SULFATHIAZOLE		BRD-K01950558-001-09-7	8.5	12.5	-23.5	20.8	18.2	5.0
712	PACHYRRHIZIN		BRD-K02070226-001-03-8	22.2	7.3	9.0	-2.9	-21.4	-28.4
713	panobinostat		BRD-K02130563-001-07-2	0.0	-12.8	11.6	59.1	-15.2	-22.5
714	AMOXAPINE		BRD-K02265150-001-15-8	-50.4	-49.4	-80.3	-71.7	-31.0	-50.6
715	GR 32191 hydrochloride		BRD-K02283807-003-01-4	-15.9	-13.8	-51.5	-70.4	-27.0	-23.1
716	CAFFEINE		BRD-K02404261-001-07-6	-0.7	6.8	25.7	10.6	23.0	23.7
717	Parbendazole		BRD-K02407574-001-04-8	6.9	5.3	-2.0	1.8	26.7	33.0
718	ETHYL PARABEN		BRD-K02464583-001-01-4	23.1	21.0	-3.2	1.8	5.1	-11.1
719	O-2050		BRD-K02590140-001-01-2	-22.2	-12.8	-3.6	-13.4	-12.9	-17.5
720	CELECOXIB		BRD-K02637541-001-06-5	10.3	23.2	-32.2	-29.8	29.5	24.4
721	RESVERATROL 4'-METHYL ETHER		BRD-K02671211-001-03-0	0.5	-3.8	16.4	-18.0	-1.4	-6.7
722	HYDRASTINE (IR, 9S)		BRD-K02715688-001-01-3	-0.7	-8.9	5.2	5.3	-2.0	22.2
723	Methiazole		BRD-K02764365-001-05-2	10.9	-4.6	42.7	33.9	17.3	28.4
724	2-METHOXYXANTHONE		BRD-K02855712-001-06-6	16.1	-1.7	151.9	127.9	7.3	-4.9
725	MINAPRINE HYDROCHLORIDE		BRD-K02867583-300-06-3	-13.8	-18.8	-3.2	-14.2	5.0	12.6
726	CLOFOCTOL		BRD-K02900412-001-07-1	-19.4	-7.1	-26.7	-16.2	9.7	1.1
727	Forskolin, 7-Deacetyl-7-[O-(N-methylpiperazino)-g-butyryl]-, Dihydrochloride		BRD-K03015355-003-01-5	-7.1	-14.5	9.6	7.6	-0.4	-2.1
728	ARACHIDONIC ACID		BRD-K03070961-001-04-4	17.6	9.7	2.5	-32.4	10.8	0.0
729	A-7 hydrochloride		BRD-K03301001-003-01-7	-53.5	-58.6	-97.0	-94.9	-75.1	-78.4
730	Linomide		BRD-K03384561-001-01-9	-6.3	-8.1	19.1	-2.4	-3.7	13.4
731	DMNB		BRD-K03564313-001-02-5	28.3	21.2	-4.2	6.3	9.1	14.1
732	U0124		BRD-K03635852-001-01-2	0.1	18.4	64.8	28.1	-36.0	-38.3
733	AY 9944		BRD-K03642198-300-01-7	-27.2	-23.5	-48.0	-41.1	-35.3	-26.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
734	Raclopride		BRD-K04111260-001-05-0	-15.8	-6.3	0.9	-2.3	10.0	13.5
735	OXCARBAZEPINE		BRD-K04196797-001-12-9	1.9	1.3	-21.0	25.6	7.9	18.9
736	SB 222200		BRD-K04414442-001-03-4	-16.0	-7.1	-4.7	-11.1	9.4	5.8
737	7-NINA		BRD-K04430056-236-01-3	14.3	14.4	14.0	2.6	3.6	2.1
738	CLEMIZOLE HYDROCHLORIDE		BRD-K04704168-003-11-9	-10.5	11.2	-13.8	-49.3	-22.2	-19.1
739	SULFISOXAZOLE ACETYL		BRD-K05009775-001-01-2	-4.5	-15.2	-28.5	2.7	13.7	13.8
740	ZK 164015		BRD-K05151076-001-01-8	0.6	3.9	-4.0	11.2	16.4	13.1
741	NGB 2904		BRD-K05181084-003-02-9	8.9	-5.0	1.6	-1.5	15.5	1.1
742	L-741,626		BRD-K05181463-001-04-0	-17.0	-6.0	-34.8	-31.2	-6.0	-1.8
743	SC-10		BRD-K05361803-001-02-1	25.0	7.6	19.9	40.5	2.2	-9.5
744	NICOTINE DITARTRATE		BRD-K05395900-322-04-7	-6.6	-3.8	2.3	-0.3	21.6	5.9
745	HA-1004		BRD-K05434375-001-03-2	3.0	7.3	-20.4	-11.0	-7.3	-3.7
746	JX 401		BRD-K05464208-001-01-6	-8.7	0.2	-41.8	-37.5	-32.1	-30.9
747	L-745,870 trihydrochloride		BRD-K05528470-305-01-4	-16.5	-6.5	-33.9	-40.1	-30.6	-28.7
748	FTAXILIDE		BRD-K05724540-001-04-4	4.5	0.2	-21.3	-2.9	17.5	19.2
749	MT001_073		BRD-K05878375-236-02-4	-5.1	-13.0	1.8	-1.9	16.9	19.4
750	FLUCONAZOLE		BRD-K05977355-001-09-1	-5.9	1.2	6.3	1.4	6.4	14.9
751	DH 97		BRD-K06014311-001-01-2	32.7	21.5	10.7	18.5	33.2	21.6
752	Telenzepine dihydrochloride		BRD-K06147391-300-04-3	-17.8	-13.7	14.8	18.8	15.6	20.2
753	CCMQ		BRD-K06159959-001-01-2	15.3	16.9	8.5	25.3	17.8	23.2
754	Carbetapentane citrate		BRD-K06181161-048-07-8	-6.6	-13.7	-13.4	-20.0	-2.3	-0.3
755	YS-035 hydrochloride		BRD-K06208435-003-03-3	4.1	2.7	7.7	18.7	18.9	22.2
756	DuP 697		BRD-K06221026-001-03-5	-13.3	2.2	19.8	38.2	39.7	39.1
757	LY 364947		BRD-K06234293-001-01-8	-4.3	-11.3	-13.2	-9.2	7.9	11.5
758	ROTENONIC ACID, METHYL ETHER		BRD-K06268662-001-03-5	-4.9	0.2	4.2	-27.8	-15.1	-3.6
759	N-METHYLANTHRANILIC ACID		BRD-K06439119-001-03-1	2.7	-26.1	56.7	56.3	3.4	12.2
760	Ro 31-8220 mesylate		BRD-K06543683-066-01-3	-5.7	-15.3	-49.5	-49.8	-46.8	-52.4
761	FAST GREEN FCF		BRD-K06561965-304-01-9	18.7	22.5	-9.7	-18.0	-32.9	-27.6
762	Cisapride		BRD-K06895174-001-01-0	-6.4	-11.1	-40.2	-50.5	-24.3	-24.3
763	MINOXIDIL		BRD-K06902185-001-10-2	18.5	18.9	17.2	3.5	16.7	23.7
764	PROMAZINE HYDROCHLORIDE		BRD-K06980535-003-15-0	-26.9	-57.0	-72.5	-74.0	-71.1	-69.5
765	XANTHURENIC ACID		BRD-K07327532-001-03-6	24.0	23.7	6.7	-10.7	-1.2	-3.8
766	BRL 37344, sodium salt		BRD-K07507905-236-01-8	2.4	-2.4	3.9	-5.8	8.7	7.4
767	curcumin		BRD-K07572174-001-19-6	36.6	44.7	-26.4	-18.7	-42.8	-45.7
768	ACECAINIDE HYDROCHLORIDE		BRD-K07753030-003-11-9	-1.0	0.6	1.6	-9.1	7.7	7.1
769	LINCOMYCIN HYDROCHLORIDE		BRD-K08033334-003-03-5	-37.8	-0.7	13.3	8.6	3.9	20.5
770	PRIMULETIN		BRD-K08048246-001-03-4	27.3	20.1	8.3	7.9	19.3	16.2
771	TETRANDRINE		BRD-K08078237-001-13-1	-28.4	-32.8	-66.4	-64.8	-73.6	-73.7
772	L-701,324		BRD-K08109516-001-02-9	30.0	-4.7	-5.7	14.8	9.2	11.2
773	AG 1288		BRD-K08115555-001-02-8	11.9	-2.0	-12.5	-13.4	-6.2	-0.1
774	AG 825		BRD-K08132273-001-01-6	-40.8	-9.4	-43.5	-30.9	-20.4	-21.1
775	5-Nonyloxytryptamine oxalate		BRD-K08219523-034-01-0	-96.6	-97.5	-110.4	-111.6	-81.8	-84.0
776	DICLOFENAC SODIUM		BRD-K08252256-236-17-1	3.3	10.8	-22.7	-26.4	-6.5	-8.5
777	GRISEOFULVIN		BRD-K08273968-001-09-1	22.9	0.8	4.3	32.9	11.8	2.8
778	BUTYL PARABEN		BRD-K08287586-001-08-5	-11.6	-8.1	-28.8	-37.3	-18.7	-12.1
779	CHLORPYRIFOS		BRD-K08303368-001-06-8	-3.6	-12.7	-13.3	7.9	-2.0	8.3

no.	Compound Name	Broad Institute ID	Normalized scores					
			HPr+ DNA		CBA		Amplex Red HRP	
			Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
780	ROtenone	BRD-K08316444-001-05-0	16.7	39.5	14.5	30.0	8.8	-10.2
781	XyLOMETAZOLINE HYDROCHLORIDE	BRD-K08356259-003-15-5	6.5	1.8	-22.3	-5.4	14.7	5.6
782	NNC 26-9100	BRD-K08438429-001-01-0	-88.7	-83.5	-111.0	-111.8	-88.2	-88.3
783	SARAFLOXACIN HYDROCHLORIDE	BRD-K08525451-003-03-7	4.7	1.5	4.5	-3.4	1.3	-0.6
784	RS 100329 hydrochloride	BRD-K08640512-003-01-5	15.3	-7.9	10.9	14.0	12.2	19.3
785	HETEROPEUCENIN, METHYL ETHER	BRD-K08745849-001-03-6	35.2	71.9	28.3	62.1	29.5	22.7
786	NARINGENIN	BRD-K08832567-001-06-5	22.8	7.6	-19.3	1.7	-11.1	-5.6
787	Co 102862	BRD-K08890269-001-01-5	36.9	12.9	25.5	42.1	24.9	26.3
788	Zolantidine dimaleate	BRD-K08996725-313-01-7	-28.2	-24.8	-39.4	-24.9	-31.0	-41.1
789	Fananserin	BRD-K08998509-001-01-6	80.5	50.6	59.7	84.1	60.2	69.1
790	PIPEMIDIC ACID	BRD-K08999871-001-13-9	16.6	5.7	19.2	11.0	13.9	12.7
791	D 4476	BRD-K09132007-001-01-8	-5.8	10.2	14.9	18.8	-14.3	-9.1
792	4'-METHOXYCHALCONE	BRD-K09233738-001-04-4	-33.8	-32.5	-88.1	-54.2	-21.9	-20.1
793	SR 57227 hydrochloride	BRD-K09397065-003-03-8	-1.4	10.7	-5.3	3.2	16.8	18.3
794	LOVASTATIN	BRD-K09416995-001-21-7	-5.8	-0.3	-45.7	-28.3	-25.7	-11.9
795	NU7026	BRD-K09537769-001-02-4	-3.2	-10.2	15.7	12.4	-4.1	1.9
796	Mibepradil dihydrochloride	BRD-K09549677-300-01-8	-52.0	-50.0	-89.2	-89.3	-67.2	-73.8
797	THIOTEPA	BRD-K09631521-001-05-7	-2.6	-3.9	-7.7	20.4	10.9	12.9
798	DEFEROXAMINE MESYLATE	BRD-K09821361-066-15-9	35.0	17.1	44.5	56.4	-6.3	-9.6
799	N-Desmethylclozapine	BRD-K10042277-001-04-3	-26.9	-29.1	-72.6	-72.0	-45.9	-50.8
800	DANTHRON	BRD-K10065684-001-06-6	30.3	9.4	19.7	9.0	19.0	9.1
801	L-701,252	BRD-K10176267-001-02-5	6.4	-16.4	-8.1	4.4	-3.2	8.7
802	PSB 11	BRD-K10177585-003-01-6	-20.3	26.3	-2.1	-19.4	-15.1	6.5
803	MECLOFENOATE HYDROCHLORIDE	BRD-K10314788-003-07-7	4.7	-4.3	-23.6	1.9	-7.9	-5.5
804	SULFASALAZINE	BRD-K10670311-001-08-0	-8.2	-11.0	-55.4	-12.5	8.2	4.4
805	SULFAPHENAZOLE	BRD-K10671814-001-09-8	-13.4	-3.4	-32.9	6.3	-8.8	1.3
806	S-Isopropylisothiourea hydrobromide	BRD-K10673031-004-01-2	-7.8	-16.4	-17.2	-23.7	1.3	5.2
807	PHENYLBUTAZONE	BRD-K10843433-001-12-8	3.4	3.4	-17.9	-6.1	23.0	19.3
808	DILOXANIDE FUROATE	BRD-K10974103-001-14-6	-10.2	-22.4	-25.6	-21.8	0.9	9.0
809	PERPHENAZINE	BRD-K10995081-001-15-4	-88.0	-89.7	-103.3	-102.4	-72.8	-75.5
810	ACETANILIDE	BRD-K11094367-001-04-4	-14.2	1.2	-24.2	1.8	31.9	17.2
811	Tiotidine	BRD-K11107424-001-01-1	3.0	19.6	24.6	32.8	12.4	28.6
812	GEMFIBROZIL	BRD-K11129031-001-15-0	-11.4	4.1	10.6	-7.2	-2.2	-0.3
813	TYRPHOSTIN B44 (-)	BRD-K11158509-001-02-0	-5.6	-0.3	24.1	21.8	19.3	19.6
814	NORFLOXACIN	BRD-K11196887-001-15-4	3.5	-14.4	57.3	42.7	-0.5	10.2
815	AMBROXOL HYDROCHLORIDE	BRD-K11223672-003-04-5	-24.5	-19.8	-22.7	9.4	2.6	2.3
816	RUTILANTINONE	BRD-K11258719-001-03-2	309.9	341.8	23.8	22.8	-26.1	-35.8
817	ZD 7155 hydrochloride	BRD-K11373525-003-01-3	8.9	16.2	14.2	26.0	19.4	19.6
818	GBR 13069 dihydrochloride	BRD-K11634954-300-01-8	19.7	21.1	-32.5	-21.1	-3.2	-10.4
819	BU 239 hydrochloride	BRD-K11696279-003-01-5	-2.2	-2.0	13.2	17.7	11.3	12.9
820	BENZBROMARONE	BRD-K11717138-001-16-2	-69.6	-65.0	-95.4	-88.7	-75.1	-77.8
821	TRIPROLIDINE HYDROCHLORIDE	BRD-K11742128-003-15-0	-18.8	-19.1	1.2	-1.1	10.6	5.9
822	FURAZOLIDONE	BRD-K11756522-001-04-0	42.4	54.3	56.4	30.7	17.2	-0.3
823	NBQX	BRD-K11796549-001-02-9	4.9	13.7	14.8	21.4	-2.3	3.9
824	GR 127935 hydrochloride	BRD-K11911061-003-02-8	-73.0	-73.7	-58.4	-96.6	-89.7	-91.5
825	ER 27319 maleate	BRD-K11927976-050-01-1	-6.2	6.8	-12.2	-16.1	-8.2	-3.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
826	alpha-MANGOSTIN		BRD-K11991978-001-03-4	-9.9	-26.2	-63.7	-83.0	-23.2	-35.5
827	PD 160170		BRD-K12079898-001-01-8	8.2	11.1	2.8	-2.9	11.7	1.8
828	NIALAMIDE		BRD-K12102668-001-14-9	36.3	33.5	42.5	14.8	21.5	13.8
829	GR 144053 trihydrochloride		BRD-K12120659-305-01-4	-5.9	-5.8	-12.7	7.4	-3.4	6.6
830	Flunarizine dihydrochloride		BRD-K12184470-300-01-8	-9.2	-4.6	1.8	13.4	-5.6	25.4
831	METHYL ORSELLINATE		BRD-K12202814-001-05-8	20.4	16.7	20.2	15.5	-8.0	5.9
832	GLIPIZIDE		BRD-K12219985-001-15-4	-14.6	-15.9	-6.0	-2.5	8.9	13.4
833	XANTHOXYLIN		BRD-K12260308-001-04-2	-7.1	7.4	-9.4	0.6	9.5	17.0
834	JUAREZIC ACID		BRD-K12345912-001-03-1	14.1	-11.3	-18.5	7.0	14.4	12.1
835	AG 490		BRD-K12357156-001-01-5	7.6	19.8	-23.6	-28.7	-41.1	-46.1
836	FENBUFEN		BRD-K12513978-001-16-7	1.4	-5.5	-17.7	-16.6	-3.8	16.8
837	Zaprinast		BRD-K12516989-001-01-9	22.6	44.8	26.7	9.2	29.1	20.5
838	NOCODAZOLE		BRD-K12539581-001-14-6	9.4	12.9	40.0	60.9	0.1	8.1
839	EXALAMIDE		BRD-K12609457-001-02-3	7.8	14.2	-35.2	-36.4	-7.7	-36.9
840	KAEMPFEROL		BRD-K12807006-001-10-2	43.3	63.0	-22.4	-7.7	-16.7	-25.9
841	MECHLORETHAMINE		BRD-K12829205-001-03-0	-32.1	-18.3	-18.5	0.4	-0.3	4.5
842	YM 976		BRD-K12932420-001-01-5	23.6	13.7	10.4	12.6	33.9	22.0
843	BERGAPTEN		BRD-K12968785-001-06-7	0.2	4.4	31.6	24.0	26.4	28.7
844	GYROMITRIN		BRD-K13037776-001-01-2	7.0	-15.6	-1.9	-6.1	0.8	9.5
845	CICLOPIROX OLAMINE		BRD-K13044802-213-09-0	95.0	100.6	25.9	38.8	7.6	3.6
846	HYDROCHLOROTHIAZIDE		BRD-K13078532-001-17-7	-24.3	0.2	12.0	-7.0	12.2	17.2
847	Artemisinin		BRD-K13112821-001-08-3	-1.8	-11.9	-9.7	-6.7	9.9	-1.6
848	ppn-schn-2		BRD-K13169950-001-07-8	28.4	37.9	25.3	25.5	1.3	28.5
849	PENTAMIDINE ISETHONIATE		BRD-K13183738-317-06-0	7.0	-16.9	11.9	0.3	6.8	9.1
850	L-741,742 hydrochloride		BRD-K13211965-003-01-0	-7.9	-6.1	-54.7	-53.4	-25.9	-36.6
851	CARSALAM		BRD-K13238618-001-01-8	-6.5	-5.6	-18.2	22.1	4.6	18.3
852	LY-163,502		BRD-K13261168-001-01-4	-3.5	-10.7	10.4	5.5	14.1	0.4
853	beta-PELTATIN		BRD-K13265046-001-02-1	35.8	36.0	57.8	33.7	7.7	-2.0
854	METHAZOLAMIDE		BRD-K13356952-001-15-2	-33.2	-8.6	-34.1	5.2	5.9	7.3
855	DESOXYPEGANINE HYDROCHLORIDE		BRD-K13819402-003-06-0	-6.1	2.4	-4.0	22.2	6.5	13.8
856	VARDENAFIL HYDROCHLORIDE		BRD-K13926615-003-02-5	-8.8	-15.3	-5.5	1.8	5.3	17.4
857	DEXPROPRANOLOL HYDROCHLORIDE		BRD-K13994703-003-10-9	6.2	18.2	-13.0	27.1	15.2	5.0
858	SULFAMONOMETHOXINE		BRD-K14116214-001-07-0	8.5	2.3	-27.4	25.2	33.7	17.4
859	ISOPROPAMIDE IODIDE		BRD-K14127446-005-15-1	-34.5	12.9	-9.3	-8.6	15.0	15.7
860	AG 556		BRD-K14441456-001-01-2	11.4	7.1	-50.5	-52.1	-52.0	-50.9
861	VERATRIC ACID		BRD-K14520048-001-04-2	-3.4	-13.9	22.1	25.8	9.9	18.6
862	IKK 16		BRD-K14618467-003-01-8	-59.1	-67.3	-78.2	-77.6	-57.4	-62.0
863	CINCHONINE		BRD-K14693417-001-03-2	-7.0	-2.1	-6.5	-0.5	11.7	3.6
864	CINOXACIN		BRD-K14704277-001-15-0	7.5	36.0	-8.7	14.7	11.2	-0.5
865	SULFATHIAZOLE		BRD-K14705039-001-08-1	-1.6	7.1	-43.9	-2.3	12.6	-15.4
866	SPIRAMYCIN		BRD-K14716343-001-03-0	18.7	9.0	6.8	13.5	13.7	21.2
867	SC 560		BRD-K14767410-001-01-5	19.4	9.8	-17.8	-3.9	8.7	7.5
868	Berberine		BRD-K14796088-003-17-7	65.8	54.0	-12.0	-6.6	4.3	1.0
869	SB 221284		BRD-K14807180-001-01-7	-3.4	-6.2	14.2	13.1	9.0	9.8
870	FCCP		BRD-K14821540-001-03-9	-22.2	6.6	-33.5	-29.6	-36.6	-41.8
871	METHYL-6,7-DIMETHOXY-4-ETHYL-beta-CARBOLINE-3-CARBOXYLATE		BRD-K14844937-001-01-6	-15.8	-14.2	-11.4	-8.2	-55.7	-48.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
872	ERYTHRROSINE SODIUM		BRD-K14920963-304-01-9	345.1	318.1	-3.3	-9.8	-5.0	-33.0
873	JNJ 10191584 maleate		BRD-K15086322-103-01-0	-10.4	-8.3	2.7	21.4	7.1	21.5
874	Apoptosis Activator 2		BRD-K15164005-001-02-3	-30.3	-6.1	-27.2	-38.7	-33.1	-23.8
875	5-HYDROXY-2',4,7,8-TETRAMETHOXYFLAVONE		BRD-K15179660-001-01-9	4.1	24.5	-35.0	-1.6	-32.6	-28.4
876	IBC 293		BRD-K15196155-001-01-5	35.2	34.8	5.3	-13.0	9.9	2.3
877	MUPIROCIN		BRD-K15262564-001-06-9	18.5	12.7	13.7	27.5	19.2	15.2
878	PENFLURIDOL		BRD-K15409150-001-01-7	-37.7	-30.9	-63.5	-62.7	-49.4	-51.0
879	1-[1-(2-BENZO[b]THIENYL)CYCLOHEXYL]PIPERIDINE		BRD-K15519488-001-01-6	-12.7	-4.7	-6.8	-24.3	-8.4	-26.2
880	Cinanserin hydrochloride		BRD-K15522385-003-01-0	7.3	17.1	-17.0	-10.5	11.9	8.0
881	PHORETIN		BRD-K15563106-001-10-7	-22.7	-11.1	-19.3	-29.0	5.9	5.0
882	PAPAVERINE HYDROCHLORIDE		BRD-K15567136-003-18-1	25.4	14.1	-12.5	-14.2	17.7	6.0
883	R-96544 hydrochloride		BRD-K15588452-003-01-9	-37.4	-45.9	-92.1	-94.4	-60.1	-64.4
884	SEW 2871		BRD-K15601958-001-01-3	17.9	39.3	4.9	12.1	5.7	11.0
885	CCCP		BRD-K15616905-001-01-5	-3.3	-10.2	28.0	32.6	6.9	-2.3
886	FLUPERLAPINE		BRD-K15715913-001-01-5	-37.9	-21.4	-33.1	-37.9	-21.2	-32.9
887	L-733,060 hydrochloride		BRD-K15791587-003-01-7	-25.5	-20.6	-69.1	-71.2	-18.2	-26.4
888	LOBENDAZOLE		BRD-K15834839-001-01-5	2.7	1.8	3.5	12.3	8.3	4.1
889	SDZ 205-557 hydrochloride		BRD-K15868788-003-02-8	-4.6	3.1	23.8	13.0	13.7	7.4
890	CLOTTRIMAZOLE		BRD-K15916496-001-14-7	-46.2	-51.5	-92.6	-96.8	-48.9	-33.8
891	ANTHRAQUINONE		BRD-K15957397-001-03-4	-6.6	-2.7	-0.5	-8.2	8.6	9.8
892	OXYMETAZOLINE HYDROCHLORIDE		BRD-K16195444-003-16-1	-13.6	6.0	23.1	34.3	-15.7	-10.1
893	Ibudilast		BRD-K16444452-001-03-4	-0.6	-0.6	23.0	16.0	28.3	25.8
894	METACETAMOL		BRD-K16474819-001-05-4	-3.8	1.2	13.7	19.9	-2.3	10.1
895	MGCD-0103		BRD-K16485616-001-04-8	10.3	9.8	-22.1	17.4	-4.7	3.2
896	GALANGIN		BRD-K16503581-001-04-9	34.1	44.6	-26.9	-21.4	-37.3	-37.3
897	PNU 22394 hydrochloride		BRD-K16551401-003-02-6	-11.8	-12.9	-0.5	4.6	-9.6	-5.3
898			BRD-K16598630-001-05-7	30.6	20.2	17.2	11.3	17.9	7.4
899	TRIMETHADIONE		BRD-K16606819-001-07-7	6.5	0.3	-7.4	8.7	20.2	14.5
900	GTP 14564		BRD-K16664969-001-02-5	-13.1	3.6	-41.3	-27.9	-4.8	4.1
901	(R)-(+)-Bay K 8644		BRD-K16695519-001-01-6	27.6	51.5	4.6	9.5	20.2	22.7
902	CHLOROXINE		BRD-K17075857-001-06-9	41.0	31.7	4.3	12.2	-24.9	-23.1
903	CHLOROXYLENOL		BRD-K17223896-001-06-8	14.5	25.5	24.7	24.3	-4.1	3.1
904	5,7-DIHYDROXY-4-METHYLCOUMARIN		BRD-K17275330-001-03-9	1.4	67.2	116.3	102.3	-3.3	-14.1
905	Typhostin B44, (+) enantiomer		BRD-K17415526-001-02-7	-3.4	-12.8	-44.8	-47.8	-41.4	-43.0
906	Butein		BRD-K17497770-001-01-0	-21.6	-11.5	-15.4	-12.9	-35.4	-37.0
907	Alsterpaullone		BRD-K17516382-001-02-5	-0.6	-9.5	-23.0	-2.9	6.4	13.6
908	AMIODARONE HYDROCHLORIDE		BRD-K17561142-003-16-8	-73.1	-81.9	-95.3	-93.3	-69.2	-66.3
909	PRIDINOL METHANESULFONATE		BRD-K17565903-066-15-7	5.1	-15.7	5.6	-1.1	8.1	9.8
910	DECOQUINATE		BRD-K17641316-001-01-4	5.4	23.1	10.6	31.5	21.2	13.7
911	N-[2-(Acetoxy)ethyl]-3-pyridinecarboxamide		BRD-K17693482-001-03-9	10.8	-9.1	4.8	32.6	17.5	18.2
912	DEMETHYLNOBILETIN		BRD-K17726681-001-01-0	-15.2	-24.1	-79.1	-64.3	-53.2	-53.4
913	KB-R7943 mesylate		BRD-K17743697-066-02-8	-20.6	-11.4	-74.5	-76.5	-41.7	-42.8
914	JWH 015		BRD-K17796732-001-02-0	26.7	33.7	9.1	6.9	23.3	18.9
915	Tramlast		BRD-K17849083-001-03-0	-14.5	-5.2	0.7	-7.9	26.6	31.6
916	(?)-Coprostenol sodium salt		BRD-K17850764-236-03-6	-5.9	11.7	17.7	13.6	30.4	38.6
917	BRL 54443		BRD-K17868609-001-02-7	31.4	28.9	2.8	12.6	-18.6	-21.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
918	2-Pyridylethylamine dihydrochloride		BRD-K17874705-300-02-4	0.8	-7.4	15.9	22.4	16.1	13.7
919	OXE LAIDIN CITRATE		BRD-K17977438-048-01-6	7.4	2.9	0.4	-7.5	9.0	6.4
920	ETHOXZOLAMIDE		BRD-K18131774-001-10-1	6.5	11.2	-27.7	4.5	-1.7	-11.6
921	MEPHENTERMINE SULFATE		BRD-K18194590-065-05-6	5.8	4.4	-3.6	-4.5	-3.4	6.3
922	O-1918		BRD-K18316707-001-01-9	11.4	-4.0	15.8	1.4	17.1	27.2
923	BERGENIN		BRD-K18550767-002-01-8	-10.3	5.9	-26.9	13.8	0.2	1.7
924	Cimetidine		BRD-K18618618-001-01-6	20.6	1.0	-2.5	19.8	8.6	20.1
925	FOLIC ACID		BRD-K18673820-001-07-2	-2.0	16.7	27.6	80.0	22.7	18.1
926	Bifemelane hydrochloride		BRD-K18779551-003-03-7	-21.1	-14.1	-53.7	-55.9	-25.8	-28.3
927	BAY 59-3074		BRD-K18799075-001-01-0	-17.1	-6.9	-4.0	-18.8	-18.1	-6.1
928	L-694,247		BRD-K18816859-001-01-4	0.1	0.7	3.4	20.6	17.3	18.0
929	NEOSTIGMINE BROMIDE		BRD-K18922609-004-14-0	-4.4	-12.3	28.5	17.2	-4.8	15.4
930	CLOFIBRIC ACID		BRD-K19111024-001-10-0	3.6	-3.6	45.2	-17.2	-6.1	4.4
931	PHENOLPHTHALEIN		BRD-K19227686-001-12-9	-19.4	-2.8	-76.6	-78.1	-34.1	-40.0
932	SALVINORIN A		BRD-K19284129-001-01-8	6.3	4.8	11.7	36.0	17.9	20.3
933	GOSSYPOL		BRD-K19295594-001-10-1	1.0	30.6	-96.9	-92.4	-75.4	-77.9
934	CNQX		BRD-K19438463-001-02-2	-16.6	7.1	15.0	8.6	11.3	7.4
935	BUFLOMIDIL HYDROCHLORIDE		BRD-K19462402-003-13-9	24.0	4.0	9.5	12.1	12.1	11.1
936	Ozagrel hydrochloride		BRD-K19525698-003-01-1	24.2	28.2	-1.2	29.6	24.2	22.5
937	ZM 241385		BRD-K19605405-001-01-9	-47.9	-40.1	-59.4	-56.9	-50.4	-49.1
938	PECTOLINARIN		BRD-K20043699-001-03-1	40.6	35.7	-13.8	8.6	-27.8	-31.5
939	Impentamine dihydrobromide		BRD-K20049318-303-01-3	-5.6	10.0	24.6	22.3	27.1	16.1
940	Tomoxetine hydrochloride		BRD-K20141153-003-03-8	-10.0	-20.5	-15.3	-14.3	-8.1	0.8
941	CEAROIN		BRD-K20420220-001-03-9	51.2	60.6	5.6	52.9	-33.3	-48.0
942	BENZOYL PAS		BRD-K20431737-001-04-0	-13.5	4.6	-28.0	5.7	-13.1	-3.8
943	cjd-pdi-3		BRD-K20482099-341-01-1	25.9	20.7	-12.5	-6.0	-32.7	-30.3
944	2-METHOXYRESORCINOL		BRD-K20559594-001-03-2	24.6	45.4	14.6	28.9	-6.3	-4.0
945	MEFEXAMIDE		BRD-K20655524-003-07-0	-10.8	3.4	-21.5	-3.6	11.1	21.8
946	RS 56812 hydrochloride		BRD-K20714604-003-01-1	4.6	-7.9	6.0	10.0	25.8	32.4
947	RS 39604 hydrochloride		BRD-K20742498-003-01-1	-87.2	-89.0	-124.8	-122.7	-72.5	-75.8
948	CROMOLYN SODIUM		BRD-K20920669-304-06-7	-25.7	7.1	-4.0	-1.6	-2.3	-3.3
949	beta-NAPHTHOL		BRD-K21164796-001-01-0	9.6	-8.6	-48.8	-33.8	-72.3	-76.1
950	Riluzole hydrochloride		BRD-K21283037-003-06-2	-14.1	-9.4	-52.2	21.1	-51.9	13.1
951	BENZTHIAZIDE		BRD-K21450440-001-08-8	-12.8	0.8	-10.7	0.7	17.5	14.7
952	SULFACETAMIDE		BRD-K21520694-001-12-3	2.3	12.9	11.9	32.8	29.3	20.8
953	XYLAZINE		BRD-K21565985-001-15-9	-0.8	9.3	24.5	31.5	15.2	30.5
954	MITOXANTRONE HYDROCHLORIDE		BRD-K21680192-300-09-4	-110.6	-105.6	-104.1	-103.9	-84.0	-82.2
955	ROFECOXIB		BRD-K21733600-001-06-7	2.2	0.0	-11.0	-2.7	8.7	4.8
956	2,4-DINITROPHENOL		BRD-K21910317-001-06-5	-6.6	1.1	-6.2	-3.8	-11.5	6.3
957	FLUORESCINE		BRD-K21913543-001-01-6	298.5	333.8	-50.7	-17.0	9.7	1.3
958	DIFLUNISAL		BRD-K22031190-001-13-7	-7.9	1.2	-26.9	-24.4	0.5	-6.9
959	1-(2-hydroxy-4-morpholin-4-yl-phenyl)ethanone		BRD-K22160761-001-01-8	0.2	-17.9	18.7	19.3	35.3	29.8
960	DIOXYBENZONE		BRD-K22193694-001-08-6	5.3	16.0	-34.3	-19.7	4.0	1.7
961	LY 303511		BRD-K22385716-001-01-7	-6.0	-2.7	17.5	17.2	23.3	16.7
962	RETINOL		BRD-K22429181-001-06-8	16.5	11.8	-1.4	-0.7	5.3	3.4
963	IRIDIN		BRD-K22550622-001-03-5	27.2	16.8	0.7	31.2	4.1	-5.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
964	HIERACIN		BRD-K22585547-001-03-3	83.6	128.3	-18.0	-8.0	-38.1	-56.9
965	2-BFI hydrochloride		BRD-K22745370-003-01-5	-4.0	-11.3	18.7	9.0	11.0	3.9
966	CHRYSIN		BRD-K22861715-001-12-5	23.1	4.9	-14.3	-15.0	-21.9	-18.0
967	DIPHENYL PYRALINE HYDROCHLORIDE		BRD-K22936972-003-15-2	-14.7	24.4	0.6	4.7	1.6	-9.5
968	CHLORAMPHENICOL		BRD-K22969690-001-03-4	-2.7	3.0	-35.9	-19.5	9.4	2.0
969	RHOIFOLIN		BRD-K23327891-001-03-1	9.6	3.6	20.6	-1.2	20.8	15.2
970	AMN 082 dihydrochloride		BRD-K23335153-300-01-7	-2.2	24.3	51.8	61.9	44.5	48.7
971	T 0901317		BRD-K23383398-001-01-6	-7.8	2.1	-21.2	-16.1	-0.1	-2.5
972	SL 327		BRD-K23432132-001-01-2	-15.2	-7.7	31.1	-1.4	1.8	21.0
973	Dimaprit 2HCl		BRD-K23541596-300-05-6	0.1	-5.8	5.5	-1.0	4.8	8.7
974	NILUTAMIDE		BRD-K23566484-001-09-4	-17.2	-5.5	-35.9	6.9	-5.9	-10.8
975	DFB		BRD-K23623876-001-01-6	5.1	5.8	15.0	9.1	15.5	25.7
976	3,4'-DIMETHOXYFLAVONE		BRD-K23644387-001-01-4	13.0	11.2	13.3	33.6	12.6	16.0
977	3,4-Dichloroisocoumarin		BRD-K23704908-001-02-4	-12.9	11.5	-0.9	4.4	23.8	14.0
978	COUMARIN		BRD-K23913458-001-13-2	7.9	6.1	14.4	9.7	17.6	21.6
979	Arcайдине propargyl ester tosylate		BRD-K23922020-075-01-1	-32.2	-15.6	-1.9	-8.1	0.4	10.4
980	DEXTROMETHORPHAN HYDROBROMIDE		BRD-K24053527-004-03-8	-7.9	-5.8	-1.6	-4.5	-1.0	-7.0
981	PARAXANTHINE		BRD-K24084088-001-06-3	7.2	-1.6	-13.9	-12.5	-10.8	-2.8
982	SB 269970 hydrochloride		BRD-K24201553-003-02-4	1.4	-11.5	16.9	-2.2	3.0	4.3
983	GYKI 52466 hydrochloride		BRD-K24240364-003-02-1	15.2	0.5	-12.4	-10.8	-0.3	15.7
984	HELICIN		BRD-K24265569-001-01-7	7.3	2.9	-21.9	0.7	8.2	-1.3
985	Levromakalim		BRD-K24526313-001-08-6	5.8	-19.4	3.7	0.9	5.6	5.5
986	PROCAINE HYDROCHLORIDE		BRD-K24616672-003-10-2	-7.1	-1.8	1.2	30.3	15.3	-7.0
987	ACTINONIN		BRD-K24621118-001-03-3	12.3	0.3	-40.4	-12.6	-8.9	-12.1
988	LY 288513		BRD-K24675965-001-02-5	32.4	31.1	21.3	22.6	-29.3	-19.3
989	3-Bromo-7-nitroindazole		BRD-K24689407-001-05-5	-15.7	-0.8	-1.8	13.3	8.5	1.1
990	ETHACRIDINE LACTATE		BRD-K24715592-043-01-4	45.2	27.8	38.4	30.1	-9.4	-6.3
991	EPIAFZELECHIN TRIMETHYL ETHER		BRD-K25064302-001-03-1	16.9	5.2	-33.8	-20.1	-11.8	-7.2
992	1-BCP		BRD-K25140590-001-02-2	-8.6	-8.7	81.3	104.5	13.4	17.8
993	TANGERITIN		BRD-K25186396-001-04-7	16.8	-4.4	29.9	34.1	-8.3	-10.8
994	PIRENPERONE		BRD-K25224017-001-15-1	1.9	-0.3	-11.8	6.7	3.0	10.8
995	OXAPROZIN		BRD-K25394294-001-08-1	4.1	0.5	-10.5	-18.3	4.0	9.8
996	MAPROTILINE HYDROCHLORIDE		BRD-K25433859-003-14-8	-1.3	-14.8	-63.7	-63.3	-30.3	-24.7
997	2-Iodomelatonin		BRD-K25649279-001-01-2	-14.2	-8.7	8.5	-7.7	4.4	1.6
998	PHYSOSTIGMINE SALICYLATE		BRD-K25650355-059-12-2	7.1	9.5	11.1	2.2	9.0	14.5
999	METHYL ROUSTONE		BRD-K25811799-001-03-5	-23.5	-46.3	-47.5	-36.9	6.1	4.9
1000	SC-9		BRD-K25875056-001-01-2	2.0	-19.7	24.0	8.9	-9.8	-5.5
1001	Immezipid dihydrobromide		BRD-K25906698-303-01-9	17.1	3.3	8.9	9.5	19.4	18.3
1002	GRAMINE		BRD-K26005076-001-06-0	-57.3	5.1	-32.9	9.7	13.7	12.9
1003	RS 45041-190 hydrochloride		BRD-K26160755-003-01-8	-0.8	13.9	-11.4	18.5	-1.4	-2.5
1004	SC-514		BRD-K26373640-001-02-8	23.9	39.2	22.7	12.8	22.2	18.4
1005	EUPARIN		BRD-K26383086-001-03-6	29.8	-2.6	-37.3	-11.5	-16.3	-19.1
1006	J 104129 fumarate		BRD-K26429091-051-01-9	11.2	3.3	5.4	0.5	18.0	20.1
1007	DMAB-anabaseine dihydrochloride		BRD-K26573499-300-01-3	1.0	-6.8	18.6	6.7	11.5	11.8
1008			BRD-K26657438-001-01-2	-4.8	9.9	22.4	22.1	23.4	34.9
1009	PIPAMPERONE		BRD-K26801045-001-01-1	-2.5	2.8	25.6	22.6	15.4	19.5

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1010	AKLOMIDE		BRD-K26807903-001-03-5	12.7	3.3	-9.8	-8.3	-5.3	-1.7
1011	PROTOPORPHYRIN IX		BRD-K26813314-001-04-4	1.1	7.4	-26.7	3.6	13.0	27.6
1012	Costunolide		BRD-K26833429-001-01-0	-11.2	-20.9	-50.9	-8.6	-15.4	-13.6
1013	3-HYDROXYPHENETHYLAMINE		BRD-K26842203-001-01-3	1.6	-5.4	10.6	-6.3	-2.2	0.3
1014	DIOSMETIN		BRD-K26862302-001-03-7	10.8	6.8	-14.7	-28.8	-35.4	-38.3
1015	3-ACETYLCOUMARIN		BRD-K26954192-001-06-8	3.0	3.8	-15.3	-15.4	3.8	-2.1
1016	SB 203186 hydrochloride		BRD-K27141178-003-02-4	-5.5	-2.1	-4.0	19.1	12.7	8.2
1017	SR 11302		BRD-K27216882-001-01-7	-4.8	-5.6	-51.2	-21.5	-16.2	-21.8
1018	BUTAMBEN		BRD-K27217864-001-15-7	2.9	5.2	1.1	24.9	-0.6	6.8
1019	H 89 dihydrochloride		BRD-K27737647-300-01-4	-35.2	-47.5	-87.3	-88.4	-75.7	-83.7
1020	(-)[3R,4S]-Chromanol 293B		BRD-K27911943-001-01-0	-0.4	-2.5	22.2	32.8	31.0	23.2
1021	XANTHYLETIN		BRD-K28108221-001-07-2	35.2	8.2	74.8	80.2	0.2	4.5
1022	WEB 2086		BRD-K28115081-001-01-9	3.0	-6.4	-8.0	2.4	2.6	1.0
1023	Loreclezole hydrochloride		BRD-K28137194-003-01-3	-4.0	11.9	-22.4	-19.8	2.7	2.8
1024	CYPROHEPTADINE HYDROCHLORIDE		BRD-K28143534-003-14-3	-24.0	-14.6	-80.0	-78.9	-50.2	-57.6
1025	CHLOROGUANIDE HYDROCHLORIDE		BRD-K28183345-003-07-2	8.1	-12.3	-4.0	-0.5	6.1	14.7
1026	Demethylasterriquinone B1		BRD-K28452984-001-01-4	-59.9	-67.5	-105.7	-103.1	-88.1	-85.7
1027	Nitrocaramiphen hydrochloride		BRD-K28453807-003-05-4	-15.2	-6.2	-0.9	-0.6	8.7	12.6
1028	SULFAMETHOXAZOLE		BRD-K28494619-001-15-9	-2.9	1.8	21.7	33.5	9.0	13.5
1029	BENZYDAMINE HYDROCHLORIDE		BRD-K28542495-003-07-7	-21.0	-13.4	-74.9	-66.7	-14.5	-28.9
1030	Cilostamide		BRD-K28578425-001-02-1	33.2	22.1	3.6	27.3	12.6	15.8
1031	METHYL-beta-CARBOLINE-3-CARBOXYLATE		BRD-K28680267-001-01-8	-4.0	-18.4	-16.1	-10.1	-12.3	-16.6
1032	ANTIAROL		BRD-K28698314-001-02-1	-3.7	3.1	-64.3	-10.5	-50.8	-43.7
1033	PNU 282987		BRD-K28863208-001-01-2	-3.9	2.1	10.9	17.7	18.6	19.1
1034	KETOTIFEN FUMARATE		BRD-K28936863-051-18-1	-30.9	-19.4	-39.3	-40.7	-5.2	-10.9
1035	DIPTERYXIN		BRD-K29004214-001-01-4	-2.6	-3.9	43.3	23.0	-39.0	-39.2
1036			BRD-K29113274-001-11-9	-29.4	-22.7	-71.8	-70.2	-46.3	-45.2
1037	7-[2-TRIFLUOROMETHYL-4-(2-HYDROXYPHENYL)-1,3-DIOXAN-cis-5-YL]-HEPT-5Z-ENOIC ACID		BRD-K29133151-001-02-4	-2.4	-4.0	-4.8	-1.1	10.9	18.2
1038	THIRAM		BRD-K29254801-001-06-3	-56.9	-59.9	18.5	17.7	-66.2	-69.6
1039			BRD-K29359156-001-23-6	-30.5	-19.5	-87.6	-93.1	-61.3	-59.9
1040	CHLORAMBUCIL		BRD-K29458283-001-17-4	27.5	26.6	10.8	18.0	-12.0	-12.6
1041	1-Naphthyl PPI		BRD-K29542628-001-01-3	-6.9	8.4	-28.7	-19.0	-1.1	-2.1
1042	SNC 80		BRD-K29546239-001-01-5	-1.5	-10.7	-4.9	-13.9	3.5	-5.4
1043	SCH 202676 hydrobromide		BRD-K29562203-004-02-6	24.3	-0.8	12.0	10.0	-3.2	-2.4
1044	FLUNARIZINE HYDROCHLORIDE		BRD-K29582677-300-06-4	6.4	13.3	9.0	24.8	4.5	-5.4
1045	BD 1063 dihydrochloride		BRD-K29668683-300-01-4	2.0	-6.3	-5.2	6.7	-0.2	0.8
1046	MEBHYSROLIN NAPHTHALENESULFONATE		BRD-K29713308-077-03-3	-1.5	-4.1	30.9	36.7	-18.2	-0.5
1047	CLOMIPHENE CITRATE		BRD-K29950728-048-08-3	-57.8	-57.3	3.5	0.8	-84.7	-88.6
1048	ALISKIREN HEMIFUMARATE		BRD-K30020243-051-01-7	-9.1	-11.8	13.7	1.9	18.2	22.3
1049	MEXAMINE		BRD-K30197592-003-02-9	0.1	-4.9	16.9	13.5	10.1	12.1
1050	1400W dihydrochloride		BRD-K30237152-300-01-7	-18.9	-20.9	14.3	4.6	21.4	24.6
1051	CLEMASTINE		BRD-K30240666-051-08-4	-22.9	-23.4	-2.4	3.3	-35.1	-39.2
1052	TIMOLOL MALEATE		BRD-K30421593-050-03-1	2.5	5.5	5.0	0.3	13.8	13.8
1053	ELLAGIC ACID		BRD-K30466858-001-05-4	58.8	100.1	-26.4	-3.8	3.5	-4.2
1054	HESPERETIN		BRD-K30553453-001-08-2	34.5	-0.5	46.3	62.5	8.6	6.0
1055	LEVOTHYROXINE		BRD-K30685142-001-08-9	57.1	43.7	10.3	23.7	0.0	-12.4

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1056	SB 216641 hydrochloride		BRD-K30867024-003-01-7	-46.0	-41.3	-96.0	-96.1	-74.6	-74.5
1057	AT-DYRK-01		BRD-K30984264-003-06-8	-2.0	-2.9	86.3	88.4	45.0	32.7
1058	FR 122047 hydrochloride		BRD-K30990140-003-01-6	-29.8	-26.1	-35.0	-35.4	-48.9	-56.3
1059	PURPUROGALLIN		BRD-K31023358-001-10-7	32.3	29.2	52.2	32.1	-7.1	-8.8
1060	BMY 7378 dihydrochloride		BRD-K31054881-300-01-3	5.1	0.3	-6.6	3.7	10.7	11.1
1061	Devazepide		BRD-K31238592-001-01-6	-6.1	-10.2	-39.3	-39.3	-4.6	-0.8
1062	Diacylglycerol Kinase Inhibitor II		BRD-K31273080-001-01-2	2.1	-13.5	-9.8	-20.6	12.7	7.7
1063	SDZ SER 082 fumarate		BRD-K31339597-051-01-2	9.3	7.4	12.0	21.1	9.1	11.1
1064	1-PHENYLBIGUANIDE HYDROCHLORIDE		BRD-K31491153-003-04-2	44.0	-15.8	28.5	18.7	20.1	28.9
1065	Mycophenolic acid		BRD-K31542390-001-01-5	47.1	34.0	21.2	15.6	12.2	14.8
1066	DAU 5884 hydrochloride		BRD-K31633810-003-01-0	4.1	16.5	6.6	20.0	21.1	35.8
1067	ISOBERGAPTENE		BRD-K31678817-001-06-1	-2.7	-5.7	3.9	2.9	6.6	12.2
1068	SULFAMETHIZOLE		BRD-K31682896-001-15-8	-3.4	-6.1	18.4	14.5	9.1	10.1
1069	DMeOB		BRD-K31699485-001-01-9	-3.9	-3.8	0.3	9.0	7.1	4.0
1070	T 0070907		BRD-K31843556-001-01-7	-1.2	1.9	-17.4	3.0	1.9	13.8
1071	CGP 71683 hydrochloride		BRD-K31912990-003-01-0	-51.9	-77.4	-81.2	-78.3	-70.0	-73.7
1072	Oleylethanolamide		BRD-K31987754-001-01-2	0.7	6.9	-12.7	-19.5	15.5	29.5
1073	SULFACHLORPYRIDAZINE		BRD-K32021043-001-09-3	21.1	17.6	51.2	46.7	29.8	31.4
1074	temozolomide		BRD-K32107296-001-04-5	10.9	8.7	6.4	30.4	18.4	25.4
1075	TOLAZAMIDE		BRD-K32164935-001-17-5	11.1	36.2	23.7	56.3	-1.6	-2.8
1076	PRIMIDONE		BRD-K32247306-001-17-9	5.8	-4.1	6.6	1.6	-4.6	-8.9
1077	CINNARAZINE		BRD-K32256916-001-03-2	-13.5	-5.0	22.1	19.5	-1.3	-1.8
1078	SULFADIAZINE		BRD-K32273377-001-09-6	-1.5	-0.5	10.4	13.5	4.3	0.0
1079	CGP 53353		BRD-K32292990-001-01-0	23.1	51.8	55.5	38.6	12.1	15.0
1080	R(-)-2,11-DIHYDROXY-10-METHOXYAPORPHINE		BRD-K32412559-001-01-7	55.8	57.5	23.8	9.6	-18.8	-18.7
1081	3,6-DIMETHOXYFLAVONE		BRD-K32480606-001-01-7	16.1	-6.7	8.9	30.4	3.2	-3.9
1082	GBR 12909 dihydrochloride		BRD-K32501161-300-04-7	-13.9	10.2	-30.7	-3.9	-25.9	-19.4
1083	DCEBIO		BRD-K32526544-001-01-2	-5.8	-8.8	-25.4	-22.6	-2.7	-4.2
1084	DIPROPYL-5CT		BRD-K32645441-001-01-4	-5.6	-9.5	25.9	17.7	-3.8	13.5
1085	2-Aminobenzenesulfonamide		BRD-K32681104-001-03-3	13.8	4.6	9.8	28.7	15.0	12.9
1086	tetraethylthiuram disulfide		BRD-K32744045-001-17-1	-34.9	-31.7	-39.1	-35.7	-32.0	-48.6
1087	AZATHIOPRINE		BRD-K32821942-001-10-6	-9.7	3.1	10.5	-0.6	22.6	18.5
1088	Guanfacine hydrochloride		BRD-K32830106-003-11-3	1.2	4.6	8.7	32.7	19.9	18.1
1089	EUGENOL		BRD-K32977963-001-03-5	3.3	-1.1	0.7	23.6	-25.9	-30.4
1090	SPHONDIN		BRD-K33260002-001-06-1	-19.6	-15.9	-2.7	17.0	32.0	32.7
1091	INCA-6		BRD-K33308633-001-01-6	1.2	-7.0	-108.6	-109.5	-85.6	-85.5
1092	CRYPTOTANSHINONE		BRD-K33336844-001-05-3	31.9	30.2	33.5	54.2	20.2	15.2
1093	A 68930		BRD-K33400588-003-01-2	2.8	-4.6	78.1	84.6	34.1	36.9
1094	meta-CRESYL ACETATE		BRD-K33442414-001-01-8	3.5	6.9	25.1	21.7	19.4	24.2
1095	DTG		BRD-K33459542-001-02-5	3.1	18.6	11.8	20.1	18.5	18.2
1096			BRD-K33583600-001-03-9	15.0	-6.4	4.9	1.7	-16.6	-17.1
1097	Lavendustin B		BRD-K33781562-001-02-7	-54.4	-36.8	-14.4	-13.4	7.2	1.8
1098	GW 3965 hydrochloride		BRD-K33818169-003-01-2	-60.2	-64.6	-92.1	-91.4	-86.4	-88.4
1099	LY 225910		BRD-K33864865-001-01-7	-3.0	-10.6	-5.5	-1.1	1.5	-2.5
1100	ZK 93423		BRD-K33882852-003-01-0	7.4	6.3	-11.0	-18.9	-10.6	-17.7
1101	NAPROXOL		BRD-K34014345-001-03-4	-1.7	-8.9	-19.2	7.5	-1.1	-11.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1102	GBR 12783 dihydrochloride		BRD-K34034388-300-01-0	-8.9	12.2	-24.0	-9.5	-1.9	-4.8
1103	Arvanil		BRD-K34092021-001-02-3	12.4	8.1	10.3	11.2	-23.7	-21.8
1104	DENATONIUM BENZOATE		BRD-K34122555-057-06-5	3.5	-3.1	9.6	23.1	20.6	19.2
1105	Tracazolate hydrochloride		BRD-K34154330-003-04-9	20.2	-6.7	-32.0	-4.5	14.2	1.9
1106	Fexaramine		BRD-K34170797-001-01-1	7.0	-10.5	0.9	8.3	1.4	12.1
1107	METHICILLIN SODIUM		BRD-K34388247-236-04-1	-22.9	18.6	23.4	14.3	10.5	6.0
1108	TRIMETHOBENZAMIDE HYDROCHLORIDE		BRD-K34415467-003-08-0	0.2	4.8	19.4	39.3	32.8	38.0
1109	AG 494		BRD-K34533029-001-01-0	25.5	5.2	-26.6	-36.4	-45.5	-41.6
1110	TILORONE		BRD-K34568562-001-03-5	-15.9	-21.7	1.1	-16.8	-19.9	-19.7
1111	GP 2a		BRD-K34608650-001-01-6	7.7	6.5	4.9	35.3	31.7	30.6
1112	6-Chloromelatonin		BRD-K34663752-001-02-6	-10.0	-8.4	10.5	7.4	-3.8	-1.6
1113	METHYLERGONOVINE MALEATE		BRD-K34685430-050-06-7	19.3	14.8	12.4	-5.7	3.2	-7.3
1114	THEOBROMINE		BRD-K34888156-001-08-8	2.1	1.1	18.7	3.0	5.1	9.8
1115	SU1498		BRD-K34995470-001-03-1	8.8	5.1	27.7	19.3	26.7	9.1
1116	3,7-DIHYDROXYFLAVONE		BRD-K35133923-001-03-1	48.5	-3.5	27.9	35.0	-4.7	4.2
1117			BRD-K35240538-001-11-4	21.9	-1.5	6.7	33.7	5.9	8.1
1118	SR 59230A hydrochloride		BRD-K35430135-003-01-5	-7.6	-3.8	-33.3	-33.1	-28.4	-27.0
1119	MCI-186		BRD-K35458079-001-12-5	17.5	14.2	20.3	22.1	-2.2	2.6
1120	BPIQ-II		BRD-K35473459-001-01-7	0.4	4.8	12.4	23.7	7.0	21.2
1121	ALRESTATIN		BRD-K35498378-001-05-3	-4.7	-2.1	-5.2	14.1	20.1	15.7
1122			BRD-K35520305-001-07-8	-2.6	0.7	0.4	1.0	11.1	14.9
1123	2,6-DIHYDROXY-4-METHOXYTOLUENE		BRD-K35568433-001-03-1	14.2	-11.2	21.4	10.4	-4.1	-5.2
1124	SR 27897		BRD-K35629949-001-01-2	1.5	2.2	-13.8	-9.8	0.9	7.8
1125	niclosamide		BRD-K35960502-001-11-9	2.7	6.7	8.5	20.0	-9.5	-11.3
1126	NNC 63-0532		BRD-K36009368-001-01-8	-3.9	-7.0	12.0	18.1	11.1	21.2
1127	ABT 702 dihydrochloride		BRD-K36021395-300-01-6	-35.5	-34.2	-62.5	-59.8	-28.8	-32.3
1128	PYRITHYLDIONE		BRD-K36116267-001-08-8	-10.5	-17.1	33.8	19.9	9.5	22.7
1129	PLUMBAGIN		BRD-K36137799-001-03-2	26.0	28.4	8.8	22.8	-47.4	-50.1
1130	WAY 170523		BRD-K36198571-001-01-2	3.6	-17.9	7.0	8.8	18.5	11.0
1131	AZ 10417808		BRD-K36258877-001-01-5	5.7	1.2	4.5	25.5	15.5	17.7
1132	SB 206553 hydrochloride		BRD-K36395411-003-01-4	-17.4	-16.7	13.3	17.2	16.1	25.6
1133	AZTREONAM		BRD-K36547807-001-02-4	0.0	-5.6	14.5	-1.2	-3.4	5.8
1134	Doxepin hydrochloride		BRD-K36616567-003-01-5	-8.1	-6.9	-35.8	-6.6	-3.4	1.4
1135	IPRIFLAVONE		BRD-K36646537-001-02-1	-2.1	-1.3	10.4	29.8	14.5	14.0
1136	BUFEXAMAC		BRD-K36660044-001-15-0	10.6	0.0	-12.3	-8.5	11.4	-0.4
1137	GUAIAZULENE		BRD-K36719159-001-04-9	2.6	-0.7	10.5	12.1	10.0	11.7
1138	ETHAVERINE HYDROCHLORIDE		BRD-K36756879-003-06-1	-15.6	-15.3	23.1	28.4	6.7	7.5
1139	5-alpha-PREGNANE-3-alpha-2,1-DIOL-20-ONE		BRD-K36764776-001-01-4	-6.6	-8.8	4.3	-2.8	-9.6	-8.2
1140	TRIM		BRD-K36851334-001-05-5	10.4	-3.2	-20.1	-12.1	-3.9	-13.6
1141	HYDROFLUMETHIAZIDE		BRD-K36862742-001-15-7	12.7	3.7	40.4	20.6	-5.9	10.5
1142	BD 1047 dihydrobromide		BRD-K36864847-303-01-7	-4.4	-11.8	-28.6	-24.9	-2.0	2.8
1143			BRD-K36927236-001-17-7	11.9	2.4	10.2	-0.3	11.8	21.6
1144	m-Chlorophenylbiguanide hydrochloride		BRD-K36965586-003-03-9	6.2	19.1	26.4	2.4	18.3	19.4
1145	S-ISOCORYDINE (+)		BRD-K37049577-001-08-5	1.7	2.6	6.8	15.5	-25.3	-27.0
1146	ASTEMIZOLE		BRD-K37249724-001-16-6	-32.1	-34.7	11.6	25.0	-51.0	-48.2
1147	CLOZAPINE		BRD-K37289225-001-23-2	12.5	12.1	-22.8	-11.0	-10.1	-8.6

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1148	Kenpaualone		BRD-K37312348-001-06-9	6.9	-0.4	-9.6	0.0	8.0	9.4
1149	NSC 632839 hydrochloride		BRD-K37392901-003-01-7	-37.2	-19.9	-41.5	-41.9	-19.8	-20.3
1150	IDEBENONE		BRD-K37516142-001-01-4	6.9	14.7	20.2	25.9	-26.0	-29.2
1151	Zardaverine		BRD-K37561857-001-06-4	41.1	16.4	28.8	34.1	25.5	24.9
1152	MRS 1220		BRD-K37618799-001-01-4	-8.1	-9.0	-3.7	1.3	-1.1	10.1
1153	PIROMIDIC ACID		BRD-K37682401-001-06-9	18.0	-4.1	6.8	20.8	10.6	16.7
1154	FIPEXIDE HYDROCHLORIDE		BRD-K37688416-003-08-1	-1.5	-1.3	31.4	39.7	-1.1	-3.0
1155	ABT 724 trihydrochloride		BRD-K37714784-305-01-3	8.0	-9.4	26.1	22.0	22.4	11.5
1156	Denbufylline		BRD-K37792168-001-01-0	2.4	-14.0	18.0	25.9	24.6	38.3
1157			BRD-K37798499-001-05-8	6.9	6.2	14.3	1.8	-2.2	-8.1
1158	ACEPROMAZINE MALEATE		BRD-K37814297-050-05-4	-20.0	-28.4	29.7	6.5	-3.7	-7.7
1159	3,3'-DIINDOLYL METHANE		BRD-K37846922-001-06-0	32.2	26.8	19.8	12.6	-8.9	-15.5
1160	N-(4-BROMOBENZYL)-5-METHOXYTRYPTAMINE		BRD-K37883585-001-01-2	-8.3	-1.4	-6.9	-5.3	8.9	1.2
1161	CAMPTOTHECIN		BRD-K37890730-001-10-2	2.1	6.8	123.2	135.1	26.6	28.2
1162	Paroxetine maleate		BRD-K37991163-050-05-1	-15.4	-21.5	-47.1	-47.8	-38.3	-40.0
1163	ETHAMIVAN		BRD-K38055836-001-13-8	18.7	14.3	15.0	31.8	1.4	-2.1
1164	BUMETANIDE		BRD-K38197229-001-17-4	9.4	5.4	12.6	40.8	26.6	27.0
1165	Paxilline		BRD-K38251852-001-06-6	-18.4	-27.4	20.2	8.9	-18.3	-24.1
1166	DOMPERIDONE		BRD-K38305202-001-08-3	-15.6	-11.7	-11.9	-10.3	20.0	16.1
1167	PHENACETIN		BRD-K38323065-001-09-0	-2.9	18.6	-1.0	-6.1	0.5	-1.7
1168	8-CYCLOPENTYLTHEOPHYLLINE		BRD-K38347298-001-06-4	5.0	1.7	6.1	4.8	25.6	20.7
1169	3-(4-Allylpiperazin-1-yl)-2-quinoxalinecarbonitrile maleate		BRD-K38370968-103-01-0	-4.0	-7.0	-2.4	9.2	-9.0	0.2
1170	IMIPRAMINE HYDROCHLORIDE		BRD-K38436528-003-15-4	-10.1	2.9	-26.0	-8.8	-28.9	-32.3
1171	Bohemine		BRD-K38622899-001-01-4	-4.8	16.9	-10.6	-23.5	8.8	8.3
1172	ROXITHROMYCIN		BRD-K38684403-001-03-9	5.1	0.4	27.4	11.5	14.1	20.3
1173			BRD-K38775274-001-06-4	-6.9	-8.8	9.3	7.9	15.4	12.8
1174	CINCHONIDINE		BRD-K39079086-001-05-0	22.9	11.7	37.6	34.5	21.6	20.1
1175	BITHIONATE SODIUM		BRD-K39120595-304-03-9	-27.9	-25.5	-94.7	-94.5	-69.9	-66.4
1176	4-Chlorophenylguanidine hydrochloride		BRD-K39160765-003-01-1	10.3	20.1	-21.5	4.6	-22.0	3.4
1177	(R)-2,10,11-TRIHYDROXYAPORPHINE		BRD-K39187410-001-01-7	48.5	48.5	-13.3	-24.1	-57.9	-60.0
1178	NITHIAMIDE		BRD-K39467894-001-01-8	1.7	2.8	37.4	25.9	23.8	25.7
1179	Amthamine dihydrobromide		BRD-K39670393-303-01-3	11.8	0.5	36.8	17.1	13.3	15.1
1180	L-161982		BRD-K39733634-001-01-8	-28.6	-33.6	-68.8	-53.5	-20.1	-28.9
1181	LOXAPINE SUCCINATE		BRD-K39915878-036-15-2	-5.4	3.1	-18.1	-25.0	-7.6	-14.5
1182	BISACODYL		BRD-K39987650-001-15-9	18.8	-10.0	38.2	36.0	28.4	16.8
1183	TYRPHOSTIN 9		BRD-K40255344-001-04-4	-10.7	-23.4	-29.0	-41.8	-25.0	-32.5
1184	GR 79236		BRD-K40578143-001-01-8	-8.8	-7.3	0.0	12.5	-6.6	8.5
1185	LARIXINIC ACID		BRD-K40619305-001-12-1	0.7	10.9	12.5	10.3	1.7	-0.2
1186	ZM 39923 hydrochloride		BRD-K40624912-003-02-3	-60.8	-61.4	15.4	14.5	-71.3	-74.8
1187	L-165,041		BRD-K40656405-001-01-5	-36.9	-39.1	-80.2	-81.4	-30.1	-22.0
1188	QX 222		BRD-K40782193-003-01-1	10.8	4.3	-0.4	4.7	7.1	8.3
1189	RITANSERIN		BRD-K40887525-001-14-4	15.0	-3.7	-28.3	-11.9	16.5	6.5
1190	CINANSERIN		BRD-K40901640-001-01-0	-2.2	-2.0	4.8	-4.6	1.1	0.4
1191	PHENACEMIDE		BRD-K40905133-001-03-1	-5.6	-11.0	-3.3	11.2	5.4	6.8
1192	CYANOPINDOLOL		BRD-K40965114-001-01-2	1.5	-3.7	-6.0	-7.0	-4.5	-4.9
1193	N,N-Hexamethyleneamiloride		BRD-K40990712-001-02-4	-4.1	-18.6	3.1	1.5	-8.8	12.8

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1194	PARACHLOROPHENOL		BRD-K40992116-001-05-5	1.5	-1.8	5.2	7.8	-16.4	-10.9
1195	N20C hydrochloride		BRD-K41143549-003-01-6	-13.7	-14.8	-15.2	-7.3	4.0	11.4
1196	Fenobam		BRD-K41160163-001-01-9	15.4	9.1	25.9	35.3	3.5	6.4
1197	ZM 306416 hydrochloride		BRD-K41337261-003-01-0	-4.9	-7.9	-36.0	-25.9	-33.5	-22.9
1198	SULFAPYRIDINE		BRD-K41406082-001-09-7	3.5	-5.9	9.1	-4.5	1.4	-1.9
1199	A23187, free acid		BRD-K41431477-001-05-6	35.4	28.8	-62.7	-76.4	-61.1	-68.6
1200	BISPHENOL A		BRD-K41494493-001-04-7	8.2	-12.5	22.7	17.3	-1.3	-6.5
1201	Acetaminophen		BRD-K41524689-001-08-6	-0.2	2.3	14.9	13.7	-33.0	-25.7
1202	6,2'-DIMETHOXYFLAVONE		BRD-K41557448-001-01-3	10.9	-0.4	32.8	23.9	-8.7	-3.3
1203	Purvalanol B		BRD-K41564320-001-01-2	4.7	-17.6	26.6	17.2	27.5	29.0
1204	SB 334867		BRD-K41567364-001-01-2	11.4	-16.3	-45.7	-46.5	-19.1	-12.2
1205	GANGALEOIDIN		BRD-K41603276-001-03-8	-3.6	4.5	15.5	28.5	-21.4	-24.0
1206	E-4031 dihydrochloride		BRD-K41713976-300-01-8	12.2	-3.8	2.6	30.8	11.8	13.4
1207	TRICLOSAN		BRD-K41731458-001-04-5	-5.9	-9.7	-2.2	2.3	-35.2	-36.3
1208	IRIGENIN, DIBENZYL ETHER		BRD-K41762421-001-03-6	7.3	-10.2	20.3	31.6	7.1	13.4
1209	1,3-Dipropyl-8-phenylxanthine		BRD-K41853443-001-01-1	4.7	0.8	1.3	-2.7	-10.7	-13.3
1210	W-5 hydrochloride		BRD-K41868777-003-02-9	-1.9	-7.9	0.8	-10.8	4.9	3.1
1211	2-Phenylmelatonin		BRD-K41869275-001-01-0	-21.8	-25.9	4.1	6.7	18.0	28.1
1212	TIOXOLONE		BRD-K41876534-001-06-1	20.0	55.5	9.6	15.2	-25.3	-30.1
1213	Daidzein		BRD-K42095107-001-08-0	0.9	-9.2	7.1	24.0	-7.9	-11.4
1214	PROTRYPTYLINE HYDROCHLORIDE		BRD-K42098891-003-13-0	-22.4	-37.3	25.8	33.5	-28.4	-40.2
1215	NNC 711		BRD-K42221274-003-02-8	24.8	14.2	24.4	15.7	14.7	14.7
1216	CYCLOBENZAPRINE HYDROCHLORIDE		BRD-K42348709-003-08-1	-38.8	-21.2	30.2	17.1	-36.2	-33.9
1217	EO 1428		BRD-K42452249-001-01-7	-9.7	10.5	-8.8	-8.4	-3.1	4.2
1218	CGP 57380		BRD-K42500029-001-01-9	22.3	38.7	30.6	47.4	1.6	10.0
1219	2-(1-Thienyl)ethyl 3,4-dihydroxybenzylidenecyanoacetate		BRD-K42663584-001-01-2	20.8	15.0	-31.2	-20.9	-30.7	-35.7
1220	Y-27152		BRD-K42679050-001-01-3	2.8	4.5	-24.8	-21.5	-3.1	-1.7
1221	Glimiperide		BRD-K42693031-001-01-8	-3.1	-11.2	-6.8	9.2	24.6	18.3
1222	XE 991 dihydrochloride		BRD-K42748308-300-01-2	10.3	5.9	-20.1	-20.9	9.5	9.6
1223	CFM-2		BRD-K42859542-001-02-5	-5.6	-6.6	-2.1	-7.5	-0.4	-1.7
1224	PD 156273		BRD-K43030839-001-01-6	6.4	1.9	5.0	-0.8	17.6	19.5
1225	AMG 9810		BRD-K43068349-001-01-9	-2.9	-9.5	-6.5	-8.2	1.1	12.4
1226	2',5'-DIHYDROXY-4-METHOXYSALCONE		BRD-K43285163-001-02-0	29.4	28.4	28.9	27.9	-49.1	-54.9
1227	RO 04-6790		BRD-K43290182-001-01-9	-3.2	-2.8	-4.6	6.0	7.0	14.5
1228	JTE 013		BRD-K43330982-001-01-5	15.2	12.1	-8.4	0.6	-34.4	-28.1
1229	FLOPROPIONE		BRD-K43383936-001-03-7	-12.4	-5.0	32.0	22.9	43.2	46.9
1230			BRD-K43389675-003-03-5	15.4	11.1	-16.9	-5.7	8.1	4.2
1231	Tamoxifen citrate		BRD-K43744935-048-01-6	-60.8	-67.1	-73.8	-73.4	-62.8	-70.3
1232	PSEUDO-ANISATIN		BRD-K43770188-001-02-2	2.0	-5.3	25.5	21.3	23.5	19.4
1233	RLM-1-127		BRD-K43796186-001-01-1	-1.8	-4.3	-1.9	-10.0	-12.7	-9.6
1234	GENISTEIN		BRD-K43797669-001-10-6	-6.2	-10.5	8.0	0.8	7.7	1.4
1235	PENICILLIN V POTASSIUM		BRD-K43966364-237-03-0	3.7	-1.9	28.0	14.9	21.7	27.2
1236	ISOSAFROLE		BRD-K44005821-001-07-4	1.0	-16.4	13.0	-12.8	-0.2	7.5
1237	FLUFENAMIC ACID		BRD-K44067360-001-16-2	-7.8	-4.9	-59.0	-67.4	-23.8	-27.6
1238	Y-27632		BRD-K44084986-300-02-7	-5.9	-11.3	-19.0	-3.0	-1.4	6.5
1239	L-PHENYLALANINOL		BRD-K44204252-001-04-8	-0.6	1.6	19.5	8.6	22.5	26.3

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1240	TRYPTAMINE		BRD-K44218819-001-05-1	24.7	7.5	19.6	34.6	11.8	8.2
1241	TOLNAFTATE		BRD-K44273375-001-14-4	-6.9	-15.3	29.8	37.7	27.2	32.3
1242	(R)-(-)-Niguldipine hydrochloride		BRD-K44309363-003-01-3	-12.3	-10.8	-27.5	-20.5	-46.2	-44.2
1243	N-METHYLBENZYLAMINE HYDROCHLORIDE		BRD-K44558320-003-01-7	3.6	0.2	8.3	14.5	11.0	11.1
1244	BECLAMIDE		BRD-K44824027-001-01-3	2.4	0.6	8.4	11.5	-4.3	4.0
1245	S-(-)-Atenolol		BRD-K44993696-001-05-7	-4.7	18.5	17.0	14.0	17.0	10.3
1246	FAMCICLOVIR		BRD-K45033733-001-05-6	-8.6	-7.7	12.0	6.1	2.2	-2.1
1247	SNC-162		BRD-K45042519-001-01-6	-0.1	-4.5	4.5	6.6	14.3	9.4
1248	W-13 hydrochloride		BRD-K45068323-003-02-1	-29.6	-26.5	-39.7	-61.9	-16.4	-39.2
1249	TETRACAINE HYDROCHLORIDE		BRD-K45071273-003-15-7	-4.8	-3.2	38.5	37.7	-11.6	-12.5
1250	Y-26763		BRD-K45117373-001-01-1	12.1	5.9	-19.8	38.8	11.8	42.9
1251	VALSARTAN		BRD-K45158365-001-05-6	-7.7	-3.4	23.3	20.4	15.5	9.8
1252	CLOFIBRATE		BRD-K45252063-001-06-0	13.2	13.9	5.8	10.4	4.5	7.2
1253	ZD 7114 hydrochloride		BRD-K45296539-003-01-0	-2.6	-6.9	-8.5	-14.3	2.0	9.2
1254	DIETHYLSTILBESTROL		BRD-K45330754-001-09-2	6.5	5.1	32.5	12.1	2.2	3.2
1255	SCH 23390 hydrochloride		BRD-K45435259-003-03-8	-4.6	2.2	24.3	29.0	12.3	16.0
1256	5-Methylfurmethiodide		BRD-K45437867-005-01-7	7.8	-6.9	3.0	12.0	24.5	25.5
1257	BP 554 maleate		BRD-K45479396-103-01-2	4.2	20.3	10.9	23.8	11.4	5.9
1258	Broad-PET-Sai-52		BRD-K45528773-001-03-1	-8.6	-9.3	3.2	-18.5	-1.8	-9.0
1259	DIETHYLCARBAMAZINE CITRATE		BRD-K45542189-048-15-5	-1.5	-15.8	6.4	-0.2	3.9	8.0
1260	3'-Fluorobenzylspiperone maleate		BRD-K45662124-103-01-2	-5.6	-6.7	-0.2	-2.0	-6.6	-5.3
1261	AZAPERONE		BRD-K45861246-001-08-4	13.2	3.4	42.6	8.5	13.6	24.0
1262	AMRINONE		BRD-K45924332-001-07-7	33.5	39.1	-4.5	14.7	-12.0	-12.2
1263	LUPININE		BRD-K45978015-001-03-6	-11.6	-1.1	11.5	17.1	2.7	-2.2
1264	TMS		BRD-K45988865-001-01-0	6.2	-7.7	-1.9	11.3	-17.8	31.9
1265	BEZAFIBRATE		BRD-K46018455-001-17-7	-8.8	-5.1	19.1	6.9	15.9	24.2
1266	RS 67333 hydrochloride		BRD-K46142322-003-01-6	2.8	-2.1	28.6	17.4	18.9	9.4
1267	TOLAZOLINE HYDROCHLORIDE		BRD-K46211610-003-15-0	-11.4	0.2	2.9	7.7	3.1	8.4
1268	PROADIFEN HYDROCHLORIDE		BRD-K46317332-003-10-3	-17.2	-11.7	-31.9	-29.8	-8.7	-12.1
1269	o-3M3FBS		BRD-K46384212-001-01-1	16.0	-0.1	10.9	-6.4	14.7	7.4
1270	Hymecromone		BRD-K46424862-001-04-2	0.2	5.7	19.9	16.1	12.3	14.3
1271	LIOTHYRONINE		BRD-K46428823-001-01-7	5.0	-1.3	8.9	6.0	-32.1	-22.6
1272	VALACYCLOVIR HYDROCHLORIDE		BRD-K46435977-003-03-8	1.3	-4.1	16.5	-2.7	11.0	16.7
1273	GR 55562 dihydrochloride		BRD-K46441700-300-01-4	-27.6	-13.4	9.1	7.9	-62.1	-30.0
1274	SCH 442416		BRD-K46469693-001-01-8	10.6	5.2	5.6	34.1	15.5	22.6
1275	SACCHARIN		BRD-K46493214-001-03-4	-10.3	-10.9	-3.0	8.0	13.7	2.1
1276	PRAMOXINE HYDROCHLORIDE		BRD-K46523383-003-14-6	-22.3	-6.2	14.3	43.4	-26.5	-29.5
1277	METHYLBENZETHONIUM CHLORIDE		BRD-K46531780-003-09-8	-55.4	-57.8	21.9	14.7	-65.3	-70.0
1278	DIPLOSALSALATE		BRD-K46585355-001-09-3	2.1	-7.1	15.9	17.2	24.8	19.3
1279	S 14506 hydrochloride		BRD-K46766488-003-01-2	-7.7	4.1	-20.0	-22.6	-10.3	-11.9
1280	6,4'-DIHYDROXYFLAVONE		BRD-K46836114-001-04-3	-8.3	-3.0	19.2	33.1	6.8	4.6
1281	Metyrapone		BRD-K46862739-001-03-6	6.8	9.9	20.4	3.5	8.4	1.3
1282	ANTIPYRINE		BRD-K46937689-001-08-5	-4.1	-8.9	19.1	7.1	1.9	5.8
1283	CLOXYQUIN		BRD-K46982791-001-04-5	34.8	13.0	15.2	33.0	-25.1	-26.9
1284	DIPHENHYDRAMINE HYDROCHLORIDE		BRD-K47278471-003-15-6	18.7	-2.3	2.3	14.5	11.8	9.9
1285	METHAPYRILENE HYDROCHLORIDE		BRD-K47323024-003-15-2	-11.3	-9.9	2.8	4.5	9.6	16.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1286	4-(4-Fluorobenzoyl)-1-(4-phenylbutyl)-piperidine oxalate		BRD-K47337578-034-01-7	-10.1	-11.2	-0.6	-2.3	0.1	3.7
1287	NIFENAZONE		BRD-K47407372-001-09-8	-9.3	11.4	18.9	21.4	8.0	7.1
1288	NORHARMAN		BRD-K47467075-001-13-4	-0.1	-1.8	7.5	-1.9	15.1	15.1
1289	PP 1		BRD-K47598052-001-06-7	-9.6	-6.8	-13.4	5.3	2.4	-0.8
1290	DIPYROCETYL		BRD-K47608922-001-02-1	-4.9	13.2	14.3	14.4	3.1	17.6
1291	BROMHEXINE HYDROCHLORIDE		BRD-K47631482-003-03-9	-7.6	-3.0	-42.4	-47.5	-40.9	-26.0
1292	EMD 386088 hydrochloride		BRD-K47659338-003-01-0	-6.5	-10.9	-16.4	-15.0	-17.9	-27.5
1293	NBQX disodium salt		BRD-K47717570-304-01-5	50.8	25.9	-9.3	-11.6	-11.1	-7.7
1294	6,3'-DIMETHOXYFLAVONE		BRD-K47724892-001-03-0	3.8	-3.1	52.5	10.8	25.7	21.5
1295	PD 168077 maleate		BRD-K47761761-103-01-8	11.5	-6.0	27.8	33.6	25.9	25.6
1296	DUARTIN (-)		BRD-K47814830-001-03-4	-21.4	26.7	14.6	9.7	-35.3	-33.3
1297	PODOFILOX		BRD-K47869605-001-18-9	24.6	44.3	36.5	38.5	3.6	6.6
1298	Piribedil dihydrochloride		BRD-K47936004-003-04-9	23.4	23.4	12.2	18.3	2.1	10.9
1299	TYRPHOSTIN 51		BRD-K47943470-001-03-6	29.5	63.0	-2.8	-0.4	-40.1	-40.1
1300	OBAAA		BRD-K48029790-001-01-0	-19.3	-5.6	-48.6	-43.7	-40.6	-31.7
1301	YM 298198, Desmethyl-		BRD-K48059230-003-01-1	10.5	-27.1	-9.0	-2.3	-18.0	-16.8
1302	PROPYLTHIOURACIL		BRD-K48168960-001-08-5	-28.1	-55.9	25.1	26.3	20.9	15.7
1303	QUININE SULFATE		BRD-K48278478-065-03-3	39.5	9.7	11.8	24.8	0.7	6.1
1304	Zonisamide		BRD-K48300629-001-03-8	-8.2	-1.1	-3.3	13.1	21.6	27.2
1305	ICI 215,001 hydrochloride		BRD-K48311056-003-01-7	7.7	13.2	-5.4	29.6	19.6	29.4
1306	FEBUXOSTAT		BRD-K48367671-001-01-8	-16.4	4.4	15.8	-2.8	25.5	20.2
1307	Y 29794 oxalate		BRD-K48449073-034-01-9	-60.7	-65.8	17.3	8.5	-69.4	-72.8
1308	NU 1025		BRD-K48692744-001-01-2	5.3	-4.3	3.4	10.1	7.1	-0.7
1309	TL HSV 09		BRD-K48722258-300-06-0	14.2	-0.1	10.2	-15.4	-5.0	-10.3
1310	PD 158780		BRD-K48735772-001-01-4	15.1	18.4	-11.4	-4.0	-36.0	-32.4
1311	PSB 1115		BRD-K49027941-237-01-1	8.0	-1.2	91.8	114.8	1.9	6.3
1312	CGS 15943		BRD-K49049886-001-03-8	18.3	17.2	0.5	4.5	-6.6	-2.7
1313	ETHYL-beta-CARBOLINE-3-CARBOXYLATE		BRD-K49061529-001-01-0	-25.2	-47.1	-16.4	1.3	-1.0	0.0
1314	SECURININE		BRD-K49071277-001-03-9	-9.9	0.6	2.5	6.3	-12.0	-9.4
1315	PRAZOSIN HYDROCHLORIDE		BRD-K49111258-003-16-4	-75.1	-73.5	10.2	26.4	-65.8	-69.7
1316	TMPH hydrochloride		BRD-K49119234-003-01-8	-4.1	-6.6	-20.5	-20.4	-9.9	-8.9
1317	CYCLOVERATRYLENE		BRD-K49154891-001-02-1	4.9	-5.2	8.9	4.9	-8.1	-7.8
1318	RETUSIN		BRD-K49158532-001-02-7	6.8	-4.5	55.3	15.0	23.4	28.4
1319	4-METHYLDAPHNETIN		BRD-K49207204-001-04-5	40.7	3.8	26.2	18.6	-45.2	-45.5
1320	6-Iodo-nordihydrocapsaicin		BRD-K49236613-001-01-5	-6.1	13.3	-14.1	1.1	-18.6	-20.9
1321	BIBU 1361 dihydrochloride		BRD-K49294207-300-01-2	-46.2	-45.7	-98.6	-98.9	-77.7	-81.4
1322	Immethidine dihydrobromide		BRD-K49519092-303-01-4	-5.4	-15.2	9.5	2.0	13.6	11.9
1323	7,8-DIHYDROXYFLAVONE		BRD-K49535716-001-03-2	-6.7	27.2	37.6	43.3	-48.1	-53.6
1324	AG 18		BRD-K49657628-001-05-6	42.1	32.5	13.7	25.5	-31.5	-32.7
1325	CLARITHROMYCIN		BRD-K49668410-001-07-1	14.9	7.7	29.6	16.2	9.4	14.1
1326	TTNPB		BRD-K49685476-001-05-0	-3.0	-8.7	4.5	-2.7	-3.7	-21.9
1327	2-METHYL-3-HYDROXYETHYLENEPYRAN-4-ONE		BRD-K49745710-001-02-5	-18.2	-3.8	2.3	5.3	6.9	8.6
1328	4-HYDROXYANTIPYRINE		BRD-K49759007-001-06-9	-73.1	-76.1	-10.0	-9.3	-41.2	-37.0
1329	Gavestinel		BRD-K49890030-236-01-6	-43.4	-36.0	-77.0	-84.6	-16.3	-12.3
1330	GR 113808		BRD-K49945136-001-03-5	34.0	5.9	13.1	4.1	6.6	-7.2
1331	RS 67506 hydrochloride		BRD-K50018155-003-01-3	23.5	-11.0	23.7	29.6	13.8	11.0

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1332	2-METHYL GRAMINE		BRD-K50054100-001-03-4	-9.1	1.0	24.5	22.9	-3.6	0.1
1333	TOLFENAMIC ACID		BRD-K50133271-001-10-4	-20.5	-27.0	41.0	38.8	-15.0	-21.4
1334	GBR 12935 dihydrochloride		BRD-K50135270-300-01-5	-6.6	-7.6	21.3	20.8	-11.0	-10.5
1335	MM 77 dihydrochloride		BRD-K50293352-300-01-3	3.3	-7.6	23.2	9.2	0.1	5.0
1336	UCL 2077		BRD-K50325075-001-01-3	-2.2	-14.5	4.4	7.0	54.8	37.0
1337	7,4'-DIHYDROXYFLAVONE		BRD-K50384076-001-01-9	18.1	-28.7	20.0	30.1	-3.3	-6.5
1338	Fenofibrate		BRD-K50388907-001-20-5	-6.9	33.5	18.7	29.3	32.8	40.8
1339	Chlormethiazole hydrochloride		BRD-K50422030-003-01-8	-27.0	5.9	0.1	21.0	-7.2	6.9
1340	POMIFERIN		BRD-K50660510-001-04-0	-63.2	-69.6	-8.9	16.3	-85.0	-85.5
1341	EPICATECHIN MONOGALLATE		BRD-K50660797-001-03-6	17.1	23.6	-42.3	-17.3	-40.4	-19.3
1342	PENTACHLOROPHENOL		BRD-K50711164-001-07-3	-15.8	-14.9	18.3	23.2	-32.3	-33.0
1343	BERBAMINE HYDROCHLORIDE		BRD-K50754849-300-03-1	-12.9	0.6	17.8	42.4	12.2	9.6
1344	Purvalanol A		BRD-K50836978-001-01-7	12.3	19.6	-58.9	-56.9	-10.4	-6.7
1345	PAC 1		BRD-K50841342-001-01-6	-29.4	-34.9	-55.3	-48.2	-29.1	-27.7
1346	SULFISOXAZOLE		BRD-K50859149-001-10-4	24.1	-10.7	23.3	31.6	11.3	13.1
1347	GR 103691		BRD-K50891186-001-03-6	7.0	-16.6	21.0	32.0	13.1	3.5
1348	TRAMADOL HYDROCHLORIDE		BRD-K51033547-003-01-8	17.7	-9.1	15.1	34.8	7.1	14.1
1349	ETHIONAMIDE		BRD-K51207550-001-09-9	-17.1	-16.8	31.7	27.2	20.4	18.9
1350	A-3 hydrochloride		BRD-K51215422-003-01-1	-21.3	-17.2	17.8	17.5	-34.5	-22.6
1351	AG 99		BRD-K51223576-001-01-3	103.9	134.4	16.9	11.6	-44.8	-47.1
1352	FENBENDAZOLE		BRD-K51318897-001-07-0	25.3	3.9	14.0	40.0	9.9	9.2
1353	TOREMIPHENE CITRATE		BRD-K51350053-048-06-6	-54.5	-54.8	15.9	3.5	-77.6	-80.1
1354	DIFFRACTAIC ACID		BRD-K51370144-001-06-4	-48.8	-40.1	31.9	19.9	-38.5	-42.4
1355	ST638		BRD-K51476772-001-01-9	12.5	11.2	-10.6	-17.5	-15.0	-22.7
1356	Ro 25-6981 maleate		BRD-K51541829-001-01-3	22.1	-1.0	-18.9	6.8	-1.6	5.9
1357	(S)-(-)-Sulpiride		BRD-K51671335-001-04-9	-9.2	2.2	19.7	12.6	10.8	12.9
1358	ESCULIN MONOHYDRATE		BRD-K51742987-002-02-1	8.3	10.6	91.0	98.9	16.4	17.6
1359	Iodophenpropit dihydrobromide		BRD-K51918615-303-01-1	-11.1	-16.3	-42.0	-28.0	4.9	-2.0
1360	deoxyrhapontin		BRD-K52015643-001-01-1	20.2	34.2	-0.6	10.3	4.8	1.8
1361	METRONIDAZOLE		BRD-K52020312-001-15-1	1.7	7.6	16.8	16.7	30.7	14.5
1362	BENZYL BENZOATE		BRD-K52072429-001-06-1	-0.1	6.6	13.5	24.7	17.5	20.5
1363	OXBENDAZOLE		BRD-K52075715-001-03-4	9.7	-1.0	59.8	57.3	44.8	38.8
1364	PIPERONYLIC ACID		BRD-K52148119-001-02-3	2.7	4.5	16.2	21.8	9.1	13.4
1365	Domoic acid		BRD-K52217427-001-02-3	12.5	1.7	10.0	42.2	18.6	11.9
1366	ICI 63197		BRD-K52219182-001-01-6	67.3	38.0	32.8	24.6	23.6	25.6
1367	CHLORHEXIDINE		BRD-K52256627-300-03-3	-88.4	-67.8	47.9	25.9	-64.0	-76.3
1368	CHINIOFON		BRD-K52284881-236-01-6	57.7	50.3	3.7	27.5	0.8	2.2
1369	CI-994		BRD-K52313696-001-08-1	7.2	-7.4	11.3	-4.2	-3.4	-2.0
1370	APIIN		BRD-K52379519-001-02-0	-12.6	3.5	-2.1	-5.3	15.3	8.6
1371	GR 159897		BRD-K52394958-001-01-9	25.6	-11.0	17.5	13.2	12.4	14.4
1372	Alprostadil		BRD-K52459643-001-10-2	-1.4	-15.4	14.2	6.4	23.8	23.4
1373	SC 19220		BRD-K52512893-001-03-0	-10.7	-3.2	-11.6	-4.3	10.6	18.5
1374	STO-609 acetate		BRD-K52620403-015-02-6	16.8	17.7	6.7	19.2	0.7	4.0
1375	LIDOCAINE HYDROCHLORIDE		BRD-K52662033-003-14-7	20.6	8.7	4.8	0.1	8.9	14.6
1376	JAK3 Inhibitor II		BRD-K52850071-001-01-2	-12.4	-4.8	-4.4	-14.4	-63.0	-65.6
1377	ACETOHEXAMIDE		BRD-K52960356-001-06-4	-20.6	19.8	41.7	30.2	18.1	15.7

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1378	CLOMIPRAMINE HYDROCHLORIDE		BRD-K52989797-003-16-5	-52.2	-52.6	54.8	47.0	-45.5	-52.3
1379	Niridazole		BRD-K53123955-001-03-0	0.5	-23.0	-2.2	4.2	14.9	12.7
1380	BUTYLATED HYDROXYTOLUENE		BRD-K53153417-001-06-2	1.2	-0.4	-1.7	7.5	0.6	-2.6
1381	TRIMETOZINE		BRD-K53220666-001-01-8	-7.4	-1.0	14.0	-2.2	-2.8	5.3
1382	HESPERIDIN		BRD-K53229386-001-03-4	16.2	5.9	27.3	26.7	8.1	12.2
1383	CITCO		BRD-K53263234-001-02-9	30.5	8.0	8.7	36.2	29.7	22.9
1384	(?)-U-50488 hydrochloride		BRD-K53532120-003-03-8	2.9	0.3	-2.4	10.9	-25.9	-20.7
1385	CNQX disodium salt		BRD-K53545112-304-01-6	-6.2	-2.2	-4.8	-4.3	15.9	13.4
1386	IRIGENIN, 7-BENZYL ETHER		BRD-K53634892-001-03-2	5.2	2.9	39.0	30.5	-11.9	-5.7
1387	AMITRIPTYLINE HYDROCHLORIDE		BRD-K53737926-003-14-6	-2.1	4.1	-35.9	-56.3	-24.7	-32.8
1388	Risperidone		BRD-K53857191-001-10-2	22.3	-4.6	0.9	3.6	1.2	0.3
1389	MMPX		BRD-K53878242-001-02-4	5.7	2.8	17.9	13.0	7.1	7.6
1390	4-HYDROXYPHENETHYLAMINE		BRD-K53893978-001-03-1	19.7	-11.8	15.3	19.9	7.5	15.1
1391	2,3,4'-TRIHYDROXY-4-METHOXYBENZOPHENONE		BRD-K53923343-001-03-4	46.3	47.7	32.8	42.0	-30.2	-28.2
1392	ALX 5407 hydrochloride		BRD-K53979406-003-01-0	-10.5	-17.5	-7.2	-17.2	-10.7	-14.6
1393	Remoxipride hydrochloride		BRD-K54094468-003-05-3	24.1	-23.8	3.4	7.5	5.1	5.8
1394	CMPD-1		BRD-K54095730-001-01-5	2.4	9.7	-54.3	-36.0	-39.2	-28.3
1395	Cirazoline hydrochloride		BRD-K54142781-003-02-7	-7.5	-12.0	-4.5	2.8	14.0	14.0
1396	Dorsomorphin dihydrochloride		BRD-K54233340-300-01-0	-20.4	-18.5	-47.2	-44.9	-20.1	-23.9
1397	SB 202190		BRD-K54330070-001-07-1	-7.2	-1.5	-24.9	-23.2	-19.4	-19.9
1398	Doxepine HCl		BRD-K54462405-003-16-5	14.5	-17.3	-6.5	-24.3	1.1	3.2
1399	CAPTOPRIL		BRD-K54529596-001-15-6	-4.1	2.4	16.1	15.6	12.0	11.2
1400	3-DEOXY-3beta-HYDROXYANGOLENSIC ACID METHYL ESTER		BRD-K54554531-001-02-0	-18.8	-11.5	13.0	6.7	0.8	0.3
1401	R 59-022		BRD-K54665485-001-04-6	16.3	9.0	12.8	-5.0	-12.8	-4.8
1402	BAY 36-7620		BRD-K54704028-001-01-3	-0.3	29.7	2.2	12.4	4.9	-1.9
1403	nTZDpa		BRD-K54708045-001-01-3	-94.9	-94.5	-96.7	-95.9	-70.6	-73.6
1404	TRIOXSALEN		BRD-K54790157-001-10-6	35.8	-0.6	1.6	21.3	-2.6	0.5
1405	PEFLOXACINE MESYLATE		BRD-K55034111-066-07-2	28.1	-5.9	42.0	34.8	16.2	9.7
1406	FLUPHENAZINE HYDROCHLORIDE		BRD-K55127134-300-07-0	-78.3	-82.5	-103.5	-104.7	-89.0	-88.2
1407	3-HYDROXYFLAVONE		BRD-K55150756-001-05-7	27.0	47.0	3.0	17.8	-18.2	-11.7
1408	2-MERCAPTOBENZOTHIAZOLE		BRD-K55160477-001-03-9	-47.3	-41.7	15.9	34.7	-4.8	-11.3
1409	EFLOXATE		BRD-K55166090-001-03-3	-8.0	-12.7	3.2	32.9	-18.3	-8.8
1410	PENICILLIN G POTASSIUM		BRD-K55191674-237-12-6	13.9	-1.9	28.9	19.6	10.5	12.7
1411	2',4'-DIHYDROXYCHALCONE 4'-GLUCOSIDE		BRD-K55202535-001-03-6	6.9	-4.4	27.9	27.0	25.8	23.3
1412	SULFADOXINE		BRD-K55250441-001-06-4	2.3	5.3	17.7	15.8	19.0	27.6
1413	5-FLUOROINDOLE-2-CARBOXYLIC ACID		BRD-K55273157-001-13-6	-10.2	-8.2	26.4	30.5	24.9	23.4
1414	CPD5		BRD-K55292075-001-01-0	26.3	19.8	-66.4	-61.8	-59.9	-60.8
1415	BU 224 hydrochloride		BRD-K55344148-003-01-8	2.5	16.7	24.1	32.7	10.9	18.7
1416	Anpirtoline hydrochloride		BRD-K55424922-003-01-0	17.5	-4.9	7.1	7.2	-0.1	0.0
1417	WAY 629 hydrochloride		BRD-K55430733-003-01-6	-0.5	-19.9	-25.9	-5.8	-32.7	-27.4
1418	TAS 301		BRD-K55454768-001-01-8	-5.0	-4.4	-22.4	-15.8	-1.5	-2.0
1419	Spiperone hydrochloride		BRD-K55468218-003-01-0	6.1	-38.2	-34.0	-17.6	-19.1	-19.4
1420	FORMONONETIN		BRD-K55567017-001-06-5	-5.1	-5.9	18.6	1.8	7.3	3.9
1421	Co 101244 hydrochloride		BRD-K55677650-003-01-1	-15.1	0.8	0.6	-21.5	-40.0	-41.9
1422	TOPOTECAN HYDROCHLORIDE		BRD-K55696337-003-08-7	77.5	73.3	31.5	24.6	8.9	2.9
1423	SCH 28080		BRD-K55748775-001-01-4	0.6	-8.3	-0.8	11.0	12.0	6.6

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1424	HYMECROMONE METHYL ETHER		BRD-K55766625-001-04-2	31.1	-8.4	38.4	33.6	18.1	19.1
1425	VEGF Receptor 2 Kinase Inhibitor II		BRD-K55823969-001-01-1	0.5	1.7	-14.5	-22.2	6.7	1.6
1426	PHENYTOIN SODIUM		BRD-K55930204-236-11-0	4.5	0.9	14.6	23.6	31.3	34.2
1427	RHC 80267		BRD-K56047318-001-03-0	-6.1	5.6	16.9	46.9	22.4	15.8
1428	METHOXYVONE		BRD-K56057104-001-03-7	-14.6	-19.0	16.2	19.1	18.0	9.7
1429	HBDDE		BRD-K56064827-001-04-7	158.4	144.3	118.3	145.4	23.7	21.5
1430	OXICONAZOLE NITRATE		BRD-K56104152-008-03-3	16.9	-9.5	40.1	37.0	-17.9	-10.6
1431	BU 226 hydrochloride		BRD-K56115039-003-01-3	-0.1	-8.0	0.5	4.8	7.5	13.9
1432	3,4',5,6,7-PENTAMETHOXYFLAVONE		BRD-K56148010-001-01-1	-6.4	-5.5	19.8	4.1	-11.4	-15.9
1433	benznidazole		BRD-K56156805-001-05-4	-12.6	-6.9	0.3	8.8	14.1	11.5
1434	trans-Triprolidine hydrochloride		BRD-K56231354-003-01-5	12.5	-3.5	18.1	11.9	14.7	18.6
1435			BRD-K56309460-001-03-0	-0.6	-0.8	38.6	6.9	3.9	4.8
1436	ZK 756326		BRD-K56403959-300-01-9	9.2	22.1	-11.0	-18.1	4.6	-7.0
1437	Calcipotriol		BRD-K56429665-001-03-9	-1.5	-7.7	-70.4	-81.1	-27.0	-30.0
1438	7-HYDROXYFLAVONE		BRD-K56450366-001-03-7	17.6	27.0	19.4	42.3	14.7	24.0
1439	CHICAGO SKY BLUE		BRD-K56483981-342-04-9	33.4	35.0	13.8	9.2	11.9	15.9
1440	BMS 182874 hydrochloride		BRD-K56509348-003-01-3	32.7	15.4	-2.3	6.8	13.7	9.4
1441	CLOFAZIMINE		BRD-K56614220-001-10-9	-9.8	-16.2	-18.8	8.4	8.8	8.0
1442	CARBADOX		BRD-K56735750-001-03-5	30.8	28.6	27.5	29.5	7.0	13.4
1443	NARINGIN		BRD-K56759808-001-03-7	18.6	12.6	18.7	23.9	3.5	4.1
1444	Ethoxyquin		BRD-K56792340-001-05-8	-27.4	-22.3	2.4	4.7	-65.9	-64.0
1445	GUANABENZ ACETATE		BRD-K56800335-015-03-1	3.3	0.9	24.7	10.3	25.6	14.3
1446	OXETHAZAINE		BRD-K56940463-001-08-8	-41.2	-48.7	28.9	8.9	-58.0	-62.0
1447	MARMESIN ACETATE		BRD-K57001030-001-02-5	-9.9	-16.9	4.7	23.7	5.1	16.9
1448	TRIPEENNAMINE CITRATE		BRD-K57033106-048-03-6	30.2	4.7	17.9	9.4	9.1	5.5
1449	CROTAMITON		BRD-K57179821-001-08-9	-0.3	-3.8	9.6	0.3	5.9	-0.5
1450	INDOMETHACIN		BRD-K57222227-001-18-6	-12.2	-16.6	1.3	4.6	-2.1	0.2
1451	5-CHLOROINDOLE-2-CARBOXYLIC ACID		BRD-K57244822-001-03-1	-9.2	-7.1	24.3	15.4	12.1	18.9
1452	MOROXYDINE HYDROCHLORIDE		BRD-K57291914-003-05-2	9.6	-17.2	21.3	21.3	15.6	27.7
1453	PRE-084 hydrochloride		BRD-K57304726-003-03-6	34.9	38.6	-15.5	-8.6	-2.8	-1.5
1454	IRIGENOL		BRD-K57398215-001-03-0	51.4	53.4	11.5	19.1	12.6	10.3
1455	TIAPRIDE HYDROCHLORIDE		BRD-K57432881-003-14-3	4.8	0.9	24.3	29.9	12.0	29.1
1456	ENALAPRIL MALEATE		BRD-K57545991-050-16-5	22.4	-14.2	7.3	20.8	8.4	2.0
1457	PENTOXIFYLLINE		BRD-K57569181-001-16-8	-37.0	1.0	-0.9	23.8	8.9	5.8
1458	1-[1-(2-BENZO[B]THIENYL)CYCLOHEXYL]PYRROLIDINE		BRD-K57586808-001-01-7	-8.1	-19.9	17.1	17.9	15.9	20.4
1459	PENTYLENETETRAZOL		BRD-K57718010-001-08-5	-12.4	-11.6	13.3	9.0	14.6	11.2
1460	Roscovitine, (S)-Isomer		BRD-K57810622-001-01-5	-5.3	-9.7	-12.1	-6.1	8.7	8.3
1461	TYRPHOSTIN AG 1295		BRD-K57926513-001-03-7	-0.8	-5.5	-5.5	-11.8	9.5	7.9
1462	ESCULETIN		BRD-K58149231-001-10-1	17.5	4.3	10.4	7.0	-50.5	-45.5
1463	METICRANE		BRD-K58265391-001-06-9	22.3	-13.1	18.6	34.8	0.5	9.8
1464	Ro 90-7501		BRD-K58299615-001-02-7	-10.3	-16.0	-6.1	-10.5	-34.2	-23.1
1465	ACETAMINOSALOL		BRD-K58464880-001-02-5	1.4	10.5	3.6	-0.4	-18.6	-20.6
1466	PALMATINE CHLORIDE		BRD-K58466253-003-07-4	13.2	18.5	22.1	10.6	7.3	1.4
1467	ROCCELLIC ACID		BRD-K58612873-001-03-6	3.1	16.2	25.9	20.4	20.5	27.9
1468	CIANIDANOL		BRD-K58736316-001-08-7	7.6	-1.2	9.7	14.0	-23.5	-29.5
1469	SANTONIN		BRD-K58787433-001-08-8	7.0	15.3	29.4	1.0	-0.9	2.0

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1470	OXYBENZONE		BRD-K59037100-001-09-7	-36.2	-13.9	10.4	3.2	-6.6	-14.3
1471	CHLORPROTHIXENE HYDROCHLORIDE		BRD-K59058766-003-15-1	-60.1	-56.7	-94.7	-93.9	-80.6	-79.7
1472	SB 216763		BRD-K59184148-001-04-2	146.0	85.6	5.4	2.3	27.4	19.2
1473	NAPROXEN(+)		BRD-K59197931-001-03-7	3.2	-3.0	19.6	16.3	21.9	16.7
1474	CHRYSTOPHANOL		BRD-K59284035-001-03-8	34.1	19.2	13.6	31.8	12.2	14.8
1475	Go 6976		BRD-K59304176-001-03-3	-15.7	-5.3	-36.7	-32.2	-14.5	-12.8
1476	SB 366791		BRD-K59331372-001-01-2	37.8	-4.1	0.6	6.1	10.1	15.3
1477	Linopirdine dihydrochloride		BRD-K59332007-300-01-9	-1.9	-4.7	-2.2	-14.9	8.5	-0.7
1478	(S)-(+)-Niguldipine hydrochloride		BRD-K59333713-003-01-2	-11.2	-5.3	-29.5	-5.3	-29.2	-29.4
1479	AH 6809		BRD-K59339270-001-01-8	-7.9	-8.1	-3.7	0.2	27.1	19.5
1480	Tozasertib VX-680 (MK-0457)		BRD-K59369769-001-02-1	-21.8	-13.9	-16.9	-24.8	-14.4	-3.3
1481	AM 281		BRD-K59419204-001-01-9	0.9	-4.4	-38.2	-41.1	-16.0	-15.4
1482	AG-879		BRD-K59469039-001-03-1	2.7	21.5	-9.1	-11.7	1.5	0.2
1483	PIPERINE		BRD-K59522102-001-08-8	2.1	-2.6	-0.7	6.9	19.8	12.5
1484	Bestatin		BRD-K59574735-001-05-0	36.9	0.8	9.3	33.4	-0.7	-7.0
1485	QUINIDINE GLUCONATE		BRD-K59632282-052-02-3	1.6	-1.2	19.7	10.9	17.5	24.6
1486	7,2'-DIHYDROXYFLAVONE		BRD-K59633395-001-01-4	78.1	26.3	20.1	24.3	16.6	3.6
1487	YM 298198 hydrochloride		BRD-K59650319-003-01-7	-14.4	-18.0	8.8	23.8	-35.4	-29.2
1488	MDL 29951		BRD-K59753853-001-01-5	-4.6	24.1	7.7	-0.4	-3.9	-1.8
1489	(R)-(+)-8-Hydroxy-DPAT hydrobromide		BRD-K59765110-004-03-8	13.0	1.8	19.1	8.9	-11.3	-17.4
1490	SULFABENZAMIDE		BRD-K59983611-001-15-1	-15.6	-28.3	6.7	4.7	13.1	8.8
1491	4a-Phorbol		BRD-K60024823-001-01-5	-5.9	8.8	0.6	-14.5	-1.0	-26.6
1492	GENTIAN VIOLET		BRD-K60025295-003-03-3	-96.7	-98.2	33.9	14.3	-85.8	-87.9
1493	IRBESARTAN		BRD-K60038276-001-03-3	-4.7	0.1	35.1	27.5	60.8	55.0
1494	N-Methyllidocaine iodide		BRD-K60060639-005-01-4	28.5	8.9	-18.7	-14.1	10.7	4.7
1495	TYRPHOSTIN 46		BRD-K60184833-001-03-1	88.3	87.3	-6.3	-2.5	-43.2	-43.5
1496	MG-132		BRD-K60230970-001-04-3	15.3	5.0	28.4	14.8	-14.0	-5.0
1497	4-NAPHTHALIMIDOBUTYRIC ACID		BRD-K60241851-001-06-9	-5.7	1.6	22.7	25.4	23.1	22.7
1498	Dephostatin		BRD-K60274257-001-01-1	89.4	78.5	41.8	39.1	-6.2	-3.0
1499	5,7-Dichlorokynurenic acid		BRD-K60287130-001-04-0	-5.0	-5.2	10.0	24.6	15.8	17.3
1500	ITE		BRD-K60298136-001-01-7	7.2	-8.9	2.3	7.1	3.4	8.1
1501	alpha-CYANO-4-HYDROXYCINNAMIC ACID		BRD-K60302405-001-04-5	4.1	-3.8	32.9	26.5	22.2	18.0
1502	1-HYDROXY-3,6,7-TRIMETHOXY-2,8-DIPRENYLXANTHONE		BRD-K60465509-001-01-1	3.6	-3.4	8.5	21.3	5.4	11.8
1503	Pravastatin		BRD-K60511616-236-02-2	-6.4	21.4	29.2	8.0	6.0	9.5
1504	DIMPYLATE		BRD-K60567437-001-04-5	-5.0	-3.6	14.8	26.5	5.2	7.6
1505	DESPRAMEINE HYDROCHLORIDE		BRD-K60762818-003-15-3	-10.1	-22.6	22.4	31.2	-31.3	-36.4
1506	PERGOLIDE MESYLATE		BRD-K60770992-066-15-1	14.0	-2.4	20.0	16.3	0.9	10.0
1507	ADIPHENINE HYDROCHLORIDE		BRD-K60907894-003-14-4	-0.9	-7.6	5.1	6.8	-14.7	-16.3
1508	R(+)-6-BROMO-APB		BRD-K60932973-001-01-7	-49.1	-49.0	-48.9	-51.7	-62.6	-62.9
1509	SB 218795		BRD-K61097567-001-03-6	-6.4	2.2	4.9	-0.3	0.0	-10.8
1510	NBI 27914 hydrochloride		BRD-K61177364-003-01-1	15.6	46.9	11.9	11.4	49.2	39.4
1511	LOPERAMIDE HYDROCHLORIDE		BRD-K61250553-003-16-5	-3.7	17.1	8.6	35.5	-10.3	-10.0
1512	Daphnetin		BRD-K61269089-001-02-2	20.4	16.8	18.9	26.3	-30.4	-29.6
1513	sb 225002		BRD-K61323504-001-03-2	27.4	1.5	2.5	3.8	-29.6	-38.5
1514	DEGUELIN(-)		BRD-K61401890-001-04-6	26.8	24.4	-15.2	3.8	-10.5	-14.4
1515	THIMEROSAL		BRD-K61443650-236-06-5	-77.8	-74.4	-92.0	-90.6	-71.3	-71.1

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1516	AG 43		BRD-K61590534-001-01-4	18.3	47.2	16.4	14.1	26.8	28.2
1517	2,3-DCPE hydrochloride		BRD-K61734568-003-01-3	-23.3	-39.1	-24.8	-12.4	-18.7	-23.4
1518	CHLORINDIONE		BRD-K61802864-001-04-7	-2.7	-26.8	3.4	21.6	-14.6	-9.8
1519	FG 7142		BRD-K61951118-001-02-0	23.2	-12.7	28.8	22.9	10.8	12.6
1520			BRD-K62008436-001-05-6	-3.8	-15.7	18.1	16.2	11.0	17.7
1521	N-Methylquipazine dimaleate		BRD-K62056274-313-01-8	-0.5	-30.9	20.5	26.9	-11.5	-3.4
1522	WIN 55,212-3 mesylate		BRD-K62085719-066-01-4	-8.9	23.4	2.4	21.2	-1.5	12.6
1523	ANAGRELIDE HYDROCHLORIDE		BRD-K62200014-003-05-5	10.5	-16.2	19.1	14.0	4.7	15.2
1524	VUF 5681 dihydrobromide		BRD-K62206109-303-01-1	-2.6	-23.7	-10.0	-1.2	13.5	14.9
1525	T 98475		BRD-K62221994-001-01-8	8.1	-7.5	-69.2	-69.1	-14.6	-12.5
1526	Lylamine hydrochloride		BRD-K62289640-003-01-9	-93.1	-87.8	-106.9	-107.9	-82.0	-83.6
1527	KOPARIN		BRD-K62331715-001-02-1	80.0	76.2	15.0	19.0	-3.9	-1.1
1528	DY131		BRD-K62353524-001-01-8	47.5	7.7	29.3	29.8	6.8	16.0
1529	DAPSONE		BRD-K62363391-001-15-7	11.4	-4.5	10.2	9.1	7.0	1.1
1530	(+)-PD 128907 hydrochloride		BRD-K62456038-003-02-2	-6.1	-1.2	4.0	15.2	-26.2	-29.2
1531	4-IBP		BRD-K62537556-001-01-7	1.7	-2.3	14.5	19.3	9.0	6.1
1532	SR 2640 hydrochloride		BRD-K62562723-003-01-9	5.2	-5.5	-16.4	-13.5	5.8	19.8
1533	PODOHYLLIN ACETATE		BRD-K62577500-001-03-6	24.9	0.3	12.9	24.7	-12.6	-10.1
1534	3-[2-[4-(2-Methoxyphenyl)piperazin-1-yl]ethyl]pyrimido[5,4-b] indole-2,4-dione		BRD-K62581435-001-02-0	-8.8	-8.2	8.0	7.6	13.4	12.2
1535	GR 125487 sulfamate		BRD-K62594868-082-03-7	-8.1	0.0	12.3	1.3	-7.3	1.8
1536	PD 98059		BRD-K62810658-001-06-4	10.9	1.1	23.4	31.5	4.2	0.2
1537	Aminopurine, 6-benzyl		BRD-K62929068-001-05-8	45.2	21.8	-10.3	0.7	20.6	-5.8
1538	NSC 625987		BRD-K62949423-001-02-3	34.5	-7.5	38.7	34.6	3.6	-0.7
1539	ORBIFLOXACIN		BRD-K63001556-001-03-9	-24.2	9.9	3.9	14.6	10.8	4.3
1540	JTE 907		BRD-K63150726-001-01-3	7.1	9.9	18.7	27.2	29.7	26.0
1541	MNITMT		BRD-K63151507-001-01-6	32.8	42.7	-1.1	16.3	9.1	9.5
1542	METHOXSALEN		BRD-K63430059-001-09-9	-6.7	-8.7	18.1	16.0	7.4	4.8
1543	SU 5416		BRD-K63504947-001-05-5	24.5	3.0	-29.6	12.2	-15.6	4.3
1544	T 0156 hydrochloride		BRD-K63516691-003-01-2	3.5	10.8	24.6	19.8	18.3	15.8
1545	AM 630		BRD-K63533170-001-01-1	7.3	-24.9	-37.6	-33.4	-15.6	-19.1
1546	ERYTHROMYCIN STEARATE		BRD-K63550407-028-03-9	15.0	-15.3	8.1	3.2	-10.7	-13.2
1547	Bufalin		BRD-K63606607-001-02-6	25.9	31.7	38.1	26.9	28.1	40.5
1548	ETHACRYNIC ACID		BRD-K63630713-001-15-9	-6.9	-1.6	7.8	8.8	-40.0	-7.9
1549	TRIFLUROMAZINE HYDROCHLORIDE		BRD-K63675182-003-14-5	-47.4	-54.4	-79.7	-78.3	-62.2	-58.0
1550	10-HYDROXYCAMPTOTHECIN		BRD-K63784565-001-03-9	48.8	45.4	41.7	41.5	18.3	11.8
1551	Arecaidine but-2-ynyl ester tosylate		BRD-K63792901-075-01-3	34.7	-30.1	-0.4	19.2	2.8	1.9
1552	RALOXIFENE HYDROCHLORIDE		BRD-K63828191-003-11-5	-18.8	-5.3	-0.1	8.7	-31.8	-29.6
1553	Thioperamide maleate		BRD-K63874012-103-01-5	-13.5	-12.6	32.2	22.7	3.3	-1.9
1554	DIHYDROSAMIDIN		BRD-K63945320-001-03-2	-4.5	-13.5	-25.5	-36.9	-13.0	-9.5
1555	2-Methyl-5-hydroxytryptamine hydrochloride		BRD-K64137799-003-01-7	31.0	21.0	15.1	32.7	-13.7	-15.8
1556	ZD 2079 hydrochloride		BRD-K64157027-003-01-9	-1.4	0.9	-7.0	6.9	6.8	6.8
1557	BTS		BRD-K64178227-001-04-1	-7.9	-17.7	8.3	13.5	7.5	8.4
1558	DIFUCOL HEXAMETHYL ETHER		BRD-K64246525-001-02-9	4.2	-6.2	13.2	19.5	24.9	20.2
1559	CFM 1571 hydrochloride		BRD-K64341947-003-01-6	-14.5	-15.4	-65.2	-64.2	-34.8	-36.9
1560	DNQX		BRD-K64400208-001-02-6	13.9	23.7	-12.6	-21.6	3.6	-6.6
1561	Ivachtin		BRD-K64402243-001-01-1	14.9	24.4	34.8	38.6	24.3	17.4

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1562	TOLTRAZURIL		BRD-K64514229-001-01-1	-24.5	-23.3	-79.3	-86.7	-41.5	-32.9
1563	SALICIN		BRD-K64614248-001-06-5	-8.4	-3.3	14.8	10.5	1.3	5.4
1564	JNJ 16259685		BRD-K64670467-001-01-2	-7.9	13.4	2.8	-4.9	12.6	22.1
1565	Etazolate hydrochloride		BRD-K64755930-003-02-4	15.1	10.3	9.6	18.8	22.8	23.7
1566	PHLORACETOPHENONE		BRD-K64824948-001-03-0	13.6	14.2	-13.1	-6.5	26.6	34.1
1567	NABUMETONE		BRD-K65146499-001-14-7	7.0	-0.1	-14.2	-6.2	2.8	-2.0
1568	BPDQ		BRD-K65185756-001-01-0	-6.2	-3.7	17.3	5.5	11.1	14.9
1569	N- (9-FLUORENYLMETHOXCARBONYL)-L-LEUCINE		BRD-K65275554-001-03-9	8.6	3.5	-48.0	-48.9	-6.6	-13.8
1570	GP 1a		BRD-K65285700-001-01-5	-22.2	-35.1	-51.8	-56.0	-32.9	-13.7
1571	MONOCROTALINE		BRD-K65508953-001-08-9	31.2	14.7	58.8	59.4	24.9	24.7
1572	ICARIN		BRD-K65639003-001-05-8	10.4	19.4	13.1	13.5	7.8	-0.9
1573	KINETIN		BRD-K65667145-001-07-4	6.1	14.3	24.6	21.4	25.4	21.0
1574	CGP 7930		BRD-K65786282-001-02-6	-23.5	-11.2	-29.0	-18.1	-23.3	-23.2
1575	Diphenyleneiodonium chloride		BRD-K65814004-003-01-1	-93.2	-98.0	-73.7	-73.4	-56.4	-60.3
1576	(S)(+)-Ropivacaine		BRD-K65856711-001-01-0	-12.7	20.2	-9.7	5.2	5.7	7.3
1577	FGIN-1-43		BRD-K66093087-001-02-3	2.8	1.6	3.8	7.5	-2.2	1.6
1578	FLUVASTATIN		BRD-K66296774-001-02-0	-15.2	-11.8	-53.2	-57.9	-18.7	-27.3
1579	ZOXAZOLAMINE		BRD-K66353228-001-08-8	21.1	30.2	13.5	34.4	16.2	13.9
1580	ACETOSYRINGONE		BRD-K66643401-001-04-0	20.0	27.7	-4.6	20.3	-17.4	-24.5
1581	(+)-UH 232		BRD-K66715657-001-01-3	24.8	-8.5	34.6	-4.6	12.9	18.0
1582	ICI-162,846		BRD-K66782112-001-01-2	-13.7	-9.2	5.6	6.1	13.1	20.1
1583	Pifithrin- <alpha> hydrobromide</alpha>		BRD-K66874953-004-01-3	-9.6	-15.2	12.9	4.9	10.5	16.2
1584	Luzindole		BRD-K67013324-001-01-5	7.6	-2.7	7.1	25.7	33.8	40.6
1585	CILOSTAZOL		BRD-K67017579-001-16-6	39.7	-3.6	-3.9	9.4	2.0	3.0
1586	ALTRETAMINE		BRD-K67043667-001-15-7	2.7	2.5	-1.6	-4.3	26.1	7.0
1587	Milrinone		BRD-K67080878-001-05-5	-8.6	-12.8	0.9	14.4	11.6	12.5
1588	4-Phenylbutyrate, sodium salt		BRD-K67102207-236-01-0	18.4	-19.2	-6.8	-2.3	18.4	19.2
1589	FENTHION		BRD-K67217586-001-04-9	-4.0	-7.4	-13.7	19.9	12.1	13.3
1590	GIBBERELLIC ACID		BRD-K67237946-001-04-2	-0.7	-6.7	11.7	12.5	44.8	32.1
1591	SB 431542		BRD-K67298865-001-03-3	14.9	-5.6	3.2	16.3	6.6	12.0
1592	TC 2559 difumarate		BRD-K67352070-364-01-5	-13.6	17.2	4.1	1.6	16.8	9.2
1593	SIB 1893		BRD-K67439147-001-01-7	-4.7	0.4	-0.1	12.7	8.3	10.2
1594	Flurofamide		BRD-K67445247-001-01-3	14.9	36.4	-11.6	-18.3	12.6	13.9
1595	AG-126		BRD-K67506692-001-04-6	23.0	25.1	-27.0	-9.2	7.7	17.7
1596	PQ 401		BRD-K67537649-001-01-1	-4.1	-7.8	-65.0	-56.6	-28.7	-31.2
1597	MYOSMINE		BRD-K67556876-001-04-9	-12.3	-14.9	-20.9	-21.2	16.0	12.1
1598	ACEMETACIN		BRD-K67563174-001-09-3	-0.3	15.7	17.0	0.2	32.2	30.3
1599	CI 966 hydrochloride		BRD-K67680372-003-01-8	-8.7	10.1	-51.2	-60.7	-35.1	-29.4
1600	PHYSCION		BRD-K67772619-001-03-6	20.0	4.0	13.1	15.2	13.2	-1.5
1601	Haloperidol hydrochloride		BRD-K67783091-003-03-6	29.0	14.7	-4.2	-9.7	19.5	11.1
1602	ZM 323881 hydrochloride		BRD-K67831364-003-01-7	16.7	34.8	6.0	7.2	15.5	19.7
1603	Palmitoyl ethanolamide		BRD-K68095457-001-04-4	-9.6	-21.2	-5.2	-4.5	5.2	5.9
1604	CGS 20625		BRD-K68103045-001-01-1	-2.2	1.0	-4.1	-4.9	-20.4	-15.0
1605	TERBINAFINE HYDROCHLORIDE		BRD-K68132782-003-05-4	-5.9	4.5	24.8	56.6	38.8	14.2
1606	GR 46611		BRD-K68190965-001-01-4	-9.8	5.9	-23.8	-31.8	-15.6	-13.3
1607	UK 14,304 tartrate		BRD-K68264559-045-01-6	48.1	61.9	24.3	45.0	27.5	25.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1608	Statil		BRD-K68332390-001-03-3	-27.7	-5.2	15.3	3.4	11.3	24.2
1609	W-9 hydrochloride		BRD-K68341547-003-01-6	-44.9	-35.3	-75.0	-61.2	-51.3	-60.8
1610	ZK 93426 hydrochloride		BRD-K68392338-003-01-2	-17.6	-15.0	-51.1	-55.9	-24.8	-26.0
1611	ML 9 hydrochloride		BRD-K68402494-003-01-9	-35.2	-34.3	-67.3	-63.5	-58.9	-52.8
1612			BRD-K68432770-001-08-0	-0.9	-2.0	-0.1	-1.0	10.8	3.6
1613	DICYCLOMINE HYDROCHLORIDE		BRD-K68507560-003-15-4	-24.4	-21.8	-61.0	-75.1	-26.9	-29.7
1614	Phorbol 12-Myristate 13-Acetate		BRD-K68552125-001-04-6	-3.5	-7.8	85.6	82.1	30.4	32.4
1615	TODRALAZINE HYDROCHLORIDE		BRD-K68553471-003-07-3	10.1	5.1	8.8	18.0	-28.5	-32.8
1616	DERACOXIB		BRD-K68558722-001-03-2	-0.3	27.2	-69.7	-77.4	-4.8	17.0
1617	ACDPP hydrochloride		BRD-K68633617-003-01-1	12.7	24.9	18.9	22.4	21.0	21.6
1618	QUETIAPINE		BRD-K68867920-001-05-2	-19.5	-29.8	-76.2	-80.1	-44.2	-50.3
1619	VISNAGIN		BRD-K68995359-001-06-9	-11.6	-4.5	-3.1	1.3	20.2	7.2
1620	2,4-DICHLOROPHENOXYBUTYRIC ACID		BRD-K69188402-001-04-2	47.9	3.0	41.7	-26.6	18.3	8.7
1621	NAN-190 hydrobromide		BRD-K69195780-004-03-5	8.4	6.8	3.5	21.3	2.8	-6.1
1622	RYANODINE		BRD-K69556541-001-02-6	-1.6	-12.6	28.2	25.7	24.6	21.0
1623	3-HYDROXYMETHYL-beta-CARBOLINE		BRD-K69585439-001-01-2	-23.5	-36.7	52.8	39.1	4.6	1.0
1624	TACROLIMUS		BRD-K69608737-001-03-7	-9.1	-8.8	-58.5	-34.4	-13.5	-20.5
1625			BRD-K69650333-001-02-9	7.6	0.9	-29.1	-26.4	-4.7	-11.0
1626	LY 341495		BRD-K69763916-001-01-7	24.6	16.3	-4.1	20.2	13.9	21.1
1627	Trap 101		BRD-K69837166-003-01-2	6.4	-3.1	-22.6	-3.0	-8.6	16.1
1628	L-692,585		BRD-K70241288-001-01-1	-9.0	2.1	22.5	16.5	33.9	45.9
1629	RIBOFLAVIN		BRD-K70246307-001-03-3	294.8	308.9	-6.6	0.3	11.3	3.7
1630	U 99194 maleate		BRD-K70281171-103-01-1	10.1	-4.2	17.1	17.0	10.6	20.0
1631	ESCITALOPRAM OXALATE		BRD-K70301876-034-06-1	38.9	58.4	-3.2	19.8	12.3	9.5
1632	SURAMIN		BRD-K70327167-348-09-2	12.2	-8.4	7.1	4.0	1.5	8.5
1633	BENZOXIQUINE		BRD-K70327191-001-01-4	8.7	2.2	16.6	18.5	-3.5	-4.5
1634	AMANTADINE HYDROCHLORIDE		BRD-K70330367-003-03-8	17.4	33.9	12.3	5.4	3.5	6.4
1635	1-(2-METHOXYPHENYL)PIERAZINE HYDROCHLORIDE		BRD-K70343553-003-06-8	2.2	13.6	11.8	3.0	5.8	-6.1
1636	ARPIPRAZOLE		BRD-K70358946-001-06-6	-9.9	-38.9	-70.1	-53.4	-52.0	-44.5
1637	RANITIDINE		BRD-K70505054-001-02-9	-2.0	-5.3	-5.7	-2.2	5.0	-3.3
1638	H-9 dihydrochloride		BRD-K70577657-300-04-1	5.3	-3.2	-7.6	5.5	-0.6	6.0
1639	1-EBIO		BRD-K70586315-001-01-6	0.5	17.5	28.2	29.6	26.2	27.4
1640	TRAZODONE HYDROCHLORIDE		BRD-K70778732-003-15-0	-8.4	-0.2	6.6	3.4	3.4	2.4
1641	10-DEBC hydrochloride		BRD-K70792160-003-01-2	-100.3	-93.3	-100.0	-100.8	-82.7	-82.5
1642	HOMOPTEROCARPIN		BRD-K71093375-001-03-5	17.2	12.6	-9.8	-14.5	4.5	6.7
1643	SULFADIMETHOXINE		BRD-K71125014-001-17-2	-2.8	-11.3	6.3	7.7	12.3	13.7
1644	SULFAQUINOXALINE SODIUM		BRD-K71133585-236-08-6	5.4	7.6	-6.2	2.2	10.9	-1.0
1645	ISOPEONOL		BRD-K71175374-001-02-3	9.2	2.2	4.8	15.8	11.2	1.4
1646	Clobenpropit dihydrom bromide		BRD-K71430621-303-01-5	3.1	7.5	4.1	-2.6	11.8	2.7
1647	MORANTEL CITRATE		BRD-K71454870-048-03-0	-8.5	-22.4	-4.9	-4.3	12.4	6.1
1648	GW 9508		BRD-K71534238-001-03-5	-2.1	-5.7	-47.7	-46.5	-5.4	0.3
1649	PNU 120596		BRD-K71731651-001-01-9	2.1	-6.8	14.8	19.9	-1.0	4.8
1650	CARBAMAZEPINE		BRD-K71799949-001-18-2	22.1	-2.3	-8.8	4.1	4.9	5.3
1651	Cdk2/5 Inhibitor		BRD-K71860425-001-01-1	33.9	1.7	43.1	31.1	23.3	15.6
1652			BRD-K71879491-001-15-0	-10.4	12.0	1.4	5.3	-0.1	-4.6
1653	MRS 1754		BRD-K72024482-001-01-3	-2.6	-3.3	22.5	19.9	16.1	17.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1654	PROBUCOL		BRD-K72029282-001-15-4	14.3	3.9	-6.5	-7.4	4.0	5.3
1655	DERRUSNIN		BRD-K72066653-001-03-3	2.8	-9.6	-19.5	-16.9	2.7	-8.1
1656	BPIQ-I		BRD-K72211743-001-01-1	-3.4	-5.2	15.7	9.0	7.0	4.6
1657	QUINAPRIL HYDROCHLORIDE		BRD-K7222507-003-07-7	-6.4	-13.8	8.5	9.6	27.5	21.9
1658	ISOPIMPINELLIN		BRD-K72253829-001-07-7	6.6	1.3	-4.1	23.1	33.5	24.8
1659	DYCLONINE HYDROCHLORIDE		BRD-K72259270-003-15-7	-62.3	-62.5	-93.1	-92.7	-86.4	-85.1
1660	BAICALEIN		BRD-K72327355-001-06-3	86.7	59.0	49.8	65.8	-12.6	-16.5
1661	C-1		BRD-K72462751-001-01-9	-7.8	-11.4	-9.0	-17.6	-8.4	8.9
1662	Fluvoxamine maleate		BRD-K72676686-103-01-8	-9.2	-15.2	-53.5	-57.6	-18.2	-24.4
1663	ZM 447439		BRD-K72703948-001-02-8	7.4	-7.9	-25.4	-19.0	-16.3	-9.7
1664	BENZETHONIUM CHLORIDE		BRD-K72723676-003-10-3	-77.2	-76.5	-98.0	-97.5	-87.9	-86.7
1665	Arcyriafavin A		BRD-K72726508-001-01-3	41.0	31.4	-13.5	-9.6	-19.3	-19.0
1666	AG 555		BRD-K72783841-001-01-0	3.3	5.7	44.5	-54.1	-53.5	-60.0
1667	SSR 69071		BRD-K72895815-001-01-4	-32.2	-24.7	-87.2	-87.5	-50.8	-54.2
1668	ZIDOVUDINE [AZT]		BRD-K72903603-001-14-5	16.7	18.0	-2.8	-2.6	0.1	-2.2
1669	CINCHOPHEN		BRD-K72915123-001-11-6	-4.0	-4.0	-11.1	13.1	20.0	14.5
1670	PEUCENIN		BRD-K73103240-001-03-3	18.7	2.6	-36.4	-26.9	-17.3	-24.4
1671	DIATOXIDE		BRD-K73109821-001-10-2	-18.1	-4.6	18.9	44.0	26.0	17.3
1672	PHENYL AMINOSALICYLATE		BRD-K73157543-001-03-3	8.3	12.6	7.2	16.8	-0.3	12.3
1673	ALIZARIN		BRD-K73191876-001-04-7	8.7	7.0	13.2	22.1	-12.6	-21.0
1674	URAPIDIL HYDROCHLORIDE		BRD-K73196317-003-07-2	-8.5	-13.5	-13.2	-0.5	4.2	1.7
1675	TRIPTOPHENOLIDE		BRD-K73210450-001-03-1	-13.3	-9.5	-43.1	-39.7	-54.0	-54.0
1676	CLORGILINE HYDROCHLORIDE		BRD-K73251053-003-13-1	3.5	-7.9	-17.8	-13.6	-8.4	-11.1
1677	ICI-199,441 hydrochloride		BRD-K73290745-003-01-8	-27.1	-27.8	-65.4	-72.7	-59.2	-49.4
1678	BIOCHANIN A		BRD-K73303757-001-12-5	-1.8	-0.8	-28.3	-19.5	8.4	-0.5
1679	OXOLINIC ACID		BRD-K73394555-001-08-6	-4.1	3.8	-2.2	-1.8	14.2	10.4
1680	ARP 101		BRD-K73395020-001-01-5	-6.6	-23.8	-44.0	-54.0	-24.7	-18.7
1681	Purmorphamine		BRD-K73397362-001-01-7	4.3	-8.4	1.3	18.0	26.8	23.2
1682	DIBUTYL PHTHALATE		BRD-K73477617-001-04-4	5.8	8.0	20.0	35.9	19.4	22.9
1683	NIZATIDINE		BRD-K73589491-001-05-4	-10.0	-4.2	4.5	2.4	4.1	2.3
1684	BROMOPRIDE		BRD-K73642618-001-08-3	9.4	-3.1	-1.2	-4.6	7.2	11.8
1685	N-Acetyltryptamine		BRD-K73700643-001-04-7	8.6	13.9	37.8	39.3	9.8	15.2
1686	ZM 336372		BRD-K73789395-001-05-7	-32.4	-19.3	27.7	44.3	48.2	40.8
1687	SKATOLE		BRD-K73824630-001-03-2	6.7	7.0	27.2	11.6	34.8	38.0
1688	N-hydroxy-2-phenylacetamide		BRD-K74112339-001-03-5	7.2	10.8	5.8	-9.2	8.1	9.3
1689	(-)Cytisine		BRD-K74186897-001-04-1	5.4	-1.4	-0.3	-3.1	23.5	22.3
1690	RESORCINOL		BRD-K74190368-001-02-7	4.8	5.7	7.5	15.4	-16.9	-20.7
1691	Irsogladine maleate		BRD-K74195153-050-03-0	6.6	-8.9	18.5	16.7	13.0	2.7
1692	DCB		BRD-K74430258-001-01-2	-17.5	20.7	-4.1	-1.2	6.9	-1.5
1693	AZITHROMYCIN		BRD-K74501079-001-07-4	28.2	37.2	16.5	22.2	32.7	33.0
1694	2-METHYL-4-(PIPERIDIN-1-YLCARBOXY)-5-ISOPROPYLPHENYLTRIMETHYLAMMONIUM CHLORIDE		BRD-K74534237-003-01-3	-11.7	4.3	11.9	43.5	16.3	24.1
1695	CATECHIN TETRAMETHYLETHER		BRD-K74727418-001-03-4	-13.9	-15.0	-16.4	3.1	7.2	-7.1
1696	BW 373U86		BRD-K74990253-001-01-0	-2.7	-12.1	32.1	16.6	10.4	11.3
1697	PROCAINAMIDE HYDROCHLORIDE		BRD-K75089421-003-15-3	9.9	2.7	9.7	8.5	12.0	10.5
1698	Cdk1 Inhibitor III		BRD-K75127215-001-01-5	-0.7	18.6	20.1	32.7	4.1	17.1
1699	PROTIONAMIDE		BRD-K75360161-001-09-9	2.6	4.6	5.5	17.7	10.2	14.3

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1700	BENZOCAINE		BRD-K75466013-001-08-6	1.6	5.0	48.2	57.2	26.3	23.4
1701	GS39783		BRD-K75478907-001-01-5	11.6	19.1	1.5	13.9	-2.8	31.9
1702	(R)-(-)-Rolipram		BRD-K75516118-001-01-7	-3.9	25.7	-16.3	17.0	39.2	41.8
1703	HYDROXYTOLUIC ACID		BRD-K75608666-001-03-4	-4.7	4.8	0.6	2.6	10.3	10.6
1704	B-HT 920		BRD-K75615183-300-02-1	30.8	32.4	12.7	26.9	16.3	24.0
1705	METOCLOPRAMIDE HYDROCHLORIDE		BRD-K75641298-003-16-9	8.5	-1.4	9.2	16.3	5.8	-3.9
1706	RIZATRIPTAN BENZOATE		BRD-K75699339-057-03-2	-1.5	13.7	10.3	5.8	0.6	5.7
1707	3,7-DIMETHOXYFLAVONE		BRD-K75745696-001-03-8	-10.8	-14.1	-31.2	-31.6	-4.8	-3.9
1708	Im-CPP hydrochloride		BRD-K75844781-003-03-1	-2.3	-0.7	-8.1	-1.2	5.6	0.0
1709	IDOQUINOL		BRD-K75855670-001-06-8	36.3	45.7	-25.1	-10.9	-12.6	-10.0
1710	PIZOTYLINE MALATE		BRD-K75958195-037-04-5	-3.9	-4.8	-41.8	-37.0	-7.1	-1.7
1711	LOSARTAN		BRD-K76205745-001-04-1	12.4	4.8	23.0	20.3	16.0	19.6
1712	PHENAZOPYRIDINE HYDROCHLORIDE		BRD-K76304753-003-08-8	3.6	4.1	-10.3	2.2	0.7	8.5
1713	NITROMIDE		BRD-K7631435-001-04-5	1.7	-0.3	8.2	29.1	17.3	18.8
1714	ENROFLOXACIN		BRD-K76334306-001-11-0	-10.0	-6.5	21.8	33.1	25.4	30.4
1715	PHTPP		BRD-K76568384-001-01-4	18.0	31.0	36.3	20.6	32.8	29.4
1716	HA-1077		BRD-K76617868-300-04-4	-10.6	-0.4	-14.2	-20.3	-10.0	8.4
1717	Homoharringtonine		BRD-K76674262-001-01-7	-6.5	-3.4	14.9	9.3	6.3	7.0
1718	(+)-AJ 76 hydrochloride		BRD-K76677554-003-01-3	1.1	11.9	-4.5	12.7	16.7	9.3
1719	NIMESULIDE		BRD-K76775527-001-18-7	-6.8	-13.1	-28.8	-24.7	-11.3	-17.0
1720	SB 415286		BRD-K76805682-001-05-0	62.5	50.8	-29.6	-21.1	-37.5	-40.5
1721	DIPYRONE		BRD-K76812510-236-08-0	-17.2	-40.3	31.8	42.5	-24.8	-28.5
1722	RS 17053 hydrochloride		BRD-K76840893-003-01-7	-62.4	-64.5	-74.3	-76.9	-67.7	-70.5
1723	SULFANITRAN		BRD-K76845197-001-02-1	6.0	5.9	-13.6	-22.5	0.2	-4.8
1724	Proxyfan maleate		BRD-K77171813-050-01-4	18.6	8.3	7.1	7.6	7.2	2.8
1725	4-HYDROXY-6-METHYL PYRAN-2-ONE		BRD-K77202630-001-03-7	4.4	-1.2	8.4	17.9	27.8	15.3
1726	RAUWOLSCINE HYDROCHLORIDE		BRD-K77474816-003-09-1	13.8	12.9	6.5	21.2	22.2	16.7
1727	A 205804		BRD-K77627880-001-01-6	4.5	21.9	-11.8	-11.6	18.8	26.5
1728	AEG 3482		BRD-K77634909-001-02-7	-3.8	-13.9	-12.9	-24.4	6.4	13.2
1729	NAPHAZOLINE HYDROCHLORIDE		BRD-K77641333-003-15-6	-1.3	14.5	-3.8	12.1	17.1	14.6
1730	SB 200646 hydrochloride		BRD-K77677632-003-01-8	-24.7	-27.8	-16.0	-5.3	-1.3	-13.3
1731	ACACETIN		BRD-K77685744-001-07-7	9.0	-12.7	-8.7	7.7	11.7	14.0
1732	THIABENDAZOLE		BRD-K77695569-001-16-9	3.0	8.0	19.8	-6.6	17.4	18.6
1733	Moxonidine hydrochloride		BRD-K77771411-003-03-2	12.2	5.5	-7.9	4.9	6.3	10.5
1734	HA 1100 hydrochloride		BRD-K77793136-003-02-2	-1.9	5.1	31.5	15.3	11.9	7.0
1735	MS-275		BRD-K77908580-001-04-7	2.5	3.6	20.0	10.6	-0.8	8.2
1736	PD 81723		BRD-K77951111-001-01-1	2.1	2.7	0.1	21.7	15.9	8.6
1737	MEBENDAZOLE		BRD-K77987382-001-08-2	10.2	17.4	37.3	38.3	-6.1	8.6
1738	FUROSEMIDE		BRD-K78010432-001-10-8	-2.4	10.4	-27.3	3.8	19.6	16.3
1739	4-PPBP maleate		BRD-K78061844-103-01-6	22.3	7.5	29.2	29.5	16.3	15.4
1740	ENOXAECIN		BRD-K78113049-001-07-1	3.6	3.9	10.1	7.3	10.0	12.9
1741	NNC 55-0396 dihydrochloride		BRD-K78122587-300-01-9	-106.4	-104.0	-94.2	-93.6	-79.0	-81.4
1742	MENADIONE		BRD-K78126613-001-16-0	-16.1	-15.8	-56.0	-54.1	-61.6	-62.2
1743	ANHYDROBRAZILIC ACID		BRD-K78414110-001-03-6	21.6	20.0	15.2	19.8	26.7	30.8
1744	OLMESARTAN MEDOXOMIL		BRD-K78485176-001-03-7	10.4	17.2	7.9	26.3	30.8	25.5
1745	SCS		BRD-K78496197-001-02-1	9.5	7.4	-9.6	-4.8	-9.3	-10.3

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1746	LONIDAMINE		BRD-K78513633-001-06-6	2.8	4.4	58.1	25.7	26.3	9.9
1747	ELETRIPTAN HYDROBROMIDE		BRD-K78537690-004-01-0	9.1	5.2	22.4	-11.2	5.8	8.4
1748	CITROPTEN		BRD-K78612426-001-05-9	-7.7	-1.9	81.8	89.9	-7.5	-20.5
1749	Exo1		BRD-K78633253-001-04-6	10.6	-0.5	14.5	36.2	9.2	22.5
1750	LY 320135		BRD-K78637815-001-01-4	-9.3	-3.1	-2.9	-2.0	13.3	2.4
1751	BROMPERIDOL		BRD-K78643075-001-06-6	-28.3	-23.2	-60.2	-67.6	-53.1	-63.4
1752	Leflunomide		BRD-K78692225-001-11-2	-8.9	-11.1	3.5	11.5	10.0	4.7
1753	SUXIBUZONE		BRD-K78815826-001-08-8	1.6	8.1	0.4	24.1	5.2	-5.2
1754	ASPARTAME		BRD-K78841970-001-06-2	6.9	12.0	-10.8	13.2	10.0	8.9
1755	N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide		BRD-K78844995-001-01-8	-8.8	23.1	-4.4	-9.9	-4.8	0.8
1756	FPL 64176		BRD-K78959463-001-05-8	-0.6	6.7	-4.1	10.7	-2.2	-3.2
1757	NITROFURAZONE		BRD-K79092138-001-06-0	11.7	22.5	8.8	44.7	17.0	17.9
1758	ALBENDAZOLE		BRD-K79131256-001-08-8	23.5	22.6	-11.7	33.0	6.6	31.3
1759	CY 208-243		BRD-K79353516-001-03-5	22.4	11.9	-19.9	-15.9	-7.9	-10.9
1760	COTARNINE CHLORIDE		BRD-K79535367-003-02-5	7.1	2.5	-18.8	-11.0	9.8	-13.2
1761	Metformin (1,1-Dimethylbiguanide, Hydrochloride)		BRD-K79602928-003-04-1	-13.8	-15.3	28.9	11.5	0.1	9.9
1762	Ro 10-5824		BRD-K79684402-300-01-0	0.7	9.9	-0.7	-12.6	9.4	1.0
1763	THIAMPHENICOL		BRD-K79711234-001-11-8	7.0	1.1	3.9	7.6	-0.1	-0.9
1764	SILDENAFIL CITRATE		BRD-K79759585-048-01-4	-0.9	-0.7	5.8	18.7	23.6	31.7
1765	Gabazine		BRD-K79905821-001-01-6	-10.8	-8.0	16.8	15.7	11.5	15.4
1766	GW 583340 dihydrochloride		BRD-K79930101-300-01-1	-18.9	-19.8	-13.9	-16.9	-21.3	-4.8
1767	CLOPIDOL		BRD-K80036624-001-03-2	5.2	-0.9	6.2	30.0	10.9	16.2
1768	DPPE fumarate		BRD-K80315159-051-01-2	-17.7	-17.2	-15.1	-15.7	-13.6	-6.0
1769	(+/-)-abscisic acid		BRD-K80342836-001-01-2	-2.0	-22.0	-9.2	3.7	25.3	22.5
1770	SILIBININ		BRD-K80353138-001-07-1	32.5	43.5	-31.2	-14.9	-22.3	-32.6
1771	KHELLIN		BRD-K80353807-001-16-2	-22.3	-9.8	-0.3	25.4	21.5	29.8
1772	Zamifenacin fumarate		BRD-K80451230-051-01-8	-3.8	-16.6	-8.1	-20.6	1.5	0.5
1773	6,7-DICHLOROQUINOXALINE-2,3-DIONE		BRD-K80576679-001-03-1	7.7	2.7	17.5	35.1	0.7	5.3
1774	SB 258585 hydrochloride		BRD-K80639402-003-01-1	-0.2	-1.8	-31.0	-35.9	-30.3	-29.4
1775	RS 16566 hydrochloride		BRD-K80725821-300-01-1	7.9	32.7	-7.1	-14.3	14.7	16.3
1776	Resveratrol		BRD-K80738081-001-07-0	-26.6	-39.0	12.9	12.5	-18.4	-15.6
1777	Ro 19-4605		BRD-K80778372-001-01-7	16.1	-9.5	14.0	13.9	19.1	20.1
1778	N-PHENYLANTHRANILIC ACID		BRD-K80863915-001-05-2	19.4	19.4	-7.8	11.7	8.2	-0.8
1779	TRIACETYLRESVERATROL		BRD-K80946661-001-03-6	6.3	4.9	-15.9	-40.1	2.7	2.7
1780	METHYLXANTHOXYLIN		BRD-K81120886-001-01-0	7.2	2.0	0.3	15.7	2.7	0.0
1781	SALICYLAMIDE		BRD-K81130846-001-12-5	15.3	8.3	33.1	60.1	4.6	16.4
1782	Cerivastatin		BRD-K81169441-236-04-1	-7.0	-8.8	17.7	-26.3	24.5	-8.7
1783	SCH 58261		BRD-K81225797-001-01-5	-24.1	24.4	12.1	-16.2	10.9	8.8
1784	Dantrolene, sodium salt		BRD-K81272440-236-06-9	-32.1	4.4	-38.0	-48.1	-9.4	-22.1
1785	CHRYSSIN DIMETHYL ETHER		BRD-K81298036-001-06-2	-17.8	-10.1	-49.2	-50.2	-14.0	-15.7
1786	TCS 359		BRD-K81376179-001-01-4	6.2	5.6	29.1	28.6	-3.0	0.4
1787	SAHA		BRD-K81418486-001-18-6	14.4	-5.4	-5.4	0.3	-9.0	5.0
1788	TACRINE HYDROCHLORIDE		BRD-K81473089-003-15-4	-3.4	2.4	12.7	14.0	10.8	8.6
1789	DICYCLOHEXYLUREA		BRD-K81521265-001-02-8	-8.6	-25.8	9.8	8.8	22.2	28.5
1790	EIT hydrobromide		BRD-K81623406-004-03-4	2.5	2.5	1.6	4.9	10.3	8.5
1791	AQ-RA 741		BRD-K81729199-001-01-0	-3.5	-2.0	12.8	12.1	5.4	15.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1792	PRENYLETIN		BRD-K81750404-001-03-3	40.7	10.5	-12.6	-15.7	-18.3	-26.8
1793	PICROPODOPHYLLIN		BRD-K81829253-001-03-7	25.8	21.3	-17.1	1.0	-4.5	7.3
1794	CP 93129 dihydrochloride		BRD-K81876028-300-01-2	14.3	4.3	25.2	40.7	17.4	23.5
1795	1,3,5-TRIMETHOXYBENZENE		BRD-K81884069-001-03-6	0.0	2.8	-6.4	0.4	27.4	18.4
1796	TRICLABENDAZOLE		BRD-K81916719-001-05-5	46.6	21.2	17.4	23.9	27.8	47.0
1797			BRD-K81965037-001-03-2	-83.4	-84.6	-78.1	-77.6	-60.9	-65.9
1798	SERTRALINE HYDROCHLORIDE		BRD-K82036761-003-07-0	-44.0	-42.0	-64.2	-61.4	-49.4	-45.7
1799	BETAMIPRON		BRD-K82142815-001-12-6	38.2	6.5	8.9	22.7	18.9	2.1
1800	PYRITINOL		BRD-K82181219-001-01-9	5.9	10.7	0.1	11.6	4.1	15.4
1801	2',4'-DIHYDROXY-4-METHOXYPHENYLCHALCONES		BRD-K82207906-001-01-0	27.8	2.5	-27.6	-14.8	8.5	2.7
1802	ISOSORBIDE MONONITRATE		BRD-K82225283-001-01-5	-3.1	-3.6	10.2	31.2	5.8	9.1
1803	N-METHYL (-)EPHEDRINE		BRD-K82236108-001-03-1	9.5	-6.1	-21.0	-12.7	3.8	2.8
1804	DICUMAROL		BRD-K82236179-001-06-8	-1.2	6.6	-42.8	-50.4	4.5	-1.3
1805	PROPOFOL		BRD-K82255054-001-08-4	12.7	8.1	1.8	27.3	-2.0	3.4
1806	Carmoxirole hydrochloride		BRD-K82484965-003-02-7	29.2	16.7	20.3	26.0	38.6	30.9
1807	WHI-P180, Hydrochloride		BRD-K82708110-003-01-5	64.8	19.2	12.0	12.8	16.7	11.5
1808	Olomoucine		BRD-K82731415-001-05-4	20.1	-19.0	-1.5	26.5	12.8	12.7
1809	LORATADINE		BRD-K82795137-001-14-8	5.3	0.6	-40.8	-42.5	-4.6	-19.7
1810	Ro 15-4513		BRD-K82823076-001-01-8	8.7	7.7	15.9	7.5	16.8	24.6
1811	ROSUVASTATIN CALCIUM		BRD-K82941592-238-02-9	-0.3	-4.1	-6.7	1.6	5.8	17.0
1812	GR 135531		BRD-K83023055-001-01-9	-5.1	-5.8	3.7	18.0	6.0	10.0
1813	SALICYLANILIDE		BRD-K83036479-001-04-3	15.7	42.8	-13.4	-3.4	-0.5	-1.7
1814	RS 102895 hydrochloride		BRD-K83063356-003-01-7	2.8	-2.5	-23.2	-37.1	-2.9	-7.3
1815	Etofylline		BRD-K83064458-001-05-7	-7.6	-3.7	6.5	-4.9	0.1	-3.0
1816	(S)-(+)-Dimethindene maleate		BRD-K83192048-050-01-9	-15.2	-24.3	-4.9	-7.2	8.3	-1.7
1817	CHLOROPYRAMINE HYDROCHLORIDE		BRD-K83257731-003-14-4	-12.5	-10.4	-45.9	-55.5	-24.9	-14.9
1818	Protopine		BRD-K83302049-003-01-2	-4.9	-20.6	41.6	19.2	19.4	20.5
1819	L-693,403 maleate		BRD-K83322645-103-01-6	2.7	-17.4	23.9	15.0	10.8	13.9
1820	BARBITAL		BRD-K83359602-001-01-5	13.7	-8.4	-2.3	-6.6	5.6	-7.7
1821	SINOMENINE		BRD-K83459933-001-03-9	-6.6	-2.0	-6.7	-0.1	-18.4	-25.0
1822	FK 888		BRD-K83508485-001-01-9	-18.1	-22.6	-35.7	-32.7	-14.8	-19.9
1823	PARGYLINE HYDROCHLORIDE		BRD-K83597974-003-15-6	37.3	14.5	-0.7	14.2	4.2	-1.9
1824	SANT-1		BRD-K83637872-001-01-7	22.0	31.1	38.1	29.9	-1.0	12.9
1825	7-Chlorokynurenic acid		BRD-K84214706-001-04-0	-0.7	-0.6	15.8	24.9	15.0	11.9
1826	BRL 50481		BRD-K84266862-001-01-6	27.2	15.1	11.3	16.6	15.6	15.4
1827	2'-METHOXYFORMONETIN		BRD-K84390227-001-03-0	-17.6	-21.0	-1.1	-3.0	3.5	11.1
1828	R(+)-SKF-81297		BRD-K84421793-001-01-1	7.0	5.3	28.2	26.2	-8.0	-11.6
1829	3,4-DIMETHOXYDALBERGIONE		BRD-K84463716-001-02-5	31.2	25.2	-18.3	11.0	-34.0	-35.1
1830	NATEGLINIDE		BRD-K84658672-001-03-0	7.4	11.4	-8.2	-6.9	-5.6	-9.4
1831	Trequinsin hydrochloride		BRD-K84663978-001-03-1	-1.1	1.2	-36.6	-29.5	-1.6	-3.6
1832	Caffeic acid phenethyl ester		BRD-K84709232-001-02-6	-9.2	-15.4	-84.7	-86.2	-67.8	-65.3
1833	TANSHINONE IIA SULFONATE SODIUM		BRD-K84798689-236-01-1	16.1	16.8	13.0	17.0	31.6	30.7
1834	SINENSETIN		BRD-K84996949-001-01-5	-5.5	0.1	35.3	33.7	-18.8	-29.3
1835	AURAPTENE		BRD-K85013741-001-05-9	20.3	21.9	82.1	89.4	30.5	21.5
1836	NNC 05-2090 hydrochloride		BRD-K85015012-003-01-1	-18.0	-20.7	-96.6	-93.1	-70.0	-67.0
1837	4'-HYDROXYCHALCONES		BRD-K85068298-001-03-5	2.0	6.0	-43.4	-49.7	-7.3	-12.9

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1838	PILOCARPINE NITRATE		BRD-K85090592-008-15-1	15.5	-2.6	8.0	-9.2	4.7	4.2
1839	3-ACETAMIDOCOUMARIN		BRD-K85104575-001-07-3	-7.1	15.5	21.3	31.6	24.1	27.5
1840	TOLBUTAMIDE		BRD-K85119730-001-17-2	-0.2	5.4	13.6	5.1	3.9	6.6
1841	DNQX disodium salt		BRD-K85266041-304-01-7	-6.0	-17.1	-1.8	-20.8	13.2	7.3
1842	RAMIFENAZONE		BRD-K85333151-003-08-4	7.6	5.0	20.1	15.0	-18.6	-18.8
1843			BRD-K85555482-001-04-5	-19.4	5.1	-11.2	-2.9	5.2	8.6
1844	RESORCINOL MONOACETATE		BRD-K85603128-001-02-7	-12.5	17.1	9.5	14.7	-3.7	6.5
1845	IRIGENIN TRIMETHYL ETHER		BRD-K85880973-001-03-5	5.8	9.7	7.6	-3.1	5.2	4.7
1846			BRD-K85883481-001-08-3	1.7	1.8	12.0	24.7	23.2	24.9
1847	OBTUSAQUINONE		BRD-K85971060-001-03-6	58.6	73.9	7.0	53.8	6.7	11.8
1848	EMF-bca1-1		BRD-K85985071-001-16-5	7.4	14.6	-45.6	-50.7	-37.2	-52.6
1849	Eltoprazine hydrochloride		BRD-K86171477-003-01-9	2.4	-2.2	1.0	10.0	10.2	11.1
1850	DIPYRIDAMOLE		BRD-K86301799-001-19-9	25.4	20.5	8.5	26.5	-25.1	-20.0
1851	(R)-(-)-Deprenyl hydrochloride		BRD-K86434416-003-06-4	-10.9	-12.2	-2.4	0.4	15.6	9.2
1852	ISO-OLOMOUCINE		BRD-K86509404-001-03-8	-20.2	-8.0	-12.1	-5.7	11.8	13.1
1853	RS 79948 hydrochloride		BRD-K86600316-003-01-2	-3.8	-15.3	24.3	8.1	6.5	11.1
1854	Embelin		BRD-K86727142-001-06-6	-60.7	-69.4	-87.6	-86.9	-67.8	-71.0
1855	Olvanil		BRD-K86958018-001-01-9	21.0	13.8	49.6	41.1	-4.4	-2.3
1856	RS 102221 hydrochloride		BRD-K87048468-003-01-9	7.0	9.3	-35.6	-33.2	-43.1	-35.9
1857	Fusaric acid		BRD-K87049188-001-03-6	2.9	-1.9	36.9	28.0	25.1	32.4
1858	CARBIMAZOLE		BRD-K87156652-001-06-9	2.1	-17.6	-7.9	-0.6	-7.3	-6.6
1859	BENZAMIL HYDROCHLORIDE		BRD-K87158025-003-01-2	6.3	10.6	-12.9	-18.5	4.1	6.1
1860	?-CCB		BRD-K87349602-001-02-0	1.1	-0.2	32.4	20.5	10.8	5.3
1861	TrkA Inhibitor		BRD-K87484409-001-01-2	0.2	16.8	15.2	-2.8	17.4	13.3
1862	SULFAMETER		BRD-K87492696-001-09-0	8.8	-3.9	4.1	23.8	22.1	26.9
1863	RS 504393		BRD-K87510569-001-01-0	18.6	6.3	-12.2	-10.3	-0.9	-6.0
1864	MPMQ hydrochloride		BRD-K87696786-003-01-0	0.3	-4.6	0.1	-16.1	0.1	-1.7
1865	CETYLPYRIDINIUM CHLORIDE		BRD-K87700323-003-03-6	-93.8	-94.0	-83.5	-82.2	-79.5	-77.1
1866	DUARTIN, DIMETHYL ETHER		BRD-K87798455-001-03-4	-4.7	-2.2	-15.4	-19.6	9.8	-3.9
1867	AG-825		BRD-K87919739-001-04-2	-1.4	-6.5	-4.7	-1.8	-21.1	-5.1
1868	PIMETHIXENE MALEATE		BRD-K88090157-050-06-6	-6.5	0.4	-61.9	-57.4	-39.4	-44.5
1869	ASARYLALDEHYDE		BRD-K88219015-001-05-8	-7.8	27.7	11.5	18.9	4.5	7.4
1870	WIN 55,212-2 mesylate		BRD-K88282786-066-04-9	23.7	15.5	-58.9	-59.3	7.7	4.5
1871	2,5-DI-t-BUTYL-4-HYDROXYANISOLE		BRD-K88329126-001-01-0	-10.2	-15.2	-45.9	-29.6	-22.0	-41.0
1872	Xaliproden hydrochloride		BRD-K88358234-003-01-4	-1.9	-10.1	10.7	-1.4	6.9	8.3
1873	TRIMETAZIDINE DIHYDROCHLORIDE		BRD-K88366685-300-04-5	-8.3	-2.4	3.8	13.5	20.1	7.1
1874	THONZYLAMINE HYDROCHLORIDE		BRD-K88405679-003-02-3	9.5	5.2	-0.1	9.2	9.2	-2.5
1875	PYRIMETHAMINE		BRD-K88429204-001-18-7	16.9	-6.1	-25.8	-3.2	-13.8	-12.1
1876	IPRONIAZID SULFATE		BRD-K88568253-065-03-9	32.6	35.0	22.6	15.5	11.2	2.6
1877	ANIRACETAM		BRD-K88611939-001-13-3	16.5	2.0	13.9	18.9	28.1	21.8
1878	NONOXYNOL-9		BRD-K88625236-001-03-4	-104.8	-98.6	-112.6	-113.2	-77.3	-77.1
1879	ARECOLINE HYDROBROMIDE		BRD-K88646909-004-10-5	4.0	13.3	8.9	39.6	39.5	46.5
1880	PD 198306		BRD-K88677950-001-01-3	2.6	13.0	26.5	12.2	27.9	18.1
1881	CHLOROTHIAZIDE		BRD-K88682005-001-07-5	2.2	40.6	5.2	4.3	27.6	24.5
1882	Methyl 2,5-dihydroxycinnamate		BRD-K88741031-001-01-0	34.5	41.1	16.5	4.0	-42.5	-45.5
1883	EMD 66684		BRD-K88759641-003-01-0	2.7	-11.2	11.0	4.4	12.3	16.4

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1884	LOBARIC ACID		BRD-K88849294-001-08-8	-42.2	-54.4	-83.8	-79.9	-73.6	-74.0
1885	OBLIQUIN		BRD-K88954184-001-03-0	1.5	-1.3	25.1	40.8	10.5	4.2
1886	Cdk Inhibitor, p35		BRD-K88988070-001-01-9	7.7	-10.9	9.4	-6.0	11.4	21.3
1887	ALVERINE CITRATE		BRD-K89055274-048-14-4	12.7	16.0	-11.1	-8.4	-1.4	-8.8
1888	CHLOROCRESOL		BRD-K89056082-001-03-6	27.2	26.8	-0.5	13.8	-17.3	-19.9
1889	EMD 41000		BRD-K89271983-001-01-5	-22.7	-25.9	-10.0	7.1	-6.5	3.1
1890	NPPB		BRD-K89272762-001-07-7	12.3	2.1	-27.5	-39.4	-17.1	-14.5
1891	DMP 543		BRD-K89274813-001-01-5	-7.3	4.5	-9.7	-7.2	1.8	-5.3
1892	PIRENZEPINE HYDROCHLORIDE		BRD-K89375097-300-06-2	27.0	14.8	-11.5	15.6	-9.7	1.2
1893	L 655240		BRD-K89402695-001-01-5	-58.9	-41.5	-94.4	-92.2	-76.0	-68.2
1894	CHLORPHENIRAMINE (S) MALEATE		BRD-K89595132-050-03-0	-10.4	-8.7	-13.1	0.8	8.2	-1.8
1895	VINCAMINE		BRD-K89704198-001-08-1	2.5	36.9	19.9	27.4	11.6	11.2
1896	TRIFLUOPERAZINE HYDROCHLORIDE		BRD-K89732114-300-07-1	-80.3	92.5	-94.8	-94.0	-88.6	-88.6
1897	AG 592		BRD-K89930444-001-01-9	58.5	58.3	-14.1	-24.0	-9.9	-8.4
1898	GALANGIN TRIMETHYL ETHER		BRD-K89975061-001-02-4	-9.5	7.5	-15.2	-14.1	-19.1	-31.5
1899	CHLORPROMAZINE		BRD-K89997465-001-05-3	-81.0	-78.3	-95.6	-96.0	-87.3	-86.5
1900	AMPROLIUM		BRD-K90027121-300-08-2	37.5	11.6	13.3	12.2	22.0	24.9
1901	5-Iodo-A-85380 dihydrochloride		BRD-K90065682-300-01-8	-9.2	-2.8	3.7	6.9	1.4	21.4
1902	DIMETHYL 4,4-o-PHENYLENE-BIS (3-THIOPHANATE)		BRD-K90168339-001-04-5	4.7	-2.7	27.0	25.9	21.0	8.6
1903			BRD-K90230846-001-04-9	17.8	31.0	37.7	35.2	-14.9	-3.2
1904	W-7 hydrochloride		BRD-K90259198-003-07-1	-38.3	-41.5	-70.3	-66.4	-42.2	-48.0
1905	MY-5445		BRD-K90524085-001-06-0	-6.5	4.9	-30.2	-32.3	4.5	-1.1
1906	2-Phenylbenzimidazole		BRD-K90551865-001-05-1	5.7	32.9	17.7	9.7	23.3	16.5
1907	Ipsapirone		BRD-K90574421-001-01-9	-16.5	-21.5	-7.2	-14.6	13.6	14.3
1908	EPIAFZELECHIN (2R,3R)(-)		BRD-K90607708-001-03-7	24.2	4.4	-2.6	-11.9	1.4	-4.2
1909	Nefazodone hydrochloride		BRD-K90789829-003-03-3	-0.6	-1.5	-52.2	-52.9	-31.9	-27.3
1910	SR 142948		BRD-K91243525-001-01-5	-1.9	5.2	19.5	19.5	9.9	13.6
1911	ANISOMYCIN		BRD-K91370081-001-17-8	27.0	19.7	-4.6	9.4	17.7	2.8
1912	PICEATANNOL		BRD-K91509126-001-04-6	47.4	44.5	-19.9	-17.6	-59.2	-58.3
1913	DIOSMIN		BRD-K91548452-001-03-0	95.3	109.4	20.3	27.7	8.4	12.6
1914	4-HQN		BRD-K91758890-001-03-5	-14.4	-10.0	4.8	-4.3	19.4	12.7
1915	3H-1,2-DITHIOLE-3-THIONE		BRD-K91781484-001-01-3	-11.0	-11.8	17.6	27.1	11.2	15.0
1916	2-[1-(4-Piperonyl)piperazinyl]benzothiazole		BRD-K91868854-001-02-8	-1.8	-10.7	8.5	3.6	4.5	-1.8
1917	SD 169		BRD-K91904471-001-01-6	-19.8	-30.2	23.9	24.5	11.9	20.3
1918	AM 251		BRD-K92000912-001-06-8	-9.4	-14.0	-24.9	-25.2	-8.3	-6.1
1919	GBR 12783		BRD-K92015269-001-01-6	0.9	-14.0	-32.0	-25.2	-14.4	-10.4
1920	TRIAMTERENE		BRD-K92049597-001-10-9	10.0	-4.8	81.8	89.1	-8.8	-30.2
1921	3-HYDROXY-3',4'-DIMETHOXYFLAVONE		BRD-K92171060-001-03-4	62.7	92.4	11.2	13.0	6.2	5.8
1922	5-Carboxamidotryptamine maleate		BRD-K92382976-103-01-8	-4.3	-13.7	33.4	-6.5	8.2	11.0
1923	MYCOPHENOLATE MOFETIL		BRD-K92428153-001-01-0	67.5	37.8	43.1	23.0	24.1	19.7
1924	LY255283		BRD-K92492521-001-01-1	-37.8	-36.8	-76.1	-84.7	-23.7	-34.1
1925	2-Chloro-11-(4-methylpiperazino)dibenz[b,f]oxepin maleate		BRD-K92588747-051-01-9	-23.7	-19.6	25.6	27.2	-34.5	-45.4
1926			BRD-K92723993-066-04-5	-28.7	-30.2	-40.9	-31.0	-27.9	-35.2
1927	PERINDOPRIL ERBUMINE		BRD-K92731339-227-03-1	-6.1	-8.0	-11.3	-6.4	-1.7	8.6
1928	MEFENAMIC ACID		BRD-K92778217-001-17-8	38.6	16.3	-5.4	10.5	-0.7	14.5
1929	(R)-(+)-Propranolol hydrochloride		BRD-K92830582-003-04-8	-2.0	-4.7	-18.0	2.3	-18.8	-4.0

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1930	2,4,5-TRICHLOROPHOXYACETIC ACID		BRD-K92860374-001-03-3	-2.9	-3.2	-6.0	7.0	21.2	15.1
1931	Melperone hydrochloride		BRD-K9294783-003-02-4	-1.5	-10.0	-10.7	-3.7	8.9	11.2
1932	ARC 239 dihydrochloride		BRD-K93188295-300-01-4	23.7	16.0	17.4	43.5	2.0	-8.4
1933	PIMPINELLIN		BRD-K93197368-001-03-7	15.8	-24.2	-19.6	-19.0	7.1	-1.2
1934	ETHAMBUTOL HYDROCHLORIDE		BRD-K93231391-300-03-1	2.8	-6.7	-9.9	7.6	-1.0	3.0
1935	DINITOLMIDE		BRD-K93240442-001-04-3	47.3	22.5	14.4	39.1	14.7	26.3
1936	GW 9662		BRD-K93258693-001-05-8	-9.9	-3.8	21.4	15.7	29.3	18.4
1937	Lamotrigine isethionate		BRD-K93460210-071-01-6	24.6	-1.7	0.4	5.9	5.2	10.4
1938	BUSPIRONE HYDROCHLORIDE		BRD-K93461745-003-14-4	4.6	8.6	11.0	11.6	29.5	23.5
1939	SULFAMERAZINE		BRD-K93524252-001-15-5	11.5	17.5	24.6	28.5	22.1	23.0
1940	N-Chlorophenyl-N-hexylpiperazine		BRD-K93541117-001-01-4	5.6	-12.7	-20.3	-15.3	8.0	16.9
1941			BRD-K93568044-001-11-4	-9.6	-25.3	2.1	-3.4	17.3	13.4
1942	DIACETAMATE		BRD-K93611241-001-01-4	-14.2	-0.7	-12.8	-9.8	-14.4	-23.0
1943	TADALAFIL		BRD-K93645900-001-04-8	21.8	-5.0	-4.2	-8.6	-6.7	-12.8
1944	K-252c		BRD-K93879806-001-01-4	188.9	55.2	14.0	19.6	12.6	12.8
1945	DIETHYLTOLUAMIDE		BRD-K94080537-001-05-5	-1.0	7.8	-11.2	-4.6	16.8	13.5
1946	COTININE		BRD-K94144010-001-09-7	6.2	1.7	0.1	12.5	0.1	-7.4
1947	PAEONOL		BRD-K94239562-001-03-0	2.6	5.8	23.1	33.3	11.2	8.5
1948	RONIDAZOLE		BRD-K94266545-001-15-9	-2.3	0.5	5.7	8.1	18.6	22.2
1949	SCH 39166 hydrobromide		BRD-K94270326-004-01-0	0.8	6.4	-19.8	-7.7	-7.2	-10.0
1950	METAMECONINE		BRD-K94324294-001-03-5	-10.4	-7.5	-10.5	-11.2	3.9	14.8
1951	KINETIN RIBOSIDE		BRD-K94325918-001-05-3	12.9	5.9	36.5	16.1	16.0	17.7
1952	BML-190		BRD-K94379058-001-03-5	-10.2	-13.4	-23.4	-18.3	-17.8	-16.4
1953	Mevastatin		BRD-K94441233-001-03-1	26.9	-8.1	-36.4	-42.5	-7.2	-12.7
1954	AMI-193		BRD-K94512704-001-02-1	-6.2	6.7	-17.3	16.5	7.6	-1.0
1955	PINOCEMBRIN		BRD-K94689771-001-02-5	-5.9	-3.6	6.2	10.8	-1.2	-4.1
1956	CHROMOCARB		BRD-K94720315-001-05-4	6.4	-11.7	8.6	8.9	13.0	-0.6
1957	Y 134		BRD-K94832621-001-01-5	-16.4	-12.0	-53.2	-50.5	-40.8	-42.7
1958	(+)-Anabasine hydrochloride		BRD-K94837957-003-01-4	55.9	51.1	31.9	44.8	47.0	37.4
1959	1-(3-trifluoromethyl) phenylpiperazine monohydrochloride		BRD-K94887716-001-01-5	10.6	15.2	13.9	13.0	29.3	20.9
1960	DR 2313		BRD-K94920105-001-01-3	-7.5	-9.0	-2.7	0.1	5.5	10.9
1961	ISOBUTYLMETHYLXANTHINE		BRD-K94979336-001-09-3	8.1	7.8	14.6	12.3	17.9	15.9
1962	APOTOXICAROL		BRD-K95048371-001-01-9	23.3	20.4	-11.0	-0.7	7.0	1.0
1963	OCTISALATE		BRD-K95161686-001-01-0	20.4	15.3	-27.8	46.0	4.9	22.5
1964	PROBENECID		BRD-K95237249-001-15-8	-1.0	-23.5	9.6	15.1	7.1	-0.2
1965	DIENESTROL		BRD-K95309561-001-15-5	14.0	14.5	-67.6	-47.3	-22.7	-6.3
1966	PHA 665752		BRD-K95435023-001-01-0	-37.3	-19.4	-96.8	-92.0	-50.0	-56.4
1967	SINAPIC ACID		BRD-K95487349-001-04-2	-18.0	-7.8	55.5	94.8	-31.7	-32.3
1968	PICROTOXININ		BRD-K95554982-001-04-1	14.2	17.8	-3.8	25.6	15.1	16.1
1969	(S)-(-)-Pindolol		BRD-K95598440-001-03-6	2.5	-11.3	21.0	5.6	3.9	10.4
1970	BHQ		BRD-K95603879-001-06-7	45.3	51.4	34.3	28.9	15.4	16.8
1971	BMS 191011		BRD-K95609758-001-01-1	-17.0	-29.2	-70.2	-71.8	-49.2	-46.0
1972	Tetraabenazine		BRD-K95739795-001-01-1	-3.7	-3.4	14.8	14.5	-3.2	9.4
1973	Trapidil		BRD-K95763993-001-03-7	1.4	-12.7	13.1	-1.1	1.9	8.7
1974	CGP 13501		BRD-K95851186-001-02-9	12.9	-5.8	2.6	11.1	14.3	20.9
1975	HEXAMETHYLQUERCETAGETIN		BRD-K95885906-001-01-8	-14.8	-17.1	-20.9	-5.0	-18.8	-25.6

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+ DNA		CBA		Amplex Red HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
1976	LY 344864 hydrochloride		BRD-K95899059-003-01-0	-2.1	-24.9	-10.7	-15.1	1.2	0.1
1977	RESERPINE		BRD-K95921201-001-07-0	-8.1	-1.6	-16.5	2.6	-13.0	-10.6
1978	ISAXONINE		BRD-K95957366-001-01-8	33.2	5.5	4.0	25.3	12.0	12.6
1979	1-Acetyl-4-methylpiperazine hydrochloride		BRD-K96055017-003-01-9	7.7	36.7	-6.1	12.7	5.1	11.0
1980	SCOPOLETIN		BRD-K96163925-001-09-9	41.0	24.3	53.7	59.0	-9.8	-6.4
1981	CEPHARANTHINE		BRD-K96194081-001-06-0	-19.6	-10.7	-44.2	-34.6	-29.4	-33.6
1982	DIMETHYLCAFFEIC ACID		BRD-K96256403-001-05-0	-4.1	5.9	-1.5	-17.7	0.0	-1.4
1983	GW 7647		BRD-K96263742-001-02-3	-95.3	-97.0	-132.9	-131.0	-78.3	-82.8
1984	PHENTERMINE		BRD-K96319534-001-01-7	24.1	15.4	21.1	10.5	-1.1	7.2
1985	NIFEDIPINE		BRD-K96354014-001-10-4	120.8	119.2	27.8	24.8	-42.8	-44.8
1986	CHLORAMPHENICOL PALMITATE		BRD-K96424892-001-01-1	-1.1	30.2	1.1	43.0	8.8	14.5
1987	LEOIDIN		BRD-K96660256-001-03-6	-48.5	-47.9	-100.2	-100.4	-78.0	-77.6
1988	SR 49059		BRD-K96720755-001-01-8	-24.5	7.7	-4.1	-5.9	0.2	-11.1
1989	SKF 86002 dihydrochloride		BRD-K96809896-300-01-5	22.2	-19.9	-0.9	11.3	15.2	13.8
1990	Pirfenidone		BRD-K96862998-001-03-1	-3.2	-2.7	3.4	-2.6	8.4	9.4
1991	QUININE ETHYL CARBONATE		BRD-K97028990-001-03-6	2.9	4.6	6.1	-6.3	15.6	7.4
1992	TBB		BRD-K97118047-001-02-0	-60.2	-57.1	-94.6	-100.0	-44.3	-48.3
1993	3-METHOXYCATECHOL		BRD-K97139501-001-03-3	77.8	83.5	45.5	45.1	-58.9	-59.4
1994	DROPERIDOL		BRD-K97158071-001-08-2	-1.1	-3.8	-13.7	-2.8	17.4	13.7
1995	THIOTHIXENE		BRD-K97309399-001-05-2	-64.3	-59.6	-73.1	-73.0	-53.1	-52.2
1996	PI 828		BRD-K97365803-001-01-3	-5.9	-10.5	2.7	24.4	2.6	9.2
1997	QUERCETIN		BRD-K97399794-001-09-6	58.3	76.5	-16.7	8.0	-22.9	-42.0
1998	ACEDAPSONE		BRD-K97417064-001-01-6	-20.7	-22.7	-27.3	-17.8	4.0	-3.3
1999	coumestrol		BRD-K97509413-001-01-8	-3.7	-8.4	71.4	43.2	-37.2	-39.0
2000	MELATONIN		BRD-K97530723-001-11-8	-14.0	-0.5	30.4	40.8	21.2	9.3
2001	Mepyramine maleate		BRD-K97564742-103-01-9	42.4	24.5	12.3	9.0	4.4	2.0
2002	THYMOQUINONE		BRD-K97566842-001-03-5	26.1	23.6	-1.5	-1.9	30.4	11.7
2003	CHLORPROPAMIDE		BRD-K97746869-001-15-5	-1.7	10.0	9.9	19.8	15.7	26.8
2004	Nicorandil		BRD-K97752965-001-01-6	-4.4	-23.9	-2.2	0.2	7.1	7.2
2005	PDGF Receptor Tyrosine Kinase Inhibitor II		BRD-K97922702-001-01-3	-0.4	6.1	19.2	24.5	36.6	28.9
2006			BRD-K98039984-001-06-3	-9.7	14.0	-1.3	-4.3	2.7	8.1
2007	Compound W		BRD-K98143539-001-01-4	-60.1	-51.9	-92.9	-91.5	-35.0	-38.8
2008	SIB 1757		BRD-K98157055-001-04-2	59.6	30.3	53.3	31.4	27.0	28.3
2009	CHLOROXAZONE		BRD-K98174813-001-08-1	9.3	7.1	6.2	17.6	12.5	9.5
2010	ANGOLENSIN (R)		BRD-K98281970-001-03-4	-3.9	-11.1	-51.3	-21.4	-21.4	-17.6
2011	N-Ethylmaleimide		BRD-K98297262-001-01-1	-5.2	-12.8	3.5	12.0	19.6	37.1
2012	AMSACRINE		BRD-K98490050-001-01-8	-74.8	-82.7	-99.3	-98.9	-84.7	-82.9
2013	CLONIDINE HYDROCHLORIDE		BRD-K98530306-003-07-6	66.3	59.8	19.6	17.3	13.0	8.3
2014	Parthenolide		BRD-K98548675-001-02-6	-39.1	-45.7	-79.0	-75.5	-53.8	-43.8
2015	4-HYDROXYINDOLE		BRD-K98735139-001-01-1	17.8	-3.9	-23.7	-16.4	-71.0	-68.2
2016	CHLOROACETOXYQUINOLINE		BRD-K98737600-001-02-5	8.3	16.1	15.9	31.9	-22.1	-25.1
2017	NIFLUMIC ACID		BRD-K98763141-001-17-5	9.4	27.2	-8.6	3.5	8.3	3.7
2018	FUMAZENIL		BRD-K98769987-001-12-0	17.1	-19.7	-6.3	6.5	13.2	14.3
2019	Felbamate		BRD-K99107520-001-09-2	-6.2	-20.0	-23.0	0.7	-2.2	0.2
2020	DIBUCAINE HYDROCHLORIDE		BRD-K99121711-003-12-2	-28.4	-16.1	-35.7	-29.2	-48.2	-41.0
2021	SB 203580, Sulfone		BRD-K99291625-001-02-3	-3.4	2.8	-6.2	-11.6	12.7	17.2

no.	Name	Compound	Broad Institute ID	Normalized scores					
				HPr+_DNA		CBA		Amplex Red_HRP	
				Plate 1	Plate 2	Plate 1	Plate 2	Plate 1	Plate 2
2022	ANTAZOLINE PHOSPHATE		BRD-K99300445-011-12-8	7.8	14.0	-20.6	19.4	-18.3	0.3
2023	TUBOCURARINE CHLORIDE		BRD-K99621550-003-03-4	2.5	15.3	8.3	28.6	7.8	7.9
2024	BUTACAIN		BRD-K99622919-001-15-6	13.3	4.1	21.1	23.8	10.3	-17.8
2025	HEXACHLOROPHEN		BRD-K99792991-001-18-2	-70.4	-66.2	-83.8	-83.5	-64.6	-64.3
2026	DPO-1		BRD-K99922388-001-01-2	29.5	17.6	2.0	11.6	16.0	13.7
2027	FLUNIXIN MEGLUMINE		BRD-K99984802-100-06-9	27.3	2.5	2.6	15.1	6.9	5.2
2028	Formoterol hemifumarate		BRD-M00539986-051-01-1	16.5	12.6	13.4	16.5	-3.9	-4.2
2029	4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride		BRD-M10474530-001-02-3	-3.8	-19.9	-3.8	7.7	3.1	-6.7

Mitigation of NADPH Oxidase 2 Activity as a Strategy to Inhibit Peroxynitrite Formation

Jacek Zielonka, Monika Zielonka, Lynn VerPlank, Gang Cheng, Micael Hardy, Olivier Ouari, Mehmet Menaf Ayhan, Radoslaw Podsiadly, Adam Sikora, J. David Lambeth and Balaraman Kalyanaraman

J. Biol. Chem. published online February 2, 2016

Access the most updated version of this article at doi: [10.1074/jbc.M115.702787](https://doi.org/10.1074/jbc.M115.702787)

Alerts:

- When this article is cited
- When a correction for this article is posted

[Click here](#) to choose from all of JBC's e-mail alerts

Supplemental material:

<http://www.jbc.org/content/suppl/2016/02/02/M115.702787.DC1.html>

This article cites 0 references, 0 of which can be accessed free at

<http://www.jbc.org/content/early/2016/02/02/jbc.M115.702787.full.html#ref-list-1>